

# Memorial Sloan Kettering Cancer Center (MSK)

## Curriculum Vitae

Name: Deb Schrag, MD, MPH

Date of Preparation: May 2025

### A. PERSONAL DATA

Current Employment:	Chair, Department of Medicine Memorial Sloan Kettering Cancer Center
---------------------	---

### B. EDUCATION

Degree	Institution Name & Location	Dates Attended	Year Awarded
B.A. History/History of Science	Harvard University, Cambridge, MA	09/82-06/86	1986
M.D. Medicine	Columbia University College of Physicians and Surgeons, New York, NY	08/87-05/91	1991
M.P.H. Health Policy and Epidemiology	Harvard University School of Public Health, Boston MA	07/96-02/98	1998

### Other Education

Description	Institution Name & Location	Dates Attended
Brigham and Women's Hospital (BWH) Leadership Program, "weekend mini-MBA"	Harvard Business School, Boston MA	09/08-06/09

### C. POSTDOCTORAL TRAINING

Title	Institution Name	Dates
Intern, Medicine	Brigham and Women's Hospital	06/91-06/92
Clinical Fellow, Medicine	Harvard Medical School	06/91-06/96
Junior Assistant Resident, Medicine	Brigham and Women's Hospital	06/92-06/93
Senior Medical Resident, Medicine	Brigham and Women's Hospital	06/93-06/94
Chief Medical Resident	West Roxbury VA Hospital	06/94-10/94
Fellow, Medical Oncology	Dana Farber Cancer Institute	06/94-06/96
Post-Doctoral Research Fellow Mentored by: Dr. Jane Weeks, Dr. Judy Garber, and Dr. Milton Weinstein	Division of Population Sciences, Center for Cancer Risk and Prevention, Dana Farber Cancer Institute and Harvard School of Public Health	06/96-06/98

**D. PROFESSIONAL POSITIONS & EMPLOYMENT****Academic Appointments**

<b>Title</b>	<b>Institution</b>	<b>Dates</b>
Instructor, Medicine	Harvard Medical School	7/1996-12/1998
Assistant Member Level I, Primary in Epidemiology and Biostatistics and Secondary in Medicine	Memorial Sloan Kettering	2/1999-6/2000
Assistant Member, Epidemiology and Biostatistics and Medicine	Memorial Sloan Kettering	7/2000-9/2005
Assistant Professor, Public Health	Weill Cornell Medical College	1/2000-9/2005
Associate Member, Epidemiology and Biostatistics and Medicine	Memorial Sloan Kettering	9/2005-12/2007
Associate Professor, Public Health and Medicine	Weill Cornell Medical College	1/2005-12/2007
Associate Professor, Medicine	Harvard Medical School	7/2008- 6/2013
Professor (with Tenure), Medicine	Harvard Medical School	7/2013- 8/2021
Professor, Health Policy	Harvard Chan School of Public Health	7/2013-8/2021
Member, Department of Medicine	Memorial Sloan Kettering	8/2021-current
Professor of Medicine	Weill Cornell Medical College	2/2022-current

**Hospital Appointments**

<b>Title</b>	<b>Institution</b>	<b>Dates</b>
Attending Physician, Medicine	Brigham and Women's Hospital	07/96-06/99
Attending Physician, Medicine	Dana Farber Cancer Institute	07/97-01/99
Assistant Attending Physician, Epidemiology & Biostatistics and Medicine	Memorial Sloan Kettering	02/99-09/05
Associate Attending Physician, Epidemiology & Biostatistics and Medicine	Memorial Sloan Kettering	09/05-12/07
Affiliate Attending, Epidemiology and Biostatistics	Memorial Sloan Kettering	01/08-12/13
Attending Physician, Medical Oncology	Dana Farber Cancer Institute	01/08-12/11
Associate Physician, Medicine	Brigham and Women's Hospital	01/08-08/21
Senior Attending Physician, Medical Oncology	Dana Farber Cancer Institute	01/12-08/21
Chief, Division of Population Sciences	Dana Farber Cancer Institute	09/13-08/21
Attending Physician, Medicine Solid Tumor GI Oncology	Memorial Sloan Kettering	09/21-current
Chair, Department of Medicine	Memorial Sloan Kettering	09/21-current

**E. LICENSURE, BOARD CERTIFICATION****Licensure:**

State Licensure:	Number	Date of Issue	Date of Expiration
New York	212739-1	01/17/1999	03/31/2027
Massachusetts	77651	05/12/1993	04/02/2027

DEA number:	BS3636567
NPI number:	1922079870

**Board Certification**

Full Name of Board	Certificate #	Dates of Certification
American Board of Internal Medicine	155377	1995-2005
American Board of Internal Medicine, Medical Oncology	155377	1997-2007
American Board of Internal Medicine Recertification	155377	2005-2015
American Board of Internal Medicine, Medical Oncology, Recertification No. 1 in Subspecialty	155377	2007-2017
American Board of Internal Medicine, Medical Oncology, Recertification No. 2 in Subspecialty	155377	2017-2027

**F. INSTITUTIONAL/HOSPITAL AFFILIATION**

Current Primary Hospital Affiliation:	Memorial Sloan Kettering, New York, NY
Other Affiliations:	Weill Cornell Medical College, New York, NY

**G. EMPLOYMENT STATUS**

Name of Current Employer(s):	Memorial Sloan Kettering
Current Employment Status:	Full-time salaried by Memorial Sloan Kettering

**H. HONORS, AWARDS (Selections)**

Name of Award	Organization	Year Awarded
Magna Cum Laude	Harvard University	1986
Katherine Ireland Fellowship	Harvard University	1986-1987
Alpha Omega Alpha	Columbia College of Physicians and Surgeons	1991

Young Investigator Award	American Society of Clinical Oncology	1998
Boyer Award for Excellence in Clinical Research	Memorial Sloan Kettering	2002
Elizabeth and Felix Rohatyn Chair for Junior Faculty	Memorial Sloan Kettering	2003-2007
Elected member, Fellow of the American Society of Clinical Oncology	American Society of Clinical Oncology	2012
Claire W. and Richard P. Morse Research Award	Dana Farber Cancer Institute	2013
Member, National Cancer Policy Forum	Institute of Medicine, National Academies of Medicine	2014-2021
Associate Editor	Journal of the American Medical Association	2014-2023
Teaching Award in recognition for contributions to career development	Brigham and Women's Hospital	2014
Stovall Research Award for Advancing Knowledge that Benefits Patients	National Coalition for Cancer Survivorship	2014
Outstanding Research Award	North American Association of Central Cancer Registries	2014
Research mentorship award	Harvard Chan School of Public Health Summer Program in Clinical Effectiveness	2015
Housestaff Teaching Award	Brigham and Women's Hospital Inpatient Oncology "Intensive Teaching Unit"	2015
Richard L. Schilsky Achievement Award in Research	Alliance for Clinical Trials in Oncology	2016
Elected Member	Association of American Physicians (AAP)	2016
Extramural Investigator Award for Research Excellence in Population Science	Division of Cancer Control and Population Sciences, National Cancer Institute	2017
George J. Bosl Faculty Endowed Chair	Memorial Sloan Kettering Cancer Center	2021
Council Member	Association of American Physicians	2022-present
ASCO-ACS Cancer Prevention Award	American Cancer Society and American Society of Clinical Oncology	2023
Giants of Cancer Care Award	Selected by Peers for Award sponsored by Oncology Live Roundtable Coalition	2023
"Top Doctor" and other consumer recognitions from New York Magazine, Boston Magazine, Castle-Connelly, WebMD, Patient's Choice,	Multi-year awardee for Oncology <i>Not accurately tracked varies by location in NY or MA</i> <i>Discontinuous election</i>	2004-
Top Alliance Manuscript 2022-2023	Alliance for Clinical Trials in Oncology	2023
Elected Member Section 4, Medicine	National Academy of Medicine (NAM)	2024

**I. PROFESSIONAL ORGANIZATIONS AND SOCIETY MEMBERSHIPS**

<b>Organization</b>	<b>Dates</b>
<b><i>American Society of Clinical Oncology</i></b>	

Associate Member	1996-1997
Member	1998-present
Member, Health Services Research Committee	2000-2003
Member, Guideline Committee for Stage II Colon Cancer	2002-2004
Chair, Technology Assessment: Chemo Sensitivity Assays	2002-2005
Chair-Elect, Chair, Past-Chair, Health Services Committee	2003-2006
Member, National Initiative on Cancer Care Quality Advisory Group	2004-2006
Member, Quality Advisory Group	2005-2008
Member, Program Committee, Health Services Track	2005-2008
Member, Finance Committee	2007-2010
Member, Quality of Care Committee	2007-2011
Member, Board of Directors	2008-2012
Member, Task Force on Costs of Care Committee	2009-2013
Member, Cancer Health Disparities Committee	2008-2014
Member, Quality Office Practice Initiative (QOPI) Steering Group	2009-2013
Member, Special Awards Selection Committee	2010-2012
Member, Cancer LinQ Data Governance Oversight Committee	2013-2017
Chair, Data Access Subcommittee of the DGOC	2014-2016
Member, Cancer Education Committee	2010, 2014, 2016
Member, Guidelines Review Committee	2018-2021
Co-Chair Cancer and Covid-19 Task Force	2020-2021
Member, President's Working Group on Future of the Oncology Workforce	2023-2025
<b><i>Society for Medical Decision Making</i></b>	
Program Planning Committee, Education Committee, Reviewer, Speaker	1996-2017
<b><i>Academy Health</i></b>	
Track leader, Abstract Reviewer, Chair, Value Frameworks, Panel	2008-2019
<b><i>American Association of Cancer Research</i></b>	
Health Disparities Committee Member, Cancer Policy and Government, Relations, Co-Chair, Health Disparities Meeting, Committee Member, Project GENIE Steering Committee, Project-GENIE BPC co-PI, Scientific Program Committee PI, Program Committee, Abstract Reviewer, Princess Takamatsu Award Selection Committee	2014-Present
<b><i>National Academy of Medicine (NAM)</i></b>	2025
Member, Internal Medicine, Pathology and Dermatology Committee	
Academy Health, American Society of Preventive Oncology, European Society of Medical Oncology, American Medical Association, Massachusetts Medical Society, North American Association of Cancer Registrars, American Society of Public Health	Discontinuous memberships

**J. PERCENT EFFORT AND INSTITUTIONAL RESPONSIBILITIES**

<b>Current MSK Effort</b>	<b>Percent Effort (%)</b>
Teaching	5%
Clinical	10%
Administrative	60%
Research	25%
<b>Total</b>	<b>100%</b>

**K. EDUCATION and TRAINING**

## Didactic Teaching

Title	Audience	Dates
Health Policy and Management 286 Milton Weinstein PhD's Decision Analysis Course, Harvard Chan School of Public Health (HCSPH)	60 postdoctoral students, primarily physicians pursuing an MPH	1996-1998
Epidemiology, and Introduction to the US Health Care System, Weill-Cornell Medical College (WCM)	30-40 medical students	2001-2006
Lectures in Health Policy and Management 299, HCSPH Research with Large Databases Course Lead: J. Ayanian	~40 physicians in the Summer Clinical Effectiveness Program	2008
Lectures in Epidemiology 1257, HCSPH Seminar in Cancer Epidemiology	~15 postdoctoral students	2008
Core Faculty for Epidemiology 208, HCSPH	24-36 postdoctoral students	2009-2020
Lectures in US Health Policy Course, HMS	Medical and dental students at HMS	2010-2013
Lectures in HPM, Health Economics Course, HCSPH Medicare and Medicaid Policy and Cancer Treatment	20-30 postdoctoral students	2008-2014
Lectures in Health Policy and Management 276, HCSPH Large Scale Administrative Database Methods Course Lead: S. Schneeweiss	~50 postdoctoral fellows in Summer Clinical Effectiveness Program	2014-2021
Lectures in Epidemiology 253, HCSPH Effectiveness Research with Healthcare Databases	~20-45 postdoctoral fellows	2014-2021

## Research Supervision and Training Seminars (excluding didactic lectures)

Title	Audience	Dates
Topics in Cancer Epidemiology, Health Services Research Methods, and Population Science at Memorial Sloan Kettering (MSK)	~30 Medical, surgical oncology fellows, residents, and medical students per year ~20 hours per year	1999-2007
Supervision in health services research/MSK	2 postdoctoral fellows ~4 hours per week	1999-2003
Supervision in health services research/MSK	3 postdoctoral fellows ~4-8 hours per week	2004-2007
Project-specific mentorship in HCSPH Clinical Effectiveness Program	~5 physicians ~60 hours per year	2008-2020
Supervision of fellows in health services research through an NCI R25 Award to MGH and DFCI	1-3 postdoctoral fellows/year ~8 hours per week	2008-2017
Thesis advisory committee/HCSPH Department of Epidemiology, Center for Decision Sciences and Department of Healthcare Policy and Management	PhD Candidates in health policy, epidemiology, statistics ~15 hours per year	2012, 2014, 2017, 2018, 2020, 2021
MPI of a T32 in Cancer Focused Population Sciences Coordinated curriculum training and led 2-3 day-long workshops in research methods each year, DFCI	6 postdoctoral fellows, 4 MDs, 2 PhDs ~70-100 hours per year	2017-2021

<b>Title</b>	<b>Audience</b>	<b>Dates</b>
Leader of seminars and journal clubs and training workshops in various topics focused on study design and guide to the biomedical literatures such as: how to interpret: a phase II clinical trial, a phase III clinical trial, a risk prediction model, a survey, decision analysis, cost-effectiveness analysis, pragmatic clinical trials.	Residents and fellows primarily Medicine & Medical Oncology/Hematology ~6-10 hours/ year	2008-2021
Founding MPI of the OPTICS T32: Cancer Care Delivery and Population Sciences	6 postdoctoral fellows ~50 hours/year	2023-Present

### **Clinical Teaching, Continuing Education and Professional Education**

The topics and approximate frequency of talks given in CME courses and at annual meetings is summarized in the table below. Lectures to the community, lay public, and patient advocacy groups are not listed.

<b>Title</b>	<b>Audience</b>	<b>Dates</b>
Lectures on quality measurement in oncology	Physicians, RNs, health care administrators attending workshops at HCSPH	2004-2019
Teaching lectures on GI Oncology Topics: Preparation for Medicine and Oncology Board Review courses, Highlights of ASCO, Great Debates Series, Advances in GI Oncology; Primarily topics related to colorectal cancer prevention, screening, diagnosis, and treatment.	Physicians, also APPs, nurses attending CME courses, Board Review Courses or training workshops held at annual meetings	2000-2021
Lectures on topics in cancer-focused population sciences at North American Association of Central Cancer Registries (NAACCR) national meetings, State Public Health Departments, and the CDC	Tumor registrars, epidemiologists, state public health leaders	2005-2017
Cost Effectiveness Analysis and Economics of Cancer Care Delivery	Physicians attending CME courses	2007-2013
“How to prepare a manuscript for JAMA” given at annual meetings during term as journal Associate Editor	Attendees at ASCO, ESMO, PCORI, ASPO, AACR meetings	2014-2019

### **L. CLINICAL PRACTICE**

I am a gastrointestinal oncologist and maintained a longitudinal outpatient oncology practice with an emphasis on lower gastrointestinal tumors (colorectal, anal, appendiceal) between 1996 and 2021. Since 2021, I have had an ad hoc outpatient practice providing backup for other gastrointestinal oncologists and working to expedite diagnostic workup for patients with newly suspected cancer diagnoses. Since 1996, I have cared for hospitalized patients on an inpatient oncology team together with interns and residents for 2-4 weeks per year. At MSK, I attend on the inpatient ST-GI Oncology Service.

<b>Duration</b>	<b>Name/Location of Practice</b>	<b>Type of Activity</b>	<b>Level of Activity</b>
1996-1998	GI Medical Oncology, DFCI	Outpatient Clinic	1.5-2 days per week
1996-1998	Solid Tumor Oncology Team, DFCI & BWH	Inpatient Attending	6 weeks per year
1999-2007	GI Medical Oncology, MSK	Outpatient Clinic	1.5 days per week

Duration	Name/Location of Practice	Type of Activity	Level of Activity
1999-2007	GI Medical Oncology, MSK	Inpatient Attending	1 month per year
2008-2015	GI Medical Oncology, DFCI	Outpatient Clinic	1.5 day per week
2015-2021	GI Medical Oncology, DFCI	Outpatient Clinic	1 day per week
2008-2013	Oncology "A" team (Resident teaching team), DFCI & BWH	Inpatient Attending	4 weeks per year
2013-2021	Oncology "A" team, DFCI & BWH	Inpatient Attending	2 weeks per year
2021-current	GI Oncology Service, (Resident teaching team), MSK	Inpatient Attending	3 weeks per year
2021-current	GI Medical Oncology, MSK	Outpatient Clinic	<i>Ad hoc</i> consults

**M. RESEARCH STATEMENT**

I am a cancer-focused population scientist and health services researcher. The questions motivating me are, how do we make cancer treatments work well outside of controlled experimental conditions? How do we generate maximal knowledge from the experiences of patients treated outside the context of clinical trials? My expertise lies in measuring the quality of cancer care, treatment effectiveness, cost-effectiveness, developing, evaluating, and implementing complex interventions and measuring the impact of policy changes on outcomes for patients with cancer. My research has informed oncology practice, clinical trial design and local, state, and federal strategies for decreasing the burden of cancer on population-health.

Over the past two decades, I have grown the field of patient-reported outcomes (PROs) by building frameworks and validated systems to elicit meaningful endpoints. This body of work has advanced knowledge about the short- and long-term consequences of cancer treatment. I have led and co-led foundational studies demonstrating that physicians trust patients' own reports of symptom severity and burdens and that PRO tracking can decrease adverse events including hospitalization and the need for emergency-level care. I am a co-developer, with former mentee, now collaborator, Dr. Ethan Basch, of the Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) system for eliciting adverse events directly from patients. PRO-CTCAE assessments have been integrated into hundreds of clinical trials and this system is recognized by the FDA as a regulatory standard. Funded by an NCI Moonshot award, I scaled this work by collaborating with cancer centers in the Mississippi Delta, Appalachia, and rural areas in New England to develop eSyM, an EPIC-integrated system for eliciting PROs in settings where access to oncology care is constrained. eSyM is now integrated into the EPIC electronic health record and is available to nearly 75% of cancer patients in the US.

I currently serve as an MPI on a 2nd NCI-funded Moonshot award evaluating the safety, quality, and effectiveness of telehealth for delivering ambulatory cancer care. I have innovated in the "real world data" analysis space and am the architect of a framework for "machine teaching" or ground truthing clinical data abstraction from EHRs. This training model, PRISMM, enables training and validation of machine learning algorithms that rely on natural language processing to extract key outcomes of cancer treatment from clinicians' notes that are trapped in unstructured text. This invention is now used by multiple cancer centers internationally and by AACR's project GENIE.

Finally, I have experience leading pragmatic clinical trials to evaluate complex health system interventions. I conceived and executed an NCI-sponsored randomized trial in locally advanced rectal cancer that has changed the prevailing care standard by demonstrating that chemotherapy can be used as an alternative to pelvic chemoradiation with equivalent survival and superior quality of life outcomes. Ongoing work seeks to identify the molecular determinants of favorable response to chemotherapy versus radiation by leveraging the extensive biospecimens acquired in this practice changing trial.

**Research Support:  
Current Research Funding**

<b>2022-2027</b>	<b>MATCHES: Making Telehealth Delivery of Cancer Care at Home Effective and Safe</b>
	National Cancer Institute (NCI)   1 P50 CA271357-01
	MPI with Dr. Michael Morris (Moonshot award, \$5,000,000)
	The MATCHES (Making Telehealth Delivery of Cancer Care at Home Effective and Safe) Telehealth Research Center will evaluate the role of telehealth in oncology by: 1) conducting pragmatic and pilot trials across our integrated network of outpatient oncology practices; 2) leveraging our substantial cache of observational data to build the evidence base necessary to establish best practices for telehealth-supported cancer care; and 3) investigating concerns about safety and addressing the risk of exacerbating disparities in access to high quality healthcare.
<b>2023-2028</b>	<b>Oncology focused Population Sciences Training Program: OPTICS</b>
	NCI   T32CA275764
	MPI with Dr. Katherine Panageas
	This award supports training for postdoctoral fellows focused on research in cancer care delivery and cancer-focused population sciences. The T32 supports 3 fellows/year for a 2-year period with intensive training and mentorship from a core group of faculty mentors.
<b>2021-2022</b>	<b>Optimizing the Treatment of Pancreatic Adenocarcinoma</b>
	NCI   R01CA212086
	Co-I, (PI: Chin Hur MD, Columbia University)
	The purpose of this study is to improve both individual patient survival and population mortality linked to pancreatic adenocarcinoma through the development of a mathematical modeling.
<b>2021-2023</b>	<b>A Web-based Patient-reported Symptom Monitoring and Self-management Portal for Adolescent and Young Adult Breast Cancer Survivors</b>
	NCI   U01CA246648
	Co-I (PIs: A. Partridge MD, DFCI and HMS, M. Naughton PhD, Ohio State University)
	The overall goal of this study is to determine the efficacy of the YES intervention, a web-based symptom monitoring and self-management tool, compared to usual care in improving quality of life in AYAs who have survived primary breast cancer treatment.
<b>2020-2025</b>	<b>Comparative Modeling of Effective Policies for Colorectal Cancer Control</b>
	NCI   U01 CA253913
	Co-I (PIs: Zaubler, A. / Knudsen, A./ Kuntz, K./ Lansdorp-Vogelaar, I./ Rutter, C.)
	This CISNET award continuation uses microsimulation modeling to evaluate and help prioritize interventions to reduce the burden of colorectal cancer.
<b>2018-2024</b> <b>No cost extension</b>	<b>SIMPRO Research Center: Integration and Implementation of PROs for Symptom Management in Oncology Practice (Moonshot Award)</b>
	NCI   UM1CA233080 (\$6,500,000)
	MPI, Founding PI at DFCI, HMS. with R. Osarogiagbon from the Baptist Health System, Memphis, TN, and S. Wong, from Dartmouth Hitchcock, Hanover, NH. Added M. Hassett as an MPI from DFCI upon transition from DFCI to MSK
	SIMPRO's goal is to develop, implement, and evaluate a scalable multi-component ePRO reporting and management system to improve symptom control for patients recovering from cancer surgery or patients receiving palliative chemotherapy in small, rural, and community cancer centers. It seeks to determine whether ePRO tracking can decrease the need for rehospitalization and emergency care.
<b>2013-present</b>	<b>The PROSPECT Trial: A Phase III trial of Neoadjuvant Chemotherapy versus Chemoradiation for Locally Advanced Rectal Cancer</b>
	Alliance for Clinical Trials Oncology (US, NCI-sponsored Cooperative Group)
	PI

	This NCI-sponsored, national cooperative group clinical trial (Alliance) randomized 1,194 patients with locally advanced rectal cancer to receive or not receive pelvic radiation as part of curative intent treatment. The study transformed the way large cooperative group clinical trials are conducted. It was the first large NCI-sponsored trial to integrate PRO-CTCAE and to longitudinally track patient-reported outcomes. The study also included a centralized imaging bank and quality of life assessment, economic assessment, molecular and imaging markers. Analyses of secondary outcomes are ongoing.
--	--

**Past Funding** (*Smaller awards, co-investigator awards, philanthropic awards not listed*)

<b>1999-2004</b>	<b>Genetic Predisposition Testing in Colorectal Cancer</b>
	NCI / K07 Mentored Training Award in Cancer Prevention
	PI on Career Development Award (Mentors: Jane Weeks MD MSc and Judy Garber MD MPH, DFCI and HMS)
	The overall aim was to assess effectiveness, measured in life-years and quality-adjusted life years, and the cost-effectiveness, of genetic testing for inherited colorectal cancer susceptibility.
<b>2004-2007</b>	<b>Reasons for Adjuvant Therapy Decisions in Colorectal Cancer</b>
	American Cancer Society
	PI
	This study evaluated the reasons that vulnerable patients in a New York City Hospital-based cohort do not initiate, and do not complete postoperative adjuvant chemotherapy following a diagnosis of colorectal cancer and the extent to which these shortcomings contribute to disparities in mortality rates.
<b>2004-2007</b>	<b>Diffusion of Chemotherapy Innovations</b>
	NCI  R21 CA2198353
	PI
	The specific aims were: 1) to describe how new chemotherapeutic strategies disseminate into oncology practice using the SEER-Medicare linked data, and 2) to measure the extent to which specific chemotherapy regimens are identifiable from the billing claims submitted to Medicare.
<b>2005-2007</b>	<b>Cost-Effectiveness of Regimens for Treatment of Pancreatic Cancer</b>
	NCI Supplement to Support Economic analyses of CALGB Protocol 80303
	PI
	The aim of this study was to use primary clinical trial data on effectiveness and health care utilization for patients with pancreas cancer as well as primary quality of life data to estimate the incremental cost-effectiveness of a new treatment regimen.
<b>2005-2009</b>	<b>The Roots of Health Disparities: The Quality of Primary Care</b>
	National Institute of Aging (NIA)   R01AG025687
	Co-I
	This proposal evaluated the reasons underlying the prevalence of racial disparities in health outcomes for patients with chronic diseases using linkages between the Community Tracking Study survey of physicians and Medicare claims data.
<b>2006-2008</b>	<b>Development of Prognostic Models in Colorectal Cancer</b>
	American Joint Commission on Cancer of the American College of Surgeons
	PI
	This study used the ACS data (known as the NCDB) and other registry data to develop a prognostic and predictive model to inform decisions about treatment of colorectal cancer.
<b>2006-2011</b>	<b>Tracking Disease Outcomes in Specialty Cancer Centers: The Colorectal Cancer Database</b>
	NCCN
	PI

	This longitudinal study measured adherence to NCCN clinical practice guidelines and evaluated the quality of colorectal cancer treatment at 22 NCI-designated cancer centers.
<b>2006-2008</b>	<b>Access to Prescription Drug Coverage for Patients Enrolled in Therapeutic Cancer Clinical Trials</b>
	PI
	NCI Supplement to Cooperative Group Study
	This award was to integrate patient and physician surveys to understand how patients and physicians cope with the potential for significant “financial toxicity” of cancer treatment.
<b>2006-2009</b>	<b>Access to Mammography Facilities and Use of Screening by African American Women Foundation</b>
	Susan Komen Foundation
	Co-PI with Elena Elkin PhD, Dept of Epidemiology and Biostatistics, MSK and WCM
	This study was to determine region-specific capacity to perform screening mammography and to understand systems level barriers to screening African American women compared to white women.
<b>2007-2010</b>	<b>Modeling Effective Health Policies for Colorectal Cancer</b>
	NCI U01CA097426
	Co-I (PI: Anne Zaubler PhD, MSK, Dept of Epidemiology and Biostatistics)
	The MISCAN-Colon model is used to estimate the absolute and relative contribution of changing lifestyle factors, screening, and improved therapy on the observed trends in CRC incidence and mortality in the US. The microsimulation model is used to examine future scenarios to evaluate the impact of developing technologies for prevention, screening, and treatment on future trends in CRC incidence and mortality in the US.
<b>2007-2010</b>	<b>A Population Based Policy Model for Colorectal Cancer</b>
	NCI U01CA088204
	Co-I (PI: Karen Kuntz PhD, University of Minnesota School of Public Health)
	To characterize treatment patterns, outcomes, and costs for chemotherapy and surgical interventions for patients with colorectal cancer.
<b>2008-2010</b>	<b>Augmenting NY Cancer Registry Data to Assess Breast and Colorectal Cancer Care</b>
	Association of Schools of Public Health (ASPH)/Center for Disease Control (CDC)
	MPI with Tumor Registrar of NY State (M. Schymura PhD)
	To develop: 1) technical reports describing the linkage steps themselves; 2) methodological reports characterizing the yield from the data source; and 3) research papers describing cancer care delivery to Medicaid recipients in these two large states (NY and CA).
<b>2008-2010</b>	<b>The Cancer Multi-Center Research Consortium Coordinating Center (CAN-DEcIDE Consortium)</b>
	Agency for Healthcare Research and Quality (AHRQ) Health and Human Services Agency (HHSA) / 290200500161
	Co-PI with S. Schneeweiss of BWH and HMS
	The goals of the project were to evaluate the real-world effectiveness of chemotherapy treatments for solid tumor malignancies using data from a variety of non-experimental sources and examine both survival outcomes and the incidence of serious treatment complications such as hospitalization, heart attacks and other major treatment complications when novel therapies are scaled beyond clinical trials to the population level.
<b>2008-2012</b>	<b>Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium II</b>
	NIH NCI 3U01CA093344
	Co-Investigator (PI: D. Harrington, PhD, Department of Biostatistics, HCSPH)
	The major goal of this project was to extend the work performed in CanCORS one to obtain a comprehensive understanding of barriers and facilitators to high quality cancer care delivery for patients with metastatic thoracic and gastrointestinal malignancies and to understand the

	reasons for the gap between efficacy and effectiveness by integrating patient and clinician perspectives with longitudinal medical records capturing the outcomes of cancer treatment.
<b>2009-2015</b>	<b>Cancer Care Delivery in Medicaid</b>
	NCI R01 CA131847 (\$2,500,500)
	PI
	This proposal sought to identify how access to safety net health insurance and race/ethnicity intersect with common cancer diagnoses. We will evaluate the extent to which novel approaches to cancer treatment are adopted for use by persons who are enrolled in Medicaid based on either disability or poverty.
<b>2009-2015</b>	<b>Cancer Care Delivery Research Program of the Dana Farber Harvard Cancer Center</b>
	NCI Core Grant 5P30CA006516-56
	PI, Program in Cancer Center Core Grant (Overall PI, L. Glimcher, MD, DFCI)
	This program builds research synergies in health services, implementation science, care delivery, comparative effectiveness, and health informatics across the 2 schools and 5 hospitals that comprise the DF/HCC. I founded this program and co-led it first with J. Ayanian MD and then with N. Keating MD. Rating: outstanding-exceptional, then exceptional by NCI reviewers.
<b>2009-2012</b>	<b>Building CER Capacity: Aligning Cancer Research Networks, Centers for Medicare &amp; Medicaid Services (CMS), and State Resources to Map Cancer Care</b>
	NIH UC2CA148185
	Co-Investigator (PI, D. Ritzwoller University of Colorado)
	The goals of this project were to support high quality cancer comparative effectiveness research that enables measurement of population-based patterns and outcomes of cancer care in patients not represented in SEER-Medicare.
<b>2010-2012</b>	<b>BWH/DFCI: CAN-DEcIDE-2</b> The CAN-DEcIDE (CAN=Cancer, DEcIDE=Developing Evidence to Inform Decisions about Effectiveness) Consortium
	AHRQ HHS290201000006I
	PI (\$2,000,000) with Dr. S. Schneeweiss, Chief of the Division of Pharmacoepidemiology and Pharmacoeconomics, BWH
	CAN-DEcIDE's portfolio evaluated the effectiveness of and health outcomes of cancer treatment and surveillance using both observational and pragmatic study designs. Key project goals were to develop methods and standards to minimize bias and support transparent conduct and reporting of observational research in oncology. This award was an extension of CAN-DEcIDE.
<b>2010-2012</b>	<b>U Mass Boston / Dana Farber Harvard Cancer Center U54 Partnership</b>
	NIH 1U54 CA156732
	Co-Investigator (PI, Dr. V. Viswanath, DFCI and HCSPH)
	This project developed a comprehensive partnership between the University of Massachusetts Boston (UMB) and the Dana Farber/Harvard Cancer Center (DF/HCC). The goal of the partnership was to address health disparities in minority populations; to improve research in basic, clinical, and population science; and to provide training and research opportunities for minority students,
<b>2010-2013</b>	<b>Quality, Disparities and Breast Cancer Care in Medicaid</b>
	Susan G. Komen for the Cure / Career Catalyst in Disparities Research (CC-DR) Grant
	MPI (Dr. M. Hassett, DFCI and HMS)
	The objectives of this project were to evaluate the quality of care for women with breast cancer who are insured by Medicaid and to generate policy and practice-ready solutions to improve it.
<b>2010-2013</b>	<b>Comparing the Long-Term and Real-World Effectiveness of Initial Management Strategies for ductal carcinoma in situ (DCIS)</b>
	AHRQ HHS290200500161
	Co-Investigator (PI, C. Greenberg BWH and HMS, then University of Wisconsin)

	The aims of this study were to systematically evaluate the outcomes for women with DCIS who select alternative treatment strategies and to inform future decisions.
<b>2010-2015</b>	<b>Black-White Differences in Advanced Cancer Communication, Acceptance, and Care</b>
	NIH NCI R01CA10637005-A1
	Co-Investigator (PI, H. Prigerson, DFCI and HMS, then WCM)
	The goal of this project was to apply the Structural Influence Model (SIM) of Health Communication to examine whether black-white disparities in communication processes (e.g., prognostic disclosures) and communication goals (e.g., acceptance of illness) mediate racial disparities in end-of-life (EOL) care, rates of treatment goal attainment and quality of life at the EOL.
<b>2010-2015</b>	<b>Lung Cancer Disparities Center: Jointly Addressing Race &amp; Socioeconomic Status</b>
	NIH 1P50CA148596-01
	Co-Investigator (PI: David Williams PhD, HCSPH)
	The goals of this project were to identify root causes of disparities in lung cancer treatment outcomes and to identify an actionable set of remediation strategies.
<b>2008-2015</b>	<b>Modeling Effective Health Policies for Colorectal Cancer</b>
	NIH U01CA152959-01
	Co-Investigator on the CISNET microsimulation model in CRC. PI: K. Kuntz.
	The goals of the project were to provide population-based answers to health policy questions of how to evaluate or implement programs of risk reduction, cancer screening, or treatment to affect CRC incidence and mortality over time.
<b>2008-2015</b>	<b>Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)</b>
	NCI HHSN26120100063C (Contract awarded to build PRO-CTCAE)
	Site PI (PI: Ethan Basch MD, MSc MSK and then, University of North Carolina)
	This was a collaboration with E. Basch, a primary mentee to create a mechanism for patient self-reporting of adverse symptom events in cancer treatment trials. This platform, the PRO-CTCAE, was built with support from this large NCI contract. A team of investigators from 8 cancer centers collaborated to develop an integrated item bank and electronic platform that is validated, reliable, sensitive, generalizable, feasible, accepted by clinicians and regulators, and interoperable with NCI and industry standards. The PRO-CTCAE has been integrated in hundreds of trials and is now a global standard for eliciting and reporting PROs in research and routine care contexts.
<b>2012-2015</b>	<b>Explaining variations in Intensity of EOL Care</b>
	NIH R01CA164021
	Co-Investigator (PI: Nancy Keating, BWH and HMS.)
	This project built on the CanCORS initiative and included patient and physician surveys as well as comprehensive medical records to examine the intensity of EOL care and expenditures among nearly 4,000 patients with advanced lung or colorectal cancer.
<b>2011-2017</b>	<b>Partnerships Between Medicaid, Tumor Registries &amp; Cancer Control Researchers</b>
	NIH KO5 CA169384
	PI
	This was a mid-career development mentoring award to expand Capacity for Tumor Registry-Medicaid-Medicare Data Linkages to Evaluate Cancer Care, evaluate the Quality and Effectiveness of Care for Medicaid Recipients with Cancer, and identify Specific Mechanisms that Explain Shortcomings and Design Interventions to Improve Care. This project led to the expansion of the NCI's SEER-Medicare linkage to include Medicaid linkages. The approach mirrored work we conducted in NY and CA tumor registry-Medicaid-Medicare linkages to evaluate cancer care quality and implementation of new treatments at the population level.

<b>2013-2015</b>	<b>Financial Consequences of Cancer Care in California</b>
	California Healthcare Foundation
	PI (\$500,000)
	This project evaluated the costs and value of cancer care delivery to Californians across categories of race, ethnicity, socioeconomic position, and comorbidity. It was used by the governor and health commissioner to set priorities, and target strategies to improve cancer care across CA.
<b>2013-2017</b>	<b>Post-treatment Surveillance in Breast Cancer</b>
	PCORI CE-1304-6543
	Co-Investigator (PI: Caprice Greenberg, MD, Brigham and Women's Hospital)
	The objective of this award was to develop risk-adapted approach to surveillance following breast cancer treatment.
<b>2013-2017</b>	<b>CRN4: Cancer Research Resources &amp; Collaboration in Integrated Health Care Systems</b>
	NIH U24CA171524
	Co-Investigator (PI: Lawrence Kushi, PhD, Kaiser Permanente, Northern California)
	Goals were to compare the effectiveness of alternative cancer treatments using Kaiser Permanente's large population.
<b>2013-2018</b>	<b>Improving the Informed Consent and Treatment Decision Making for Palliative Chemotherapy</b>
	PCORI CE-1304-6517
	PI (\$3,000,000)
	The major goal of this project was to improve patients' understanding of the benefits and risks of treatment in the setting of advanced cancer and thereby to improve goal concordant care delivery and quality of care.
<b>2013-2018</b>	<b>Clustered Semi-Competing Risks Analysis in Quality of End-of-Life Care Studies</b>
	NCI R01
	Co-Investigator (PI: Sebastien Haneuse PhD, HCSPH)
	The major goal of this project was to develop new statistical methods and software to evaluate quality of end-of-life cancer care in the US. The methods will be broadly applicable to all advanced health conditions, beyond cancer, such as Alzheimer's disease.
<b>2013-2018</b>	<b>Statistical Informatics for Cancer Research</b>
	NCI P01CA134294
	Co-Investigator (PI: Francesca Dominici PhD, HCSPH)
	This program project tackled a series of problems motivated by the analysis of high dimensional observational data arising in population-based studies of cancer.
<b>2015-2019</b>	<b>Esophageal Adenocarcinoma Screening, Treatment and Prevention</b>
	NCI R01CA140574
	Co-Investigator (PI: Chin Hur MD, Massachusetts General Hospital and then NY Presbyterian)
	This award sought to identify strategies that reduce EAC morbidity and mortality by using a simulation model to systematically evaluate the population-level impact of alternative EAC prevention, screening, and treatment strategies.
<b>2016-2020</b>	<b>Specialized Center - Cooperative Agreements EL CENTRO: Engaging Latinos in the CENTER of Cancer Treatment Options</b>
	NIH/NCI U54CA156732
	Co-Investigator (PI: V. Viswanath PhD, DFCI and HCSPH)
	The objective of this U54 study was to train students and early career stage faculty historically underrepresented in medicine in research. The specific goal of the project was to improve the quality of advanced cancer care and treatment decision making for Latinos with advanced cancer.
<b>2017-2019</b>	<b>Building the South American Center of Research Excellence to Counter Non-Communicable Diseases</b>

	NCI P20 CA217231
	Multi-PI (V. Irazola PhD, D. Schrag MD)
	The goal of this proposal was to develop the South American Center of Research Excellence in chronic non-communicable diseases to establish research programs and capacity building activities related to cancer and cardiovascular diseases prevention and control in South America
<b>2017-2019</b>	<b>Dana Farber/Harvard Cancer Center Administrative Supplement: Powering Precision Medicine in Pediatric Cancer Patients</b>
	NIH P30 CA006516-53S4
	Co-Investigator (PI: K. Janeway MD, DFCI and Boston Children's)
	The focus of this project was to accelerate capacity for precision medicine in pediatric cancer populations.
<b>2018-2020</b>	<b>PCF Challenge Award</b>
	Prostate Cancer Foundation
	Co-Investigator (PI: M. Pomerantz MD, DFCI)
	To estimate incremental effectiveness, cost-effectiveness, and cost-utility ratios for DDR germline mutation screening and risk-tailored management compared to no screening and standard management for men with, or at risk for, high-grade/locally advanced PC.
<b>2020-2021</b>	<b>PCF Challenge Award</b>
	Prostate Cancer Foundation
	Co-Investigator (PI: Eli Van Allen MD PhD, DFCI)
	A genomics-guided clinical interpretation and translational discovery engine for prostate cancer.

<b>2020-2023</b>	<b>Academic Career Skills for Junior Faculty Researchers</b>
	NIH/NCI UE5 CA246746
	Co-Investigator (MPIs: Dr. William Pirl and Dr. Jennifer Temel, MGH)
	This award was for development of early career stage faculty focused on cancer research.
<b>2019-2023</b>	<b>Precision Management of Cystic Precursors to Pancreatic Cancer</b>
	NCI R01CA237133
	Co-Investigator (PI: Pari Pandharipande Chair, Department of Radiology, Ohio State University)
	The purpose of this proposal is to optimize the management of incidentally detected cystic precursors of pancreatic cancer.
<b>2019-2023</b>	<b>Covid-19-related Cervical Cancer Treatment Interruption and Role of Neoadjuvant Chemotherapy</b>
	NIH R01CA236546
	Co-Investigator (PI: Scott Dryden-Peterson, BWH)
	A multilevel intervention to improve cancer detection and treatment initiation for patients with cervical cancer in Africa. The aim of this project is to develop, implement, and evaluate a multi-level intervention to improve cancer early diagnosis in under-resourced settings.
<b>2016-2022</b>	<b>Pragmatic Effectiveness Trial of Direct Oral Anticoagulants versus Low Molecular Weight Heparin</b>
	PCORI CER-1503-29805 \$5,000,000 in direct costs
	PI
	The goal of this award was to compare the relative benefits and burdens of DOACs versus LMWHs in management of VTE for patients with cancer. The first manuscript was published in JAMA in 2023.
<b>2017-2022</b>	<b>Training in Oncology Focused Population Sciences (TOPS)</b>
	NCI 5T32CA092203
	Founding MPI with Dr. N. Keating. Conceived this institutional postdoctoral training program

	This T32 provided support for postdoctoral fellows including PhDs and MDs focused on cancer-focused population sciences including clinical epidemiology, health services research and data science. Relinquished upon transition to MSK.
--	--

## N. MENTORING

### Mentees

*This list includes research mentees with whom I had significant sustained multi-year interactions. Clinical mentees and individuals with whom mentoring relationships are episodic are not listed.*

Name	Larissa Temple, MD
Site/Position	Surgical oncology and health services research fellow in Department of Surgery and Epidemiology and Biostatistics, MSK
Mentoring Period	2003-2007
Project	Improving quality of life for patients with rectal cancer (J Clin Oncol 2004; Dis Colon Rectum 2005; Ann Surg 2009)
Current Position	Chair Colorectal Surgery, and Professor of Surgery, University of Rochester, Rochester, NY

Name	Elena Elkin, PhD
Site/Position	Instructor to Assistant Level Phase, Department of Epidemiology and Biostatistics, MSK
Mentoring Period	2002-2007
Project	4 research manuscripts, primary mentor on her K07 award
Current Position	Professor Health Policy, Columbia University Medical School

Name	Ethan Basch, MD MSc
Site/Position	Oncology Fellow and Research Fellow to Assistant Professor in Dept of Epidemiology and Biostatistics, MSK
Mentoring Period	2003-2011
Project	Building a Platform for Patient-Reported Outcomes During Cancer Chemotherapy and later an NCI contract to develop the PRO-CTCAE K07 primary mentor.
Current Position	Goldberg Endowed Chair, Division Chief of Oncology at the University of North Carolina, Chapel Hill (Lineberger Cancer Center)

Name	Thomas Jang, MD MPH
Site/Position	Postdoctoral Health Services Research Fellow at MSK
Mentoring Period	2006-2007
Project	2 publications, Archives of Internal Medicine 2010; the Oncologist 2011
Current Position	Professor of Surgery, Robert Wood Johnson Medical School, Piscataway Township, NJ

Name	David Sher, MD, MPH
Site/Position	Radiation Oncology Resident and Postdoctoral Fellow in Health Services at DFCI and Harvard Medical School
Mentoring Period	2008-2011
Project	2 publications: (Int J Radiat Oncol Biol Phys. 2011; J Clin Oncol 2011)

Current Position	Professor and Chief of Head and Neck Radiation Oncology, University of Texas Southwestern
------------------	---

  

Name	Caprice Greenberg, MD MPH
Site/Position	Center for Outcomes and Policy Research DFCI, Instructor-Assistant Professor of Surgery
Mentoring Period	2008-2012
Project	3 publications, PCORI award Surveillance after Breast Cancer Treatment
Current Position	Professor and Chief of Surgery, University of North Carolina, Chapel Hill

  

Name	Rachel Yung, MD MPH
Site/Position	Medical Oncology Fellow and Postdoctoral Research Fellow in Health Services Research
Mentoring Period	2010-2012
Project	Remediating disparities in breast cancer treatment outcomes by age, socioeconomic status, and race. Oncologist 2011, JNCI 2012
Current Position	Associate Professor of Medicine at the Fred Hutchinson Cancer Center

  

Name	Dhruv Sharma, PhD
Site/Position	Postdoctoral Research Fellow in Data Science/Biostats Harvard Chan School of Public Health
Mentoring Period	2011-2013
Project	Comparative Effectiveness Research Methods 2 <sup>nd</sup> authored paper in JAMA 2012, Foundation awards
Current Position	Associate Professor of Biostatistics, Michigan State University

  

Name	Junya Zhu, PhD
Site/Position	Postdoctoral fellow in Health Services Research DFCI and HCSPH
Mentoring Period	2011-2013
Project	Minimizing bias in comparative effectiveness research 2 publications 1 in JAMA, 1 in the Oncologist
Current Position	Associate Professor, Johns Hopkins School of Public Health

  

Name	Gabriel Brooks, MD MPH
Site/Position	Postdoctoral research fellow and later Instructor in Medicine, DFCI HMS
Mentoring Period	2011-2016
Project	Primary mentor on ASCO Career Development Award 2015 Potentially avoidable hospitalizations in oncology and regional variation in Medicare spending and survival among older adults with advanced cancer. (JNCI 2013, Health Affairs 2014. JCO 2016)
Current Position	Associate Professor of Medicine, Dartmouth Hitchcock Medical School

  

Name	John Withington, MD
Site/Position	Commonwealth Fund, Harkness Fellow, Division of Population Sciences DFCI
Mentoring Period	2019-2020

Project	NHS White Paper: Differences in cancer policy between the US and the UK. Commonwealth Fellowship.
Current Position	Urologist, National Health Service, United Kingdom

Name	Christopher Lathan, MD, MS, MPH
Site/Position	Assistant Professor of Medicine, DFCI Harvard Medical School
Mentoring Period	2015-2020
Project	1 <sup>st</sup> author manuscript in JCO 2016, faculty recruits, new positions in organization. Provided research and career mentorship, increased the diversity of faculty and trainees at DFCI.
Current Position	Chief Diversity Equity and Inclusion Officer at DFCI in 2021, Associate Professor of Medicine, Harvard Medical School

Name	Nadine Jackson McCleary, MD MPH
Site/Position	Assistant Professor in Medicine, DFCI
Mentoring Period	2017-2021
Project	Mentored on Donahue Foundation award and co-authored several manuscripts.
Current Position	Associate Professor of Medicine, DFCI and HMS

Name	Michael Hassett, MD MPH
Site/Position	Instructor to Associate Professor career phase
Mentoring Period	2008-2020
Project	Primary mentorship on his CDA and co-I on R01 (JNCI 2011, JCO 2014, Annals of Internal Medicine 2014, Cancer 2016) now co-I on UM1
Current Position	Chief Quality Officer DFCI, Associate Professor at HMS

Name	Ken Kehl, MD MPH
Site/Position	Postdoctoral fellow to Instructor to Assistant Professor of Medicine
Mentoring Period	2016-2022
Project	K99/R00 and Doris Duke award. Site PI Project GENIE
Current Position	Assistant Professor of Medicine, DFCI and HMS

Name	Jennifer Yeh, ScD
Site/Position	Postdoctoral fellowship at the Harvard Chan School of Public Health and Instructorship at the MGH Center for Decision Sciences
Mentoring Period	2013-2016
Project	Mentor on her K08 to study and mitigate late effects of cancer treatment in the AYA population with focus on late cardiotoxicity.
Current Position	Associate Professor, Boston Children's Hospital and HMS

Name	Hanna Sanoff, MD
Site/Position	Medical Oncology Fellow at the University of North Carolina, then Assistant Professor
Mentoring Period	2008-2012

Project	Mentor on her K07 award Comparative effectiveness of treatment for Hepatocellular Cancer and several publications on comparative effectiveness of cancer treatment using SEER-Medicare data
Current Position	Professor of Medicine, University of North Carolina

Name	Matthew Mossanen, MD
Site/Position	Instructor, BWH
Period	2017-2021
Project	Comparative effectiveness research in prostate cancer and pre-rehabilitation to improve outcomes of cystectomy.
Current Position	Assistant Professor of Surgery, BWH and HMS

Name	Charlotta Lindvall, MD
Site/Position	Instructor, Assistant Professor, DFCI and Harvard Medical School
Period	2018-2021
Project	Optimizing symptom control for patients with advanced cancer using machine learning algorithms
Current Position	Assistant Professor, Department of Psychosocial Oncology and Palliative Care, DFCI and HMS

Name	Irbaz Riaz, MD
Site/Position	Postdoctoral Research Fellow
Period	2020-2021
Project	Genomic-phenomic data linkages to improve care for prostate cancer. (Co-mentor with Eli Van Allen).
Current Position	Assistant Professor of Medicine, Mayo Clinical School of Medicine, Rochester, MN

Name	Eleni Stavrou, MD
Site/Position	Medical Oncology Fellow, Dana Farber-Mass General Fellowship program
Period	2020-2021
Project	Evaluating patients and clinicians' preferences for telehealth beyond the pandemic
Current Position	Assistant Member in Breast Oncology, MSK

Name	Sun Young Kim, MD
Site/Position	Visiting Associate Professor of Medicine from Seoul, South Korea.
Period	2020-2021
Project	Optimizing quality of life for patients with rectal cancer. Health Ministry of South Korea.
Current Position	Associate Professor of Medicine, Seoul South Korea

Name	Catherine Marinac, PhD
Site/Position	Postdoctoral fellow, then Instructor in Medicine, DFCI
Period	2020-2022

Project	Cancer screening using blood-based assays: challenges to implementation and opportunities to address disparities. Several publications and K99 award.
Current Position	Assistant Professor, Division of Population Sciences, DFCI and HMS

Name	David Merola   PhD candidate
Site/Position	Candidate for PhD in Epidemiology, Harvard Chan School of Public Health. Co-mentor with Sebastian Schneeweiss, BWH
Period	2020-2021
Project	Simulation to predict outcomes for patients underrepresented in clinical trials
Current Position	Pharmacoepidemiologist in Industry

Name	Ottavia Zattra   MD candidate
Site/Position	Candidate for MD at Harvard Medical School
Period	2020-2021 full time research year
Project	Factors predisposing patients with cancer to get COVID-19 and to recover from COVID-19.
Current Position	Internal Medicine Resident at the University of Pennsylvania

Name	Andrea Enzinger, MD MPH
Site/Position	Fellowship to Assistant Professor phase
Mentoring Period	2011-2021
Project	Multiple projects related to advancing symptom control and end of life care. Primary mentor on K07 award, advisor on first R21 and R01. Multiple 1 <sup>st</sup> author publications.
Current Position	Assistant Professor, Division of Population Sciences, DFCI and HMS R01 funded independent investigator

Name	Shruti Gupta, MD, MPH
Site/Position	Mentored during postdoctoral fellowship-Instructorship career phase
Mentoring Period	2020-2021
Project	Co-mentor with David Leaf on her K23 evaluating renal toxicity of immunotherapy and chemo/immunotherapy. 2 publications
Current Position	Assistant Professor in the Division of Nephrology, BWH and HMS

Name	Christopher Manz, MD, MPH
Site/Position	Mentored during postdoctoral fellowship-Instructorship career phase at DFCI, HMS
Mentoring Period	2020-2024
Project	2 publications, Cancer in Incarcerated Patients, R01 funded
Current Position	Assistant Professor of Medicine, Division of Population Sciences, DFCI and HMS

*Significant mentoring roles:* In addition to the trainees listed above, I have served as a co-mentor or an advisor for trainees working primarily with other faculty and have served as a co-mentor or advisor on training grants including

K07s, K08s, K99s from NCI, NHLBI, NIA as well as Doris Duke, Damon-Runyon ASCO, ASH, AACR and American Cancer Society Career Development awards to over 50 medical oncology, pediatric oncology, radiation oncology, general internal medicine and surgery residents and fellows as well as to postdoctoral research fellows with PhDs in health services, biostatistics, epidemiology, health communications, behavioral science and health economics.

I served as a core faculty member from 2008 through 2020 in the Harvard School of Public Health’s Intensive Summer Training Program in Clinical Effectiveness. This involved approximately 40 contact hours of mentoring and reviewing project proposals each summer. Individual mentees are not listed.

In 2017, at DFCI/HMS served as founding co-PI with Dr. Nancy Keating of TOPS—an NCI funded T32 training program in oncology focused population sciences for postdoctoral fellows (PhDs and MDs). I had a significant mentoring role with each trainee between 2017 and 2021.

In 2022, at MSK/WCM was founding co-PI with Dr. Katherine Panageas of OPTICS—an NCI funded T32 training program focused on cancer care delivery research. Significant mentoring roles with program trainees.

**O. INSTITUTIONAL LEADERSHIP ACTIVITIES**

<i>Role(s)/Position</i>	<i>Institution/Location</i>	<i>Dates</i>
Co-Chair, Junior Faculty Council (with R. DeMatteo)	MSK	2003-2005
Chair, Committee on Institutional and Clinical Research Data	MSK	2003-2006
Deputy Associate Director, Population Sciences	Dana Farber / Harvard Cancer Center Cancer Center Support Grant (NCI Funded P50) Hereafter: (DF/HCC)	2008-2017
Population Sciences Steering Committee	DF/HCC	2011-2017
Core Faculty, Program on Clinical Effectiveness	Harvard Chan School of Public Health	2008-2020
Chair, Clinical Data Governance	DFCI	2011-2017
Chair, Avoidable Hospitalizations Committee	DFCI/BWH	2013-2016
Chair, Dana Farber/Brigham and Women’s Cancer Center (DF/BWCC) Quality Improvement Committee	DFCI/BWH	2013-2019
Co-Chair, Clinical Operations and Research Information System (CORIS)	DFCI	2013-2021
Chief, Division of Population Science and the McGraw Patterson Center for Population Science	DFCI	2013-2021
Member, Committee on Promotions and Appointments	DFCI	2014-2017
Co-Chair, Committee on Promotions and Appointments (with Dr. Todd Golub)	DFCI	2018-2021

Chair of three ad hoc committees for Professorial promotion	BWH/MGH	2015-2020
Member, Memorial Hospital Committee on Appointments and Promotions	MSK	2021-Present
Member, Cancer Center Committee on Appointments and Promotions	MSK	2021-Present

**P. INSTITUTIONAL CITIZENSHIP and ADMINISTRATIVE ACTIVITIES**

*Between 1994-1998 and between 2008 and 2021, institutional activities refer to Dana Farber Cancer Institute (DFCI as well as its affiliates Brigham and Women’s Hospital (BWH), Harvard Medical School (HMS) and the Harvard Chan School of Public Health (HCSPH) in Boston, MA. Between 1999 and 2007 and from September 2021, institutional activities refer to Memorial Sloan Kettering Cancer Center (MSK) in New York, NY.*

<b>Name of Committee</b>	<b>Role</b>	<b>Organization Institution/Location</b>	<b>Dates</b>
Search Committee for Physician-in-Chief	Member	MSK	2001-2002
Department of Medicine, Quality Assurance Committee	Member	MSK	2001-2006
Internal Funding Award Review Committees for Outcomes Research	Member	MSK	2001-2007
Department of Medicine, Fellowship Selection Committee	Member	MSK	2003-2007
Quality Evaluation Committee	Member	MSK	2005-2007
Search for Chair of Breast Surgery	Member	MSK	2006-2007
Scientific Progress Review Committee	Member	DFCI	2008-2015
Search for Chair of Nursing Research	Member	DFCI	2008-2009
DF/HCC Gastrointestinal Cancer Program Leadership Committee	Member	DFCI	2009-2011
Dean’s Committee on Comparative Effectiveness Research	Member	Harvard Medical School (HMS)	2010-2012
Residency Selection Committee	Member	Brigham and Women’s Hospital (BWH)	2010-2015
Search Committee for Chair of Medical Oncology Fellowship Program	Member	DFCI	2011-2012
Women’s Faculty Committee	Member	DFCI	2010-2012
Strategic Planning Research Committee	Member	DFCI	2012-2015
International Physician Advisory Committee	Member	DFCI	2012-2014
Research Computing Planning	Member	DFCI	2012-2015
Steering Committee for NCI Funded R25 Training Grant: Program in Cancer Outcomes Research Training (PCORT)	Member	DFCI, MGH, and BCH	2012-2017
Partners eCare Research Council (Steering Committee that Coordinated Transition to the EPIC health record	Member	Partners Healthcare (later known as	2013-2017

and established policies and governance related to research reliant on the EHR)		Massachusetts General Brigham or MGB)	
Faculty Search Committees	Member	HCSPH	2013-2021
Member, Executive Committee for Clinical Research	Member	DFCI	2013-2021
International Medical Services Committee	Member	BWH	2011-2014
Casty Award in Mentoring Selection Committee	Member	DFCI	2013-2020
Search Committee for Chair of the Department of Medicine, Cambridge Health Alliance	Member	Beth Israel Deaconess Medical Center (BIDMC), and HMS	2015-2016
Ad Hoc Promotion Committee for 5 faculty	Member	HMS, HCSPH	2015-2018
Search Committee for President and CEO	Member	DFCI	2015
Ad Hoc Review Committee for Proposed Appointment of faculty in Departments of Surgery (3), Radiology (1) Palliative care (2), Pathology (1) Informatics (2), Radiation Oncology (1)	Member	BWH, MGH, HMS	2015-2020
Ad Hoc Search Committee for Vice-Chair for Psychosocial Oncology and Palliative Care	Member	DFCI, HMS	2016
Search Committee for Chair of the Department of Biostatistics and Computational Biology at DFCI and Professor of Biostatistics at the Harvard Chan School	Member	DFCI, HCSPH	2016
Ad Hoc Search Committee for Professor of Medicine at Harvard Medical School and Chief of the Gastroenterology at Massachusetts General Hospital	Member	MGH and HMS	2018
Massachusetts Cancer Registry Advisory Committee Steering Committee	Member	MA Department of Public Health	2015-2021
Search Committee for Faculty in Cancer Epidemiology	Member	HCSPH	2018
Faculty Search Committee for Health Informatics/Machine Learning	Member	DFCI, HMS	2018
Committee on Diversity, Equity, and Inclusion	Member	DFCI, HMS	2019-2021
Cantor Center Steering Committee	Member	DFCI	2019-2021
Ad Hoc Search Committee for Director of the BIDMC Cancer Center	Member	BIDMC and HMS	2020-2021
Ad hoc Search Committee for Professor of Data Sciences and Informatics	Member	Harvard University Faculty of Arts and Sciences, HCSPH	2021
Steering Committee: Enterprise HER	Member	MSK	2022
Hospital Steering Committee	Member	MSK	2023
EPIC Executive Steering Committee	Member	MSK	2023
Steering Committee: Practice Plan Redesign	Member	MSK	2024
Search Committee for Chair of the Department of Human Oncology and Pathogenesis Program	Member	MSK	2024
Search Committee for Chief Medical Officer	Member	MSK	2024

Search Committee for Chair of the Department of Psychiatry & Behavioral Sciences	Member	MSK	2024
Search Committee for Chair of the Department of Epidemiology, Biostatistics and Computational Oncology at Memorial Sloan Kettering	Member	MSK	2025
Sponsor of the Clinical Undergraduate Research Experience (CURE) for College Students	Faculty Sponsor	MSK	2025
Sponsor of the Accelerated Review in Medical Oncology Course	Faculty Sponsor	MSK	2025

**Q. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES**

**Leadership in Extramural Organizations**

<b>Role</b>	<b>Organization</b>	<b>Dates</b>
Co-Chair Cancer Control and Health Outcomes	Cancer and Leukemia Group B (CALGB), Chicago, IL	2004-2009
<b>Chair, Health Services Research Committee</b>	<b>American Society of Clinical Oncology</b>	<b>2004-2007</b>
Chair, Colorectal Cancer (CRC) Database	National Comprehensive Cancer Network (NCCN), Fort Washington, PA	2005-2010
Elected Member, Board of Directors	American Board of Internal Medicine (ABIM), Philadelphia, PA	2007-2012
<b>Elected Member, Board of Directors</b>	<b>American Society of Clinical Oncology</b>	<b>2008-2012</b>
<b>Service on working groups, ad hoc panels and smaller meetings from 2013 onwards (QOPI advisory, QOPI steering, clinical practice guidelines, Education, Diversity, Cancer-Linq among others)</b>		<b>2013-</b>
Executive Committee	Cancer and Leukemia Group B (CALGB), Chicago, IL	2008-2013
Chair, Colorectal Cancer Committee	National Comprehensive Cancer Network, Fort Washington, PA	2008-2013
Associate Editor, JNCI	Journal of the National Cancer Institute	2012-2014
Member, National Cancer Policy Forum Planning Committee member and co-chair for 5 workshops	Institute of Medicine, Washington DC	2014-2020
Associate Editor, JAMA	Journal of the American Medical Association, Chicago, IL	2014-2023
Member	Rectal-Anal Cancer Task Force, NCI Cancer Treatment and Evaluation Program	2015-Present
Member, Board of Trustees	Board of Trustees, Alliance for Clinical Trials in Oncology, Chicago, IL	2016-Present
Member, External Scientific Advisory Board	Mount Sinai Cancer Center	2017-2021
Member, External Scientific Advisory Board	University of North Carolina, Lineberger Cancer Center	2016-Present

Member, External Scientific Advisory Board	Ontario Institutes for Cancer Research	2018-Present
Member, External Scientific Advisory Board	University of Pittsburgh, Health Policy and Epidemiology Department	2022-present
Member, External Scientific Advisory Board	Mayo Clinic Cancer Center	2023-Present
Member, External Scientific Advisory Board	BU-BMC Cancer Health Equity Research Center (CHERC)	2024-Present
Member, External Advisory Board	Princess Margaret Cancer Center	2024-Present

#### Other Service on National Committees

Name of Committee	Role	Organization Institution/Location	Dates
Clinical Economics Core	Member	Cancer and Leukemia Group B	1999-2005
Cancer Control and Health Outcomes	Member, Vice Chair	Cancer and Leukemia Group B	2002-2007
Health Services Committee	Cadre Member	Cancer and Leukemia Group B	2003-2008
Panel on Cancer Care Quality	Member	Institute of Medicine, Washington, DC	2004-2006
Colorectal Cancer Panel	Member	National Quality Forum, Washington, DC	2004-2007
Outcomes Database Steering Committee	Member	National Comprehensive Cancer Network, Fort Washington, PA	2004-2013
Quality Metrics Committee	Member	NCCN-ASCO, Alexandria, VA	2005-2006
Medicare Coverage Advisory Committee (MCAC) (now Medicare Evidence Development and Advisory Committee)	Member	Center for Medicare and Medicaid Services, Baltimore, MD	2005-2008
Cancer Survivorship Committee	Member	Institute of Medicine	2006-2008
Advisory Board	Member	Cancer Research Network (CRN), Bethesda, MD	2006-2011
Advisory Panel on Post-Treatment Surveillance	Member	National Cancer Institute (NCI), Bethesda, MD	2007
Comparative Effectiveness Research Working Group	Chair	Alliance for Clinical Trials in Oncology	2010-2012

Search Committee for New PI for the CRN	Member	Cancer Research Network, Bethesda, MD	2011
Scientific Review Committee for the Cancer Research Network	Member	National Cancer Institute	2011-2013
Strategic Planning Committee for Combined Cooperative Group	Member	CALGB- North Central Cancer Treatment Group (NCCTG)- American College of Surgeons Oncology Group (ACOSOG)	2011
Colorectal Cancer Clinical Trials Planning Workshop	Member	National Cancer Institute	2011
NCI Directors' Provocative Questions Workshop	Member	National Cancer Institute	2011
Special Awards Selection Committee	Member	ASCO	2012-2015
Health Policy Task Force	Member	American Association for Cancer Research (AACR)	2012-2021
Quality Metrics in Cancer Medicine	Member	National Quality Forum	2012-2015
Defining High Value Cancer Care	Workshop Leader	Institute of Medicine	2013
Provocative Questions Workshop (#2)	Invited Participant	National Cancer Institute (NCI) Bethesda, MD	2013
Charles A. King Trust Clinical and Health Services Research Awards Committee	Member	The Medical Foundation	2013-2019
National Cancer Policy Forum Planning Committee, Workshop on Patient Access to Cancer Drugs	Workshop Co-Chair and Planning Committee Member	Institute of Medicine	2014
Oncology Drugs Advisory Committee	Ad hoc Member	Food and Drug Administration, Washington DC	2015, 2017, 2018
Advisor to California Health Policy Commission	Ad hoc Member	California State Legislature, Sacramento, CA	2015-2018

External Advisory Board, Institute for Cancer Outcomes	Member	University of Alabama Comprehensive Cancer Center, Birmingham, AL	2016
National Center for Health Statistics Committee on the future of Population-Based Surveys	Member	National Center for Health Statistics, Washington, DC	2017-2018
Board of Trustees, Alliance for Clinical Trials in Oncology Foundation	Member	The Alliance for Clinical Trials in Oncology	2017-2020
Scientific Advisory Committee	Member	Value in Cancer Care Consortium	2017-2020
Massachusetts Health Policy Commission	Member	Payment Reform in Oncology	2018-2021
External Advisory Board	Member	The Lymphoma Epidemiology Outcomes (LEO) Cohort Study (P01)	2019-
Assistant Secretary of Health and Human Services for Planning and Evaluation for Chronic Care Delivery	Advisor	Department of Health and Human Services, Washington, DC	2019-2020
Center for Medicare and Medicaid Services	Advisor	Next Generation Oncology Performance, Washington, DC	2018-2020
Committee on Implications of Discarded Weight-Based Drugs	Member	National Academies of Sciences, Engineering, and Medicine's (The National Academies)	2019-2021
Modernizing Staging Algorithms	Member	American College of Surgeons	2020
Colorectal Cancer Alliance's Medical Scientific Advisory Committee (MSAC)	Member	Colorectal Cancer Alliance	2020
The Oncology Quality, Characterization and Assessment of Real-World Data (QCARD) initiative	Member	The Food and Drug Administration (FDA)	2021-2023
Medical Devices Advisory Committee	Standing Panel Member	The Food and Drug Administration	2023-2027

National Academy of Medicine (NAM)	Member	Internal Medicine, Pathology, and Dermatology Committee	2025-Present
------------------------------------	--------	---	--------------

**International**

<b>Name of Committee</b>	<b>Role</b>	<b>Organization Institution/Location</b>	<b>Dates</b>
Strategies and Standards for Delivery of Colorectal Cancer Treatment	Advisor	National Health Services, United Kingdom	2004-2006
Strategic Planning for Cancer Care Quality	Consultant	Swedish Health Ministry	2008-2011
I Data and Cancer Care Delivery	Advisor	Kupat Cholim, Israel Health Care System, Tel Aviv, Israel	2014-2016
Cancer Care Quality Evaluation	Advisor	French Ministry of Health, Paris France	2015-2017
Cancer Care Delivery and Reimbursement Policy, Ministry of Health	Advisor	Ministry of Health, Jerusalem, Israel	2015-2018
Strategic Initiatives in Cancer Population Science	Advisor	Cancer Research United Kingdom, London, UK	2016-2017
External Advisory Board, Cancer Care Ontario	Member	Ontario Institute for Cancer Research, Toronto, Ontario	2017-Present
External Advisory Board	Member	Princess Margaret Cancer Center	2024-Present

**Grant Reviewing/Study Sections (Selections, does not include institutional review)**

<b>Role(s)</b>	<b>Organization Name</b>	<b>Dates</b>
Member, Study Section for Program Projects in Population Sciences	National Cancer Institute, Rockville, MD	2003-2005
Member, Survivorship Awards Review Committee	MSK	2003-2006
Member, Review Committee for Boyer Awards	MSK	2005-2007
Health Services Study Section Ad Hoc Member (5 times)	National Institute of Health, Bethesda, MD	2005-2008, 2012-2016

Member, Catalyst Program, Grant Review Committee	HMS	2008-2009, 2011-2014
Member, Study Section Special Emphasis Panel for Review of Applications to Foster Systems of Care Coordination	National Institute of Health Bethesda, MD	2008
Member, Special Emphasis Panel to review Complex Patients and Comparative Effectiveness Research	Agency for Healthcare Research and Quality, Bethesda, MD	2010
Member, Special Emphasis Panel in Population Sciences: Building New Clinical Infrastructure for Comparative Effectiveness Research	Agency for Healthcare Research and Quality, Bethesda, MD	2010
Member, U54 Grant Application Review Committee	University of Massachusetts Boston– Dana Farber/Harvard Cancer Center,	2010-2016
Standing Member, Health Services Organization and Delivery Study Section (Served Several times as Study Section Chair)	National Institutes of Health, Center for Scientific Review Bethesda, MD	2013-2018
Comparative Effectiveness Research Ad hoc reviewer	Patient Centered Outcomes Research Institute, Washington, DC	2015-2017
Cancer Care Delivery Research Ad hoc reviewer	KWF-Dutch Cancer Society, Amsterdam, Netherlands	2016
Cancer Care Quality and Control Ad hoc reviewer	National Health Service, London, United Kingdom	2017
Grant Reviewer for the UK's NHS	National Health Service, United Kingdom	2018
Health Services Research-Exception Panel Member	National Institutes of Health, Center for Scientific Review Co-Chair, Bethesda, MD	2019-2021
Ad hoc reviewer P01 Review Panels, 3 times	National Institutes of Health, Center for Scientific Review Co-Chair, Bethesda, MD	2015-2019
Review Board for the New York Polyethnic-1000 project Study Section Chair	New York Genome Center, New York, NY	2020
Grant Reviewer for Ministry of Health's Cancer Control Portfolio	Government of Germany, Ministry of Health	2021
Other service as reviewer of funding proposals (Not as standing panel member)	Patient Centered Outcomes Research Institute (PCORI), AHRQ, FDA, the Center for Medicare and Medicaid Innovation (CMMI)	2012-2019

## Editorial Activities

Journal Reviewing/ad hoc reviewing This list includes journals for which I have served as a peer reviewer over a multi-year period and have reviewed 3 or more manuscripts including original research, editorials, reviews, guidelines, commentary, and opinion.

Journal / Organization Name	Dates (1 <sup>st</sup> year)
New England Journal of Medicine (NEJM) (Recognized for reviewing >3 manuscripts/year in 3 of the past 5 years thru 2022)	1998-
Journal of the American Medical Association (JAMA)	1998-
JAMA Oncology	2014-
JAMA Internal Medicine	2002
Journal of the National Cancer Institute (JNCI)	2002-
Journal of Clinical Oncology (JCO)	1998-
Journal of Oncology Practice	2005-
Medical Care	2007
Cancer	2005-
Annals of Internal Medicine	2000-
Nature	2017
Health Services Research	2011
Health Affairs	2005
Lancet Oncology	2015
The Oncologist	2007
Health Economics	2001-
The Journal of General Internal Medicine	2003-
Clinical Cancer Research	2016-
Cancer Discovery	2019-

## Editorial Board Membership

Role	Board/Organization Name	Date(s)
Editorial Board Member	Journal of Clinical Oncology	2001-2004 2006-2009 2015-2020
Editorial Board Member	Journal of the National Comprehensive Cancer Network	2006-2020
Associate Editor	The Journal of National Comprehensive Cancer Network	2010-2014
Editorial Board Member	Gastrointestinal Cancer Research	2012-2017
Associate Editor	Journal of the National Cancer Institute	2012-2014
Associate Editor	Journal of the International Society of Gastrointestinal Oncology	2013-2016
Associate Editor	Journal of the American Medical Association (JAMA)	2014-2023

## R. INVITED AND/OR PEER-SELECTED PRESENTATIONS

### Local Presentations

- This list starts in 2000 and includes research-focused presentations only. It includes approximate number of internal presentations and topics. It does not include small seminars, workshops, and presentations at lab

meetings. It does not include educational seminars for clinical trainees or seminars delivered while serving as a PI of T32s in Cancer focused Population Sciences.

- Between 2000-2007 and from September 2021 to the present, local presentations refer to those at Memorial Sloan Kettering (MSK) and/or at Weill-Cornell Medical College (WCM); both in New York, NY.
- Between 2008 and August 2021, local presentations refer to those at Dana Farber Cancer Institute (DFCI), Dana Farber Harvard Cancer Center (DF/HCC), Brigham and Women’s Hospital (BWH), Harvard Chan School of Public Health (HCSPH), Harvard Medical School (HMS), and/or Beth Israel Deaconess Medical Center (BIDMC). All these organizations are in Boston, MA. Similar versions of some presentations were given to multiple departments.
- Presentations from March 2020 through 2021 were primarily delivered by zoom or in hybrid format and are incompletely listed.
- Presentations to the community including local government as well as those for fundraising, philanthropy, community outreach and for recruiting are not displayed.

<b>Title</b>	<b>Institution</b>	<b>Dates</b>
The Impact of Hospital Procedure Volume on Outcomes Following Colon Cancer Surgery/Grand Rounds	Department of Medicine, MSK	2000
The Evidence for Volume Outcome Relationships in Cancer Surgery: Is it Robust Enough to Influence Policy?	Department of Surgery, (WCM)	2001
Using Administrative Data for Evaluating Quality of Cancer Care	Department of Public Health, WCM	2002
Measuring Dissemination and Effectiveness of New Cancer Treatments Using Population Based Data	Department of Medicine, MSK	2002
What We Know About the Quality of Care for Patients with Colorectal Cancer	Department of Surgery, MSK	2003
Adjuvant Treatment Decision-Making for Patients with Stage II Colon Cancer	Department of Surgery, MSK	2004
Measuring the Quality of Cancer Care	Department of Urology, MSK	2006
Overview of Pay for Performance Initiatives	Department of Medicine, MSK	2006
Comparative Effectiveness and the Future of Oncology Research (Medicine Grand Rounds)	Department of Medicine, MGH	2009
Cancer Care Delivery in Medicaid	Department of Health Policy, HCSPH Department of Health Policy, HMS Department of Medicine, BIDMC	2009 2010
The Ethics of Incorporating Cost Considerations into Therapeutic Encounters in the Context of Advanced Cancer	Department of Ethics, HMS Department of Medicine, BWH	2009 2009
Coordinating Care: Who Is Going to Do It and How? And other topics in cancer care delivery and cancer economics	Partners Health Future of Health Symposium	2009, 2011, 2012, 2014
Disparities in Cancer Survival for the Medicaid Insured: Causes and Solutions	DFHCC Member Retreat	2010
Eliminating Disparities in Breast Cancer Care for Women Insured by Medicaid	Department of Medical Oncology, DFCI Department of Medicine, BWH	2010 2010

The Next Frontier in the War on Cancer: The War on Cancer 40 Years Later	HMS Faculty Symposium	2010
Comparative Effectiveness Research in Oncology	Department of Medical Oncology, DFCI	2011
Personalizing Treatment for Locally Advanced Rectal Cancer	DFCI, also at MGH, BIDMC, BWH in Depts of Medicine, Surgery and Radiation Oncology	2012 and 2013
Evaluating the Quality and Outcomes of Care for Medicaid Insured Women with Breast Cancer	Cancer Center Grand Rounds, MGH	2013
Survivorship Research: Challenges and Opportunities, Cancer Survivorship: Optimizing Care and Outcomes	CME Course at DFCI	2014, 2016, 2017, 2018
Integrating Patient Reported Outcomes into Efficacy and Effectiveness Research	DFCI	2015-2018
Health Insurance Expansion and Cancer Care: Preliminary Evidence of the Effect on Treatment and Survival Outcomes	Departments of Medicine, Health Care Policy, Epidemiology at DFCI, MGH, BWH and HCSPH	2015 and 2016
Impact of ACA Reform on Cancer Screening Treatment and Prevention	HMS Health Care Policy Symposium	2015
Global Economics of Cancer Development and Population Impact Panel	Partners Healthcare World Medical Innovation Forum	2016
Integrating Patient Reported Outcomes (PROs) into Cancer Research and Clinical Care Patient-centered Comparative Effectiveness Research Center (PCERC)	BWH	2016
The Efficacy-Effectiveness Divide in Outcomes of Cancer Treatment	Department of Epidemiology, HCSPH	2017
A Roadmap for Strengthening the National Data Ecosystem to Decrease Cancer Disparities	Department of Health Care Policy, HMS	2017
The GENIE Consortium: Measuring the Impact of Next Generation Sequencing and Precision Medicine	Department of Medical Oncology, DFCI	2018
Patient Reported Outcomes: Past Present and Future Opportunities	Department of Medicine, BWH	2018
Strategies to Improve Phenomic Data	Department of Medical Oncology, DFCI	2018
Life of a Clinical Trial: From a Good Idea to Recruiting Patients and their Physicians	DFHCC	2019
Cancer Care Delivery Research using the Electronic Health Record	Department of Health Care Informatics, HMS	2020
Opportunities and Pitfalls of Cancer Screening using Blood-Based Assays-DF/HCC Symposium	DFHCC Population Sciences Retreat (held virtually due to pandemic)	2020
Genomic-Phenomic Data Linkages to Measure Impact of Precision Medicine	HCSPH Symposium	2020 (virtual)

Research Seminars on Various Topics in Cancer Focused Health Services Research and Population Sciences	Division of Population Sciences, DFCI Population Sciences Program, DFHCC	Annually 9/2007- 7/2021
Research Seminars on Topics in the Future of Cancer Care Delivery, Health Services Research and Population Sciences	MSK, to the Department of Medicine, Department of Surgery, Cancer Center's Population Sciences Research Program, Faculty Retreats, Division Seminars	2021-2023 ~2/month

### Regional Presentations

- This list includes presentations in the greater New York, NY metropolitan region, but not at MSK or WCM between 1999 and 2007.
- This list includes presentations in the greater Boston, MA, metropolitan region, but not at one of the Harvard affiliated institutions listed above between 2008-2021.

Title	Institution	Dates
Evaluating Patterns and Outcomes of Cancer Care Using SEER-Medicare	Irving Cancer Center of Columbia University, New York, NY	1999
Patterns of Care Among Patients with Colorectal Cancer: Insights from SEER-Medicare	New York City Health Department	2000
Decision Analysis to Inform Clinical Trial Design	University of Medicine and Dentistry, Robert Wood Johnson Medical School, Piscataway, NJ	2000
Integrating the Results of Decision Analyses into Clinical Practice: A Roadmap	International Center for Health Outcomes and Innovation Research (INCHOIR) Columbia University, NY, NY	2001
Do We Deliver What Works? Adjuvant Treatment for Patients with Stage III Colon Cancer	Department of Medicine, Mt. Sinai Hospital, New York, NY	2002
Cancer Registries and Improving Cancer Care Delivery	NYU Department of Medicine, New York, NY	2002
The High Cost of Targeted Cancer Chemotherapy: Strategies for Discussing Benefits and Risks with Patients	New York Cancer Society, NYU Cancer Center, New York, NY	2003
Quality of Care for Colorectal Cancer	New York City Department of Health, New York, NY	2003
Dissemination of New Chemotherapy Treatments/Seminar	Department of Medicine, Mt. Sinai Medical School, New York, NY	2005
Strategies to Improve the Quality of US Cancer Care/Seminar	Chemotherapy Foundation Symposium, New York, NY	2005

What We Do and Don't Know About Geriatric Oncology	New York University Bellevue Medical Center	2007
Racial, Ethnic, and Socioeconomic Disparities in US Cancer Care and Strategies to Overcome Them	Harlem Hospital Medical Center Harold Freeman Symposium	2007 2008
Linking Public Health Data Systems to Improve Cancer Care Delivery	New York State Department of Health, Albany, NY	2007
Patient and Physician Attitudes Towards the Escalating Costs of Cancer Treatment	Therapeutic Insight Industry-Academia- Government Roundtable, New York, NY	2008
Eliminating Disparities in Cancer Treatment Outcomes	Presidential Symposium, St. Luke's Hospital, New Bedford, MA	2009
Financial Toxicity: Coping with High-Cost Treatments: Patient, Provider and Policy Perspectives	Department of Medicine, Lahey Clinic, Burlington, MA	2009
From Efficacy to Effectiveness: A Two-day Symposium and Workshop on the Future of Health Care	Radcliffe Institute for Advanced Study, Cambridge, MA	2010
Selective Use of Radiation in Rectal Cancer, 36 <sup>th</sup> Annual Alumni Conference	MSKCC, New York, NY	2011
Examining the Role of Real-World Evidence in Personalizing Health Care	Personalized Medicine Conference, Cambridge, MA	2017
Leveraging "Real World Data" to Accelerate Progress in Cancer Medicine: Opportunities and Obstacles.	Department of Economics, Massachusetts Institute of Technology	2017
Investing in Phenomics to Enhance the Value of Genomic Data	Broad Institute Data Science Symposium, Massachusetts Institute of Technology	2018
"Real World" data standards for curation of longitudinal cancer treatment outcomes: the PRISMM framework	AACR Precision Medicine Training Workshop Boston, MA	2018, 2019
ASCO Quality of Care Symposium (presentations in ~7 of past 10 years on various topics in cancer care delivery)	Annual Symposium on Cancer Care Quality, Boston Marriott Copley Place,	2021
Mobile and Wearable Health Technologies and the Future of Cancer Care	Conference on the Future of Mobile Health Care Technology, Harvard Business School	2021
PROSPECT Trial: De-escalation of treatment and consideration of quality of life in young patients with rectal cancer	Young-Onset Colorectal Cancer Center's Annual Patient and Family Forum, Boston, MA	2024
Blood Based Tests for Cancer Screening: Opportunities and Obstacles	Baptist Health South Florida, Boca Raton Regional Hospital Internal Medicine Symposium, Boca Raton, FL	2025 (Virtual)

Effective and Safe Telehealth Delivery and Remote Patient Monitoring	NCCN Annual Conference 2025, Orlando, FL	2025
Blood Based Tests for Cancer Screening: Opportunities and Obstacles	University of Nebraska Grand Rounds, Omaha, NE	2025
Keynote Lecture	Holden Comprehensive Cancer Center Retreat, Iowa City, IA	2025 (Virtual)

## National Research Presentations

Abbreviations:

- American Society of Clinical Oncology=ASCO
- American Association of Cancer Research=AACR
- National Cancer Institute=NCI and National Institutes of Health=NIH

Title	Institution/Location	Dates
Effectiveness and Cost-Effectiveness of Prophylactic Surgery for Individuals with Germline Mutations in BRCA genes	ASCO Annual Meeting	1997
Decisions about Prophylactic Surgery for Women with BRCA1 and BRCA2 mutations	NCI, Division of Cancer Control and Prevention	1998
Medical Decision Making for Carriers of BRCA1 and BRCA2 Mutations	Women's Health Initiative NIH, Santa Fe, NM	1998
Decision Analysis to Inform Treatment Selection for Patients with Germline Cancer Susceptibility, Oral Presentation	ASCO, Los Angeles, CA	1999
Measuring the Quality and Equity of Cancer Care	Department of Medicine, University of Chicago, Chicago, IL	2000
Gleaning Information About Hospital Characteristics using American Hospital Association (AHA) and Hospitals Cost Reports Information System (HCRIS) Data/Seminar	SEER-Medicare Investigators Meeting, National Cancer Institute, Bethesda, MD	2000
Understanding Volume-Outcomes Relationships, Strengths, and Limitations of Existing Analyses/Cancer Symposium	Centers for Disease Control, Atlanta, GA	2000
Health Service Research Oral Presentation Session/Annual Meeting	American Society of Clinical Oncology, San Francisco, CA	2001
Disentangling the Role of Hospital and Surgeon as Determinants of Outcomes Center Following Cancer Surgery/Seminar	Cancer Prevention Series, MD Anderson Cancer Center, Houston, TX	2001
Explaining Trends in Colorectal Cancer Mortality/Investigators Meeting	Cancer Intervention and Surveillance Modeling Network (CISNET), National Cancer Institute, Washington, DC	2001

Population-based Resources for Measuring the Quality of US Cancer Care/Group Meeting	Cancer and Leukemia Group B, Chicago, IL	2001
Population-based Resources for Evaluating Cancer Care/Seminar	Department of Medicine, University of Miami, Miami, FL	2002
Health Services Research Oral Abstracts/Annual Meeting	American Society of Clinical Oncology, Orlando, FL	2002
Educational Session: Health Services Research Careers in Cancer/Annual Meeting	American Society of Clinical Oncology, Orlando, FL	2002
Access to Prescription Drugs for Cancer Patients/Group Meeting	Cancer and Leukemia Group B, Chicago, IL	2003
Health Services Research Oral Presentations/Research Discussion, Annual Meeting	ASCO, Chicago, IL	2003
Using Administrative Data Sources to Evaluate the Quality of US Cancer Care/Grand Rounds	Massey Cancer Center, Virginia Commonwealth University, Richmond, VA	2004
Patient Navigation and the Quality of Three US Cancer Care/Annual Meeting	Presidential Symposium, American Society of Clinical Oncology, New Orleans, LA	2005
Cancer Treatment for Elderly Patients, Understanding the Difference Between Clinical Trials and Real-World Practice Patterns/Seminar	BJ Kennedy-Paul Carbone Memorial Symposium on Geriatric Oncology, National Cancer Institute, Washington, DC	2005
Using Decision Aids to Facilitate Adjuvant Treatment Decision Making/Seminar <sup>r</sup>	5th Annual Perspectives in Colorectal Cancer Symposium, Chicago, IL	2005
Patterns of Post-Treatment Surveillance for Patients with Colon Cancer/Seminar	Joint Symposium on Cancer Survivorship, Institute of Medicine, Washington, DC	2005
Using Population-based Data Sources to Evaluate How Clinical Trial Results are Incorporated into Oncology Practice/Seminar	Indiana University Cancer Center, Indianapolis, IN	2005
Integrating Progress in Colorectal Cancer Chemotherapy into Practice/Annual Meeting	Hoosier Group Oncology, Indianapolis, IN	2005
The SEER-Medicare Linked Data and Other Population-based Approaches to Measuring the Quality of US Cancer Care/Seminar	National Cancer Advisory Board, Washington, DC	2005
Strategies and Pitfalls Associated with Linking Pay to Performance in Oncology/Seminar	United Health Care Advisory Board, Chicago, IL	2005

Integrating Health Services Research into Clinical Trial Design/Retreat	American Society of Clinical Oncology Leadership, Washington, DC	2005
Integrating Health Services Research into Clinical Trial Design/Grand Rounds	Division of Oncology, University of Chicago, Chicago, IL	2005
Strategies for Improving the Quality of US Cancer Care/Seminar	Meeting for Congress and Congressional Aides and Alliance of Dedicated Cancer Centers, Washington, DC	2005
Mary Mulready Sullivan Oncology Symposium: Defining, Measuring and Paying for High Quality Cancer Care/Grand Rounds	Department of Medicine, Hartford Hospital, Hartford, CT	2006
Implementing Cancer Survivorship Programs	Institute of Medicine, Washington, DC	2006
How to Write a "Survivorship Prescription," The Oncology Treatment Summary and Survivorship Care Plan/Annual Meeting	Education Session, American Society of Clinical Oncology, Atlanta, GA	2006
Economic Consequences of Better Cancer Chemotherapy	50th Anniversary Meeting, Cancer and Leukemia Group B, Chicago, IL	2006
Speaker and Invited Testim—y--Medicare Physician Payment: How to Build a Payment System that Provides Quality, Efficient Care for Medicare Beneficiaries	United States Congress Energy and Commerce Committee, Washington, DC	2006
Speaker Opportunities for Linking Federal Data to Prioritize Health Needs of the Nation	Department of Health and Human Services Symposium on Improving Health Services Research through Linkages, Washington, DC	2006
Data Sources for Measuring Quality of Care in the Era of Personalized Medicine/Seminar	Workshop on Strategies to Improve Cancer Care Delivery, National Cancer Institute, Bethesda, MD	2006
Pay for Performance and Quality of Care Initiatives/ Grand Rounds Speaker	University of Massachusetts Lewin Symposium, Department of Medicine, Springfield, MA	2006
What Drives Adoption of New Chemotherapy Drugs in Oncology? Symposium Speaker	Association of Health Care Economics Special Symposium on Drug Discovery in the Era of Biological Therapy, Washington, DC	2007

Invited Speaker, Evaluating the Quality and Outcomes of Care Using Cancer Registry and Claims Data	All Ireland Healthcare Joint Meeting, National Cancer Institute, Bethesda, MD	2007
Colorectal Cancer Abstracts/Research Discussant for Annual Meeting Presentations  Health Services Research Abstracts/Research Discussant for Annual Meeting Presentations	ASCO Annual Meeting, Chicago, IL	Multiple years since 2008
Invited Grand Rounds Speaker-The Pay for Performance Movement and How it Does and Does Not Foster the Quality of US Cancer Care	Midland Hospital, Midland, MI	2007
The Economics of Cancer Care and Its Implications for Care Quality	Symposium on the Quality of Cancer Care, Michigan Blue Cross Blue Shield Plans	2007
Invited Speaker and Panelist Imagining Better Delivery Systems for Cancer	Aspen Institute for Ideas, Aspen, CO	2007
Invited Speaker the Rationale for Treatment Summaries in Cancer Care	ASCO, Chicago, IL	2007
Program on Cancer Outcomes Research Training Fellows: Developing Systems to Engage Patients in Reporting Symptoms During Cancer Treatment	Massachusetts General Hospital, Boston, MA	2007
What We Can and Should Learn from the Erythropoiesis-Stimulating Agent (ESA) Story	Education Session, ASCO, Chicago, IL	2008
Can We Do Less Instead of More? Simplifying Therapy for Locally Advanced Rectal Cancer	MD Anderson Cancer Center, Houston, TX	2008
Taking Stock of the Quality-of-Care Movement in Oncology	Division of Medical Oncology, Case Western University Hospital, Cleveland, OH	2008
Building Comparative Effectiveness Research Capacity in Cancer Medicine	The Agency for Health Care Research and Quality, Washington, DC	2008
Reshaping Systems to Optimize Cancer Quality Care	Brookings Institute, Washington, DC	2009
New Paradigms in Rectal Cancer Treatment	Division of Gastroenterology, MD Anderson Cancer Center, Houston, TX	2009
Economics of Cancer Chemotherapy	Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX	2009
Comparative Effectiveness Research: What It Is and What Does It Mean for Oncology Practice?	Educational Workshop at ASCO, Orlando, FL	2009
Evidence for the Benefits and Burdens of Board Certification in Medical Oncology	Education Session, ASCO, Orlando, FL	2009

Strategies for Coping with Prescription Drug Costs for Clinical Trial Participants	Clinical Science Symposium, ASCO, Orlando, FL	2009
Incorporating Financial Considerations into Oncology Decision Making: Challenges and Opportunities	Education Session, ASCO, Orlando, FL	2009
Building Comparative Effectiveness Research Capacity	Lung Cancer Research Foundation, New York, NY	2009
The Effectiveness of Cancer Care Delivery for Indigent Patients in New York State	Mount Sinai Hospital Department of Medicine	2009
Oncology Rounds, Insuring and Ensuring High Quality Cancer Care for Our Most Vulnerable Patients	University of Michigan Comprehensive Cancer Center, Ann Arbor, MI	2009
Neoadjuvant FOLFOX-bev without Radiation for Locally Advanced Rectal Cancer/Symposium	GI Symposium, ASCO, Orlando, FL	2010
Endowed Visiting Professor, Moments in Leadership Cancer Care Delivery in Medicaid	Louisiana State University Health Sciences Center, New Orleans, LA	2010
Cancer Center Grand Rounds-Closing the Implementation Gap	Winship Cancer Center, Emory University, Atlanta, GA	2010
Partnering with Medicaid to Enhance CER in Cancer	California Cancer Registry Scientific Conference, Sacramento, CA	2010
Implementing the PRO-CTCAE system in the Context of Cooperative Group Trials	Development of the PRO-CTCAE Meeting, National Cancer Institute, Bethesda, MD	2010
Strategies for Communicating the Costs and Benefits of Medical Interventions	ASCO, Chicago, IL	2010
Neo-adjuvant FOLFOX-bevacizumab, with Selective Use of Radiation, for Locally Advanced Rectal Cancer/Annual Meeting	ASCO, Chicago, IL	2010
Speaker and Panelist on Developing platforms for comparative effectiveness research in survivorship care	NCI Workshop, Washington, DC	2011
Streamlining Rectal Cancer Therapy	ASCO Gastrointestinal Cancer Symposium, San Francisco, CA	2011
Adjuvant and Neoadjuvant Chemotherapy for Resectable Rectal Cancer	Society of Surgical Oncology Rectal Symposium, San Antonio, TX	2011
Visiting Professor Cancer Center Rounds: The Comparative Effectiveness of Chemotherapy for Colorectal Cancer	Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC	2011
Analytic Methods in Comparative Effectiveness Research, Seminar with Population Sciences Faculty and Postdoctoral Fellows	Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC.	2011
Symposium Speaker: Priority Setting in Comparative Effectiveness Research	AHRQ DEcIDE Cancer Consortium Stakeholder Meeting, Rockville, MD	2011

Importance/Value of Standardized Treatment Algorithms: What Has Been Accomplished in Oncology?	American College of Rheumatology (ACR) Clinical Research Conference, Chicago, IL	2011
The Past, Present and Future of Comparative Effectiveness Research in Oncology	John Hopkins Bloomberg School of Public Health, Baltimore, MD	2011
Comparative Effectiveness Research in Cancer Medicine	National Press Club with JAMA Editors, Washington, DC	2012
Integrating Effectiveness Research into the Cooperative Group Research Portfolio	Community Clinical Oncology Program, Bethesda, MD	2012
Measuring and Incentivizing Value in Cancer Chemotherapy	Institute of Medicine Workshop on Costs of Cancer Care, Washington, DC	2012
Invited Speaker: From Efficacy to Effectiveness: Strategies for Increasing Accrual and the Representativeness of Cancer Clinical Trials	Georgetown University Medical School and Department of Medicine, Ruesch Center Symposium, Washington, DC	2012
Preoperative Chemotherapy for Stage II, III and IV Rectal Cancer	ASCO Gastrointestinal Cancer Symposium, San Francisco, CA	2013
Hot Topics in Management of Colorectal Cancer	Great Debates & Updates in GI Malignancies, New York, NY	2013, 2014, 2016, 2017
Gastric and GE Junction Adenocarcinomas: Neoadjuvant versus Adjuvant Treatment Strategies	Great Debates & Updates in GI Malignancies, New York, NY	2013
Raising the Bar: Can We Diminish the Impact of Race, Age, and Expertise as Factors in Patient Outcomes?	ASCO, Chicago, IL	2013
The National Cancer Institute's Patient Reported Outcomes-PRO-CTCAE	ASCO, Chicago, IL	2013
Invited Speaker to Cancer Center Rounds: Strategies to Maximize Delivery of High Value Care for Patients with Advanced Cancer	University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL	2014
Visiting Faculty and Distinguished Lectureship: Strategies for Maximizing Value of Advanced Cancer Care	Virginia Commonwealth University, Massey Cancer Center, Richmond, VA	2014
Invited Speaker: Opportunities and Challenges Stemming from the Use of Observational Data in Regulatory Decisions about Cancer Treatment	Office of Hematology & Oncology Products (OHOP) and FDA members Silver Spring, MD	2014
Invited Speaker: Informing Informed Consent: Defining and Validating Comprehension Panel	Department of Health and Human Services Meeting of the Secretary's Advisory Committee on Human Research Protections (SACHRP), Rockville, MD	2014
Invited Speaker: Strategies to Improve the Value of Oncology Care	University of North Carolina Lineberger Cancer Center, Cancer Outcomes Rounds, Chapel Hill, NC	2014

21 <sup>st</sup> Century Cancer Care: Will New Models Lead to Better Care at Lower Cost?	The Alliance for Health Reform, Washington, DC	2014
Faculty Panel: Great Debates & Updates in GI Malignancies	New York, NY	2015
Setting Priorities: Career Planning at Different Stages for Women in Medical Oncology, Panel	ASCO, Chicago, IL	2015
Optimizing Palliative Care for Patients: Patient-Centered Approaches to Communication, Decision Making, and Care Delivery PCORI Annual Meeting	Progress in Building a Patient-Centered Clinical Comparative Effectiveness Research Community, Crystal City, VA	2015
Advances in Measurement of Patient Reported Outcomes in Oncology	Survivorship, Outcomes and Risk SOAR Program Seminar, MSK	2015
Capturing the Patient Perspective in Efficacy and Effectiveness Research: From Quality of Life to Toxicity to Digital-Health	Cancer Control Program Seminar, Ohio State University Comprehensive Cancer Center, Columbus, OH	2016
Policy Issues in the Development and Use of Immunotherapies for Cancer	National Cancer Policy Forum Meeting, Washington DC	2016
Sidedness and Prognosis in Colorectal Cancer	ASCO, Annual Meeting, Chicago, IL	2016
A Framework for Evaluating the Value of Progress in Cancer Therapy	ASCO, Annual Meeting, Chicago, IL	2016
What is Optimal Adjuvant Treatment for Stage II and III Rectal Cancer in 2016	ASCO, Annual Meeting, Chicago, IL	2016
Value Framework for Cancer Treatments	National Cancer Institute Annual Meeting, Rockville, MD	2016
Value Framework for Cancer Treatments, Cancer Intervention and Surveillance Modeling Network (CISNET),	Plenary Session at CISNET Annual Meeting, Rockville, MD	2016
Pilot to Populations: Quality, Efficacy and Effectiveness of Rectal Cancer Treatment	Visiting Professor, Washington University Cancer Center, St. Louis, MO	2017
Measuring and Improving Colorectal Cancer Quality of Care	Cancer Intervention and Surveillance Modeling Network (CISNET), Annual Meeting, Rockville, MD	2017
Aligning Value and Precision Medicine	ASCO, Annual Meeting, Chicago, IL	2017
Do All Patients with Locally Advanced Rectal Cancer Need Neoadjuvant Therapy? Improving Rectal Cancer Quality of Care	American Society of Colon and Rectal Surgeons, Seattle, WA	2017
DeLynn Endowed Lecture: Precision Public Health: High Value Strategies to Decrease the Burden of Cancer on the Health of Communities and Populations	West Virginia University Medical Center, Morgantown, WV	2017
Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS)	Alliance for Clinical Trials in Oncology, Chicago, IL	2017
Advances in Colorectal Oncology: Chemotherapy instead of Radiation to Improve Treatment Outcomes	Roswell Park Cancer Center, Buffalo, NY	2017
Masonic Cancer Center Visiting Professor: Bridging Efficacy and Effectiveness: Knowledge Translation through the Lens of Contemporary Management of Rectal Cancer	University of Minnesota, Minneapolis, MN	2018

Cancer, Health Justice, and Strategies to Eliminate Disparities	Yale Law School-Medical School and Public Health School Joint Conference, New Haven, CT	2018
Research Priorities to Facilitate Translation of Novel Cancer Treatments to Underserved Populations Strategies for Improving Cancer Focused Population Health	Research Center of Regional Excellence Investigators' Strategic Planning Meeting, Bethesda, MD	2018
Inaugural Cancer Health Care Delivery and Policy Symposium: Patient Reported Outcomes (PROs) in Oncology from Efficacy to Effectiveness to Implementation	University of Pittsburgh School of Public Health and Medicine, Department of Health Policy and the Cancer Center, Pittsburgh, PA	2018
The PRISMM Phenomic Data System	AACR Spring Meeting	2019
PROs to Improve Cancer Care Delivery: A Translational Journey from Feasibility to Efficacy, Effectiveness, and Implementation	Vanderbilt-Ingram Cancer Center Nashville, TN	2018
The Real Challenges of "Real World" Data	NCI Healthcare Delivery Research Branch, Bethesda, MD	2019
The PRISMM Phenomic Data System	SEER Principal Investigators Meeting, Rockville, MD	2019
Real World Evidence to Inform Research and Clinical Decision Making	PMWC Precision Medicine World Conference, Santa Clara, CA	2019
Invited Speaker at AACR Conference on Implementation of Genomic Medicine	San Diego, CA	2019
Panelist and Speaker, FDA Workshop on Real World Data Frameworks	FDA, Silver Springs, MD	2019
Actionable Social Determinants of Health and Cancer Care Delivery-National Cancer Policy Forum Workshop on Health Disparities	National Academies of Medicine, Washington DC	2019
Improving Health through Patient Reported Outcomes Annual Value in Cancer Care Summit	Fred Hutchinson Cancer Center, Seattle, WA	2019
Large Genomic Databases & Real-World Evidence	FDA-AACR Real World Evidence Workshop, Bethesda, MD	2019
Integrating Patient Reported Outcomes into Routine Cancer Care: Why, Where When and How	MD Anderson Cancer Center, Houston, TX	2019
Genomic-phenomic Data Linkages to Accelerate Discovery in Oncology: Obstacles and Opportunities	AACR, Advancing Precision Medicine Drug Development Symposium, San Diego, CA	2020
Making the Electronic Health Record work for Cancer Patients	EPIC Corporation, Verona WI	2020
Strategies for Improving the Design, Conduct and Reporting of Publicly Sponsored Clinical Trials	National Cancer Policy Forum of the National Academy, Washington, DC	2020
PROs in Oncology: From Research to Routine	UCLA Cancer Center, Los Angeles, CA	2020
Minimizing Waste of Medications in Oncology	National Academy of Medicine Panel and Workshop	2020 (virtual)
Pragmatic Clinical Trial Designs in Cancer Care	Division of Cancer Control and Prevention, NCI	2020 (virtual)
Precision Medicine and Real-World Evidence	AACR Symposium	2020 (virtual)

Priorities in Cancer Health Economics Research	Future of Cancer Health Economics Workshop, NCI	2020 (virtual)
Impact of the ACA on Cancer Treatment Outcomes	Friends of Cancer Research Symposium	2020 (virtual)
Improving the Evidence Base for Treatment Decision Making for Older Adults with Cancer	National Cancer Policy Forum of the National Academies of Sciences, Engineering, and Medicine	2021 (virtual)
Genomic-Phenomic linked data: Challenges and Opportunities	Department of Epidemiology and Biostatistics and Population Sciences Research Program, MSK	2021 (virtual)
The Impact of ACA on Cancer Prevention and Care: A Virtual Workshop	The National Academies of Science, Engineering, and Medicine	2021 (virtual)
Delivering on the Promise of Personalized Cancer Medicine	American Society for Radiation Oncology (ASTRO) Presidential Symposium	2021 (virtual)
Patient Reported Outcomes in Cancer Research	Division of Cancer Prevention, MD Anderson Cancer Center	2022 (virtual)
Integrating Artificial Intelligence into Cancer Care: Opportunities and Challenges	ASCO Annual Meeting Chicago, IL	2022
Preoperative Chemotherapy with Selective Chemoradiation versus Chemoradiation for Locally Advanced Rectal Cancer: The PROSPECT Trial (Alliance N1048)	ASCO Annual Meeting, Chicago, IL <i>Plenary Presentation (top 5 abstract of over 10,000 submissions)</i>	2023
The Promise and Perils of Multi-Cancer Early Detection Testing	AACR Annual Meeting, Orlando, FL Opening Plenary Session	2023
Multi-cancer Early Detection Testing: Promise and Perils	ASCO Annual Meeting, Chicago, IL	2023
Implementation of Patient Reported Outcomes into Cancer Clinical Trials	National Community Oncology Research Program (NCORP) Meeting honoring Dr. Wortu McCaskill, Washington DC	2023
Brooks-Ragen Endowed Lecture: Blood-Based Tests for Multi-Cancer Early Detection: The Possibilities, Perils and Path Forwards	Fred Hutchinson Cancer Center, Seattle, WA	2023
Integrating Patient Reported Outcomes into Cancer Treatment	Department of Medicine, University of Oklahoma	2023
Strategies for Improving the Design and Conduct of Cooperative Group Clinical Trials	National Cancer Institute (NCI)	2023 (virtual)
The PROSPECT Trial: Improving Outcomes for Locally Advanced Rectal Cancer	Best of ASCO, multiple locations	2023
The Kaner Endowed Lectureship: Personalizing Treatment for Locally Advanced Rectal Cancer	Dartmouth Hitchcock Cancer Center, Hanover, NH	2023
Early Cancer Detection with Blood Based Assays: Early Experience and the Path Forwards	Georgia Cancer Center	2023 (virtual)

Personalizing Treatment for Rectal Cancer	Oklahoma Society of Clinical Oncology, Inc.	2023 (virtual)
Invited Speaker: Medicine Grand Rounds – “Personalizing Treatment for Locally Advanced Rectal Cancer.”	University of Florida Cancer Center, Gainesville, FL	2024
Changing Treatment Paradigms in Locally Advanced Rectal Cancer	Emory University Digestive Seminar, Atlanta, GA	2024
Strategies for Implementing MCD Tests into Clinical Practice	National Cancer Policy Forum Workshop: Opportunities and Challenges for the Development and Adoption of Multicancer Detection Tests	2024
Blood Based Tests for Cancer Screening: Opportunities and Obstacles	Baptist Health South Florida, Boca Raton Regional Hospital Internal Medicine Symposium, Boca Raton, FL	2025 (Virtual)
Effective and Safe Telehealth Delivery and Remote Patient Monitoring	NCCN Annual Conference 2025, Orlando, FL	2025
Blood Based Tests for Cancer Screening: Opportunities and Obstacles	University of Nebraska Grand Rounds, Omaha, NE	2025
The Future of Cancer Screening	Holden Comprehensive Cancer Center Retreat, Iowa City, IA	2025 (Virtual)

#### International Invited Presentations

Title	Institution/Location	Year
Estimating the Cost Effectiveness of Universal Screening for BRCA1 and BRCA2 in Women with Newly Diagnosed Breast Cancer	Princess Margaret Cancer Center, University of Toronto	1997
Estimating the Benefits and Risks of Prophylactic Surgical Strategies for Women with Hereditary Breast Cancer	German Cancer Society, Berlin, Germany	1998
Estimating the Benefit of Prophylactic Mastectomy for Women With and Without Known Mutation in the BRCA Genes	Israel Medical Society, Jerusalem, Israel	1999
Whether, When and How Should We Measure Cost-Effectiveness in Oncology	European Society of Medical Oncology, (ESMO) Istanbul, Turkey	2006
Measuring the Quality of US Cancer Care	International Union Against Cancer (UICC), Geneva, Switzerland	2008
The US Approach to Cancer System Quality Indicators	Cancer Care Ontario, Toronto, Ontario, Canada	2009
Disparities in Outcomes of Colorectal Cancer Treatment	CISNET, Rotterdam, Netherlands	2009
Prognostic and Predictive Markers for Patients with Colorectal Cancer and Lynch Syndrome	Hadassah Medical Center, The Hebrew University, Jerusalem, Israel	2009

Comparative Effectiveness Research and International Research Collaborations in Cancer	Middle East Oncology Conference in Amman, Jordan and at the King Hussein Conference Center, Dead Sea, Jordan	2010
Measuring Cancer Incidence, Treatment and Outcomes from Tumor Registry Data		
Integrating Risk Prediction Models into Cancer Care	Institute Gustave Roussy, Paris, France	2010
Personalizing Treatment for Locally Advanced Rectal Cancer	Kantonsspital Aarau, Zurich, Switzerland	2010
Personalizing Treatment for Locally Advanced Rectal Cancer	Universitäts Hospital, Zurich, Switzerland	2010
1. When Less is More: A View of Comparative Effectiveness Research from the USA 2. The Economics of Cancer Care in the USA	Australian Society of Medical Oncology, Adelaide, Australia	2011
Prognostic and Predictive Markers in Colon Cancer: When and How They Are Used for Treatment Decision Making in the USA	Australian Society of Medical Oncology, Adelaide, Australia	2011
Identifying High Value Cancer Treatments: Patient, Physician and Public Health System Perspectives	Australian Society of Medical Oncology, Adelaide, Australia	2011
Evolving Treatment Strategies for Improving Population-Level Outcomes for Colorectal Cancer Treatment	National Cancer Institute of Canada (NCIC) Annual Meeting, Toronto, Canada	2012
Understanding Patients' Expectations of Treatment for Metastatic Cancer and Why it Matters	Faculty of Medicine, University of Frankfurt, Germany	2012
Understanding Patients' Expectations for Treatment of Metastatic Cancer and Why it Matters	Faculty of Medicine, Sao Paulo Brazil	2013
Understanding Patients' Expectations for Treatment of Metastatic Cancer and Why it Matters	Cancer Center of the Karolinska Research Institute	2013
Visiting Professor in Residence (2 weeks), Evaluating Care Quality and Effectiveness in GI Oncology Argentinean Intergroup of Gastrointestinal Tumors Treatment (IATTGI)	Buenos Aires, Argentina	2013
Visiting Professor, Balancing Cure and Toxicity: Defining Optimal Multi-Modality Strategies for Management of Locally Advanced Rectal Cancer	SAKK Swiss Oncology Society Meeting, St. Gallen, Switzerland	2014
Strategies to Modernize Cancer Registries and Improve Population-level Cancer Control	Berlin University, Berlin, Germany	2015
Population-wide Strategies for Cancer Control	Autonomous University of Madrid, Spain	2016
Quantifying the Impact of Precision Medicine at the Population Level	ESMO, Copenhagen, Denmark	2016
Value Frameworks in Oncology	Cancer Care Ontario Plenary Session, Toronto, Ontario Canada	2017

Improving Outcomes for Patients with Colorectal Cancer: The Trials We Do and the Trials We Don't Do	Visiting Professor, Cancer Research Institute of the University of Vienna, Vienna, Austria	2017
How Relevant Are the ESMO And ASCO Clinical Benefit Scales?	ESMO <sup>19</sup> th World Congress, Barcelona, Spain	2017
Patient-reported Symptom Monitoring During Cancer Treatment	Lectio Magistralis, Italian Society of Medical Oncology Annual Meeting, Milan, Italy	2018
Integrating Genomics and Phenomics to Realize the Value of Precision Medicine	The University of Milan, Milan, Italy	2018
Pan-Asian Oncology Meeting, Integrating Patient Reported Outcomes into Oncology	University of Hong Kong, Hong Kong, China	2018
Modernization of Tumor Registries to Decrease Disparities in Cancer Treatment Outcomes	National Health Service Data Science Conference, London, UK	2018
Measurement of Population Based Cancer Treatment Outcomes	University of Dublin, Dublin, Ireland	2018
The PRISMM Model: A Phenomic Data Standard for Curation of Reliable "Real world" Cancer Outcomes Including Recurrence and Progression	European – US Workshop on Cancer Data, London, UK	2019
Precision Medicine in Cancer: Integrating Genomics and Phenomics	Chinese Academy of Medical Sciences Summit, Chengdu, China	2019
1. Validity of Real-World Evidence in Oncology 2. Integrating Patient Reported Outcomes in Oncology, 3. Real World Evidence and Phenomic Data Standards to support Regulatory Decisions	ESMO GI Meeting Barcelona, Spain	2019
Value Frameworks in Oncology	International Summit on Cancer Pharmacoeconomics	2020 (virtual)
Harmonizing Genomic and Phenomic Data to Accelerate Implementation of Precision Medicine	Princess Margaret Cancer Center, Toronto, Canada	2020 (virtual)
The PATHFINDER Study of Multi-Cancer Early Detection Testing	ESMO Oral Abstract, Paris, France	2022
Strategies to Accelerate Development of Valid Multi Cancer Early Detection Tests	ESMO Symposium, Madrid, Spain	2023
De-escalation Trials in Oncology	Australia-New Zealand Clinical Trialists Investigators' Meeting	2024
Invited Speaker: The PROSPECT Trial and Future Trials in Locally Advanced Rectal Cancer	~5 talks to medical, radiation and surgical oncologists in Brazil, Korea, India and Japan reviewing the PROSPECT trial results.	2023 and 2024 (virtual)
Invited Speaker: The PROSPECT Trial and Future Trials in Locally Advanced Rectal Cancer	Brazilian Medical Society	2023 (virtual)
Invited Speaker: Keynote Address, "Past, Present and Future Strategies for Population-Wide Cancer Screening."	National University Health System Singapore Scientific and Innovation Summit	2024
Invited Speaker: "Can we avoid radiation? When and for whom can we eliminate RT?"	FiCare forum on Rectal Cancer, Brazil	2024

Invited Speaker: “Rectal Cancer in 2024: Thinking outside the box – Designing the Next Generation of Clinical Trials.”	Australian Gastro-Intestinal Trials Group (AGITG) Annual Scientific Meeting	2024
Invited Speaker: “The Future of Digital Oncology and the Transformation of Cancer Care.”	European Society of Medical Oncology (ESMO) at 50 Conference with Global Thought Leaders on the Future of Cancer Care	2025
Invited Keynote Lecture: Transforming the Cancer Clinical Trials Ecosystem	Korean Society of Medical Oncology	2025

## S. BIBLIOGRAPHY

### Peer-reviewed Research Articles:

- Greenstein AJ, Sachar DB, Gibas A, **Schrag D**, Heimann T, Janowitz HD, Aufses AH Jr. Outcome of toxic dilatation in ulcerative and Crohn’s colitis. *J Clin Gastroenterol*. 1985 Apr;7(2):137-43. PMID: 4008909.
- Schrag D**, Kuntz KM, Garber JE, Weeks JC. Decision analysis—effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. *N Engl J Med*. 1997;336(20):1465-71. PMID: 9148160.
- Redston M, Nathanson KL, Yuan ZQ, Neuhausen SL, Satagopan J, Wong N, Yang D, Nafa D, Abrahamson J, Ozcelik H, Antin-Ozerkis D, Andrulis I, Daly M, Pinsky L, **Schrag D**, Gallinger S, Kaback M, King MD, Woodage T, Brody LC, Godwin A, Warner E, Weber B, Foulkes W, Offit K. The APCI1307K allele and breast cancer risk. *Nat Genet*. 1998;20(1):13-4. PMID: 9731522.
- Syngal S, Weeks JC, **Schrag D**, Garber JE, Kuntz KM. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. *Ann Intern Med*. 1998;129(10):787-96. PMID: 9841584.
- Lu KH, Garber JE, Cramer DW, Welch WR, Niloff J, **Schrag D**, Berkowitz RS, Muto MG. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. *J Clin Oncol*. 2000;18(14):2728-32. PMID: 10894872.
- Schrag D**, Cramer LD, Bach PB, Cohen AM, Warren JL, Begg CB. Influence of hospital procedure volume on outcomes following surgery for colon cancer. *JAMA*. 2000;284(23):3028-35. PMID: 11122590.
- Schrag D**, Kuntz KM, Garber JE, Weeks JC. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. *JAMA*. 2000; 283(5):617-24. PMID: 10665701.
- Syngal S, **Schrag D**, Falchuk M, Tung N, Farraye FA, Chung D, Wright M, Whetsell A, Miller G, Garber JE. Phenotypic characteristics associated with the APC gene I1307K mutation in Ashkenazi Jewish patients with colorectal polyps. *JAMA*. 2000;284(7):857-60. PMID: 10938175.
- Bach PB, Cramer LD, **Schrag D**, Downey RJ, Gelfand SE, Begg CB. The influence of hospital volume on survival after resection for lung cancer. *N Engl J Med*. 2001;345(3):181-8. PMID: 11463014.

10. Bach PB, **Schrag D**, Nierman DM, Horak D, White P Jr, Young JW, Groeger JS. Identification of poor prognostic features among patients requiring mechanical ventilation after hematopoietic stem cell transplantation. *Blood*. 2001;98(12):3234-40. PMID: 11719359.
11. **Schrag D**, Cramer LD, Bach PB and Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. *J Natl Cancer Inst*. 2001;93(11):850-7. PMID: 11390534.
12. **Schrag D**, Gelfand SE, Bach PB, Guillem J, Minsky BD, Begg CB. Who gets adjuvant treatment for stage II and III rectal cancer? Insight from the Surveillance, Epidemiology, and End results-Medicare linked data. *J Clin Oncol*. 2001;19(17):3712-8. PMID: 11533092.
13. Bach PB, **Schrag D**, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. *JAMA*. 2002;287(16):2106-13. PMID: 11966385.
14. Begg CB, Riedel ER, Bach PB, Kattan MW, **Schrag D**, Warren JL, Scardino PT. Variations in morbidity after radical prostatectomy. *N Engl J Med*. 2002;346(15):1138-44. PMID: 11948274.
15. **Schrag D**, Panageas KS, Riedel E, Cramer LD, Guillem JG, Bach PB, Begg CB. Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection. *Ann Surg*. 2002;236(5):583-92. PMID: 12409664. PMCID: PMC1422616.
16. **Schrag D**, Rifas-Shiman S, Saltz L, Bach PB, Begg CB. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. *J Clin Oncol*. 2002;20(19):3999-4005. PMID: 12351597.
17. Warren JL, Klabunde CN, **Schrag D**, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. *Med Care*. 2002;40(8 Suppl):IV-3- 18. PMID: 12187163.
18. Bach PB, Guadagnoli E, **Schrag D**, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. *Med Care*. 2002;40 IV, 19-25. PMID: 12187164.
19. Panageas KS, **Schrag D**, Riedel E, Bach PB, Begg CB. The effect of clustering of outcomes on the association of procedure volume and surgical outcomes. *Ann Intern Med*. 2003;139(8):658-65. PMID: 14568854.
20. **Schrag D**, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB. Adherence to surveillance among patients with superficial bladder cancer. *J Natl Cancer Inst*. 2003;95(8):588-97. PMID: 12697851.
21. **Schrag D**, Panageas KS, Riedel E, Hsieh L, Bach PB, Guillem JG, Begg CB. Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection. *J Surg Oncol*. 2003;83(2):68-78. PMID: 12772198.
22. Meyerhardt JA, Catalano PJ, **Schrag D**, Ayanian JZ, Haller DG, Mayer RJ, Macdonald JS, Benson AB, Fuchs CS. Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence. *Ann Intern Med*. 2003;139(8):649-57. PMID: 14568853.
23. Bach PB, Pham HH, **Schrag D**, Tate RC, Hargraves JL. Primary care physicians who treat blacks and whites. *N Engl J Med*. 2004;351(6):575-84. PMID: 15295050.

24. Basch EM, Thaler HT, Shi W, Yakren S, **Schrag D**. Use of information resources by patients with cancer and their companions. *Cancer*. 2004;100(11):2476-83. PMID: 15160355.
25. Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, **Schrag D**, Ayanian JZ, O'Connell MJ, Weeks JC, Mayer RK, Willett CG, MacDonald JS, Benson AB, Fuchs CS. Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study. *J Clin Oncol*. 2004;22(1):166-74. PMID: 14701779.
26. Rizk NP, Bach PB, **Schrag D**, Bains MS, Turnbull MD, Karpeh M, Brennan MF, Rusch VW. The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma. *J Am Coll Surg*. 2004; 198(1):42-50. PMID: 14698310.
27. Temple LK, Hsieh L, Wong WD, Saltz L, **Schrag D**. Use of surgery among elderly patients with stage IV colorectal cancer. *J Clin Oncol*. 2004 Sep 1;22(17):3475-84. PMID: 15337795.
28. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz G, Tse A, Hamilton A, Pan D, **Schrag D**, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. *J Clin Oncol*. 2005;20:1803-10. PMID: 15677699.
29. **Schrag D**, Mitra N, Xu F, Rabbani F, Bach PB, Herr H, Begg CB. Cystectomy for muscle-invasive bladder cancer: Patterns and outcomes of care in the Medicare population. *Urology*. 2005;65:1118-25. PMID: 15922428.
30. Basch E, Artz D, Dulko D, Scher K, Sabbatini P, Hensley M, Mitra N, Speakman J, McCabe M, **Schrag D**. Patient online self-reporting of toxicity symptoms during chemotherapy. *J Clin Oncol*. 2005;23:3552-3561. PMID: 15908666.
31. Temple LK, Bacik J, Savatta SG, Gottesman L, Paty PB, Weiser MR, Guillem JG, Minsky BD, Kalman M, Thaler HT, **Schrag D**, Wong WD. The development of a validated instrument to evaluate bowel function after sphincter-preserving surgery for rectal cancer. *Dis Colon Rectum*. 2005;48:1353-65. PMID: 15868235.
32. Pham HH, **Schrag D**, Hargraves JL, Bach PB. Delivery of preventive services to older adults by primary care physicians. *JAMA*. 2005 Jul 27;294(4):473-81. PMID: 16046654.
33. **Schrag D**, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. *J Natl Cancer Inst*. 2005 Aug 17;97(16):1221-4. PMID: 16106027.
34. Elkin EB, Hudis C, Begg CB, **Schrag D**. The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999. *Cancer*. 2005. Sep 15;104(6):1149-57. PMID: 16088887.
35. Hillner BE, **Schrag D**, Sargent DJ, Fuchs CS, Goldberg RM. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. *Cancer*. 2005 Sep 21;104(9):1871-84. PMID: 16177989.
36. Chiao EY, Krown SE, Stier EA, **Schrag D**. A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. *J Acquir Immune Defic Syndr*. 2005 Dec 1;40(4):451-455. PMID: 16280701.

37. **Schrag D**, Earle CC, Xu F, Panageas KS, Yabroff KO, Bristow RW, Trimble EL, Warren JL. Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. *J Natl Cancer Inst.* 2006 Feb 1;98(3):163-71. PMID: 16449676.
38. Earle CC, **Schrag D**, Neville BA, Yabroff KR, Topor M, Fahey A, Trimble EL, Bodurka DC, Bristow RE, Carney M, Warren JL. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. *J Natl Cancer Inst.* 2006 Feb 1;98(3):172-80. PMID: 16449677.
39. Bickell NA, Wang JJ, Oluwole S, **Schrag D**, Godfrey H, Hiotis K, Mendez J, Guth AA. Missed opportunities: racial disparities in adjuvant breast cancer treatment. *J Clin Oncol.* 2006 Mar 20;24(9):1357-62. PMID: 16549830.
40. Indurkha A, Mitra N, **Schrag D**. Using propensity scores to estimate the cost effectiveness of medical therapies. *Stat Med.* 2006 May 15;25(9):1561-76. PMID: 16158412.
41. **Schrag D**, Xu F, Hanger M, Elkin E, Bickell NA, Bach PB. Fragmentation of Care for Frequently Hospitalized Urban Residents. *Med Care.* 2006 Jun;44(6):560-7. PMID: 16708005.
42. Elkin EB, Hurria A, Mitra N, **Schrag D**, Panageas KS. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observation cohort. *J Clin Oncol.* 2006 Jun 20;24(18):2757-64. PMID: 16782916.
43. Vogelaar I, van Ballegooijen M, **Schrag D**, Boer R, Winawer SJ, Habbema JD, Zauber AG. How much can current interventions reduce colorectal cancer mortality in the US?: mortality projections for scenarios of risk-factor modification, screening and treatment. *Cancer.* 2006 Oct 1;107(7):1624-33. PMID: 16933324.
44. Bekelman JE, Rosenzweig KE, Bach PB, **Schrag D**. Trends in the use of postoperative radiotherapy for resected non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys.* 2006 Oct 1;66(2):492-9. PMID: 16814952.
45. Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, **Schrag D**. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. *Lancet Oncol.* 2006 Nov;7(11):903-9. PMID: 17081915.
46. Ballas LK, Elkin EB, **Schrag D**, Minsky BD, Bach PB. Radiation therapy facilities in the United States. *Int J of Radiat Oncol Biol Phys.* 2006 Nov;6(4):1204-11. PMID: 17145535.
47. **Schrag D**, Hanger M. Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey. *J Clin Oncol.* 2007 Jan;25(2):233-7. PMID: 17210946.
48. Pham HH, **Schrag D**, O'Malley A, Wu B, Bach PB. Care Patterns in Medicare and their Implications for Pay for Performance. *N Engl J Med.* 2007 Mar 15;356(11):1130-39. PMID: 17360991.
49. Panageas KS, Ben-Porat L, Dickler MN, Chapman PB, **Schrag D**. When you look matters: the effect of assessment schedule on progression-free survival. *J Natl Cancer Inst.* 2007 Mar 21;99(6):428-32. PMID: 17374832.
50. Panageas KS, **Schrag D**, Russell Localio A, Venkatraman ES, Begg CB. Properties of analysis methods that account for clustering in volume-outcome studies when the primary predictor is cluster size. *Stat Med.* 2007 Apr 30;26(9):2017-35. PMID: 17016864.

51. Neuman HB, **Schrag D**, Cabral C, Weiser MR, Paty PB, Guillem JG, Minsky BD, Wong WD, Temple LK. Can differences in bowel function after surgery for rectal cancer be identified by the European organization for research and treatment of cancer quality of life instrument? *Ann Surg Oncol*. 2007 May;14(5):1727-34. PMID: 17265117.
52. Basch E, Artz D, Iasonos A, Speakman J, Shannon K, Lin K, Pun C, Yong H, Fearn P, Barz A, Scher HI, McCabe M, **Schrag D**. Evaluation of an Online Platform for Cancer Patient Self-reporting of Chemotherapy Toxicities. *J Am Med Inform Assoc*. 2007 May-Jun;14(3):264-68. PMID: 17329732.
53. O'Malley A, Pham HH, Wu B, **Schrag D**, Bach PB. Potentially Avoidable Hospitalizations for COPD and Pneumonia: The Role of Physician and Practice Characteristics. *Med Care*. 2007 Jun; 45:562-70. PMID: 17515784.
54. Vickers AJ, Bianco FJ, Serio AM, Eastham JA, **Schrag D**, Klein EA, Reuther AM, Kattan MW, Pontes JE, Scardino PT. The surgical learning curve for prostate cancer control after radical prostatectomy. *J Natl Cancer Inst*. 2007 Aug 1;99(15):1171-7. PMID: 17652279.
55. Klabunde CN, Legler JM, Warren JL, Baldwin LM, **Schrag D**. A Refined Comorbidity Measurement Algorithm for Claims-Based Studies of Breast, Prostate, Colorectal, and Lung Cancer Patients. *Am J of Epid*. 2007 Aug 18;17(8):584-90. PMID: 17531502.
56. Quah HM, Joseph R, **Schrag D**, Shia J, Guillem JG, Paty P, Temple LK, Wong WD, Weiser MR. Young age influences treatment but not outcome of colon cancer. *Ann Surg Oncol*. 2007 Oct;14(10):2759-2765. PMID: 17593332.
57. Elkin EB, Kim SH, Casper ES, Kissane DW, **Schrag D**. Desire for information and involvement in treatment decisions: elderly cancer patients' preferences and their physicians' perceptions. *J Clin Oncol*. 2007 Nov 20;25(33):5275-80. PMID: 18024875.
58. Basch E, Iasonos A, Barz A, Culkin A, Kris MG, Artz D, Fearn P, Speakman J, Farquhar R, Scher HI, McCabe M, **Schrag D**. Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. *J Clin Oncol*. 2007 Dec 1;25(34):5374-80. PMID: 18048818.
59. Bekelman JE, Jang T, Liu Y, Basch E, Zelefsky M, **Schrag D**. Variation in Adherence to External Beam Radiotherapy Quality Measures Among Elderly Men with Localized Prostate Cancer. *Int J Radiat Oncol Biol Phys*. 2007 Dec 1;69:1456-66. PMID: 17689880.
60. Elkin EB, Ishill N, Riley GF, Bach BP, Gonen M, Begg CB, **Schrag D**. Disenrollment from Medicare managed care among beneficiaries with and without a cancer diagnosis. *J Natl Cancer Inst*. 2008;100(14):1013-21. PMID: 18612131.
61. Weiser MR, Landmann RG, Kattan MW, Gonen M, Shia J, Chou J, Paty PB, Guillem JG, Temple LK, **Schrag D**, Saltz LB, Wong WD. Individualized prediction of colon cancer recurrence using a nomogram. *J Clin Oncol*. 2008 Jan 20;26(3):380-5. PMID: 18202413.
62. Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, Paty PB, Weiser MR, Neuman HB, Shia J, **Schrag D**, Temple LK. Squamous-cell Carcinoma of the Anal Canal: Predictors of Treatment Outcome. *Dis Colon Rectum*. 2008 Feb;51(2):147-53. PMID: 18180997.
63. Vickers AJ, Bianco FJ, Gonen M, Cronin AM, Eastham JA, **Schrag D**, Klein EA, Reuther AM, Kattan MW, Pontes JE, Scardino PT. Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. *Eur Urol*. 2008 May;53(5):960-966. PMID: 18207316.

64. Quah HM, Chour JF, Gonen M, Shia J, **Schrag D**, Landmann R, Guillem JG, Paty PB, Temple L, Wong WD, Weiser MR. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. *Dis Colon Rectum*. 2008 May;51(5):503-507. PMID: 18322753.
65. Quah HM, Chou JF, Gonen M, Shia J, **Schrag D**, Saltz LB, Goodman KA, Minsky BD, Wong WD, Weiser MR. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. *Cancer*. 2008 Jul 1;113(1):57-64. PMID: 18442099.
66. Pham HH, O'Malley AS, Bach PB, Saiontz-Martinez C, **Schrag D**. Primary Care Link to Other Physicians Through Medicare Patients: The Scope of Care Coordination. *Ann Int Med*. 2009 Feb 17;150(4):1-7. PMID: 19221375.
67. Pham HH, Landon BE, Reschovsky JD, Wu B, **Schrag D**. Rapidity and Modality of Imaging for Acute Low Back Pain in Elderly Patients. *Arch Intern Med*. 2009 May 25;169(10). PMID: 19468091.
68. Yabroff R, Warren JL, Banthin J, **Schrag D**, Mariotto A, Lawrence W, Meekins A, Topor M, Brown M. Comparison of Approaches for Estimating Prevalence Costs of Care for Cancer Patients. What is the Impact of Data Source? *Med Care*. 2009;47(7) Supp 1:64-9. PMID: 19536016.
69. Yabroff R, Warren JL, **Schrag D**, Mariotto A, Lawrence W, Meekins A, Topor M, Brown M. Comparison Approaches for Estimating Incidence Costs of Care for Colorectal Cancer Patients. *Med Care*. 2009;47(7) 1:56-63. PMID: 19536010.
70. **Schrag D**, Virnig BA, Warren JL. Linking Tumor Registry and Medicaid Claims to Evaluate Cancer Care Delivery. *Health Care Financ Rev*. 2009;30(4):61-73. PMID: 19719033.
71. Phelps AC, Maciejewski PK, Nilsson M, Balboni TA, Wright AA, Paulk ME, Trice E, **Schrag D**, Peteet JR, Block SD, Prigerson HG. Religious coping and use of intensive life-prolonging care near death in patients with advanced cancer. *JAMA*. 2009;301(11):1140-7. PMID: 19293414.
72. Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S, Culkin A, Kris MG, **Schrag D**. Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships with Clinical Outcomes. *J Natl Cancer Inst*. 2009 Dec 2;101(23):1624-32. PMID: 19920223.
73. Ku GY, O'Reilly EM, Saltz LB, **Schrag D**, Maki RG, Kelson DP, Ilson DH. Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors. *Cancer Invest*. 2009;27(4):402-6. PMID: 19219674.
74. Tew WP, Radovich D, O'Reilly E, Schwartz G, **Schrag D**, Saltz LB, Kelson DP, Kepler S, Ilson DH. Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer. *Invest New Drugs*. 2009;27(4):366-73. PMID: 18956138.
75. Temple LK, Romanus D, Niland J, Veer AT, Weiser MR, Skibber J, Wilson J, Rajput A, Benson A, Wong YN, **Schrag D**. Factors associated with sphincter-preserving surgery for rectal cancer at national comprehensive cancer network centers. *Ann Surg*. 2009 Aug;250(2):260-7. PMID: 19638922.
76. Earle CC, Weiser MR, Ter Veer A, Skibber JM, Wilson J, Rajput A, Wong YN, Benson AB, Shibata S, Romanus D, Niland J, **Schrag D**. Effect of lymph node retrieval rates on the utilization of adjuvant chemotherapy in stage II colon cancer. *J Surg Oncol*. 2009 Aug 20;100:525-28. PMID: 19697351.

77. Romanus D, Weiser MR, Skibber JM, Ter Veer A, Niland JC, Wilson JL, Rajput A, Wong Y, Benson AB, Shibata S, **Schrag D**. Concordance with NCCN Colorectal Cancer Guidelines and ASCO/NCCN Quality Measures: An NCCN Institutional Analysis. *J Natl Compr Canc Netw*. 2009 Sep;7(8):895-904. PMID: 19755049.
78. Gönen M, **Schrag D**, Weiser MR. Nodal Staging Score: A Tool to Assess Adequate Staging of Node-Negative Colon Cancer. *J Clin Oncol*. 2009;27(36):6166-71. PMID: 19901106.
79. Sima CS, Panageas KS, Heller G, **Schrag D**. Analytical Strategies for Characterizing Chemotherapy Diffusion with Patient-Level Population-Based Data. *Appl Health Econ Health Policy*. 2010;8(1):37-51. PMID: 20038192.
80. Jang JL, Bekelman JE, Liu Y, Bach PB, Basch EM, Elkin EB, Zelefsky MJ, Scardino PT, Begg CB, **Schrag D**. Physician visits prior to treatment for clinically localized prostate cancer. *Arch Intern Med*. 2010 Mar 8;170(5):440-50. PMID: 20212180.
81. Kahn KL, Adams JL, Weeks JC, Chrischilles EA, **Schrag D**, Ayanian JZ, Kiefe CI, Ganz PA, Bhoopalam N, Potosky AL, Harrington DP, Fletcher RH. Adjuvant Chemotherapy Use and Adverse Events Among Older Patients with Stage III Colon Cancer. *JAMA*. 2010 Mar;303(11):1037-45. PMID: 20233821.
82. Elkin EB, Ishill NM, Snow JG, Panageas KS, Bach PB, Liberman L, Wang F, **Schrag D**. Geographic Access, and the Use of Screening Mammography. *Med Care*. 2010 Apr;48(4):349-56. PMID: 20195174.
83. Chou JF, Row D, Gonen M, Liu YH, **Schrag D**, Weiser MR. Clinical and pathologic factors that predict lymph node yield from surgical specimens in colorectal cancer: a population-based study. *Cancer*. 2010 Jun 1;116(11):2560-70. PMID: 20499400.
84. Rajput A, Romanus D, Weiser MR, ter Veer A, Niland J, Wilson J, Skibber JM, Wong YN, Benson A, Earle CC, **Schrag D**. Meeting the 12-lymph node (LN) benchmark in colon cancer. *J Surg Oncol*. 2010 Jul;102(1):3-9. PMID: 20578172.
85. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, **Schrag D**, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). *J Clin Oncol*. 2010 Aug 1;28(22):3617-22. PMID: 20606091.
86. Sima CS, Panageas KS, **Schrag D**. Cancer screening among patients with advanced cancer. *JAMA*. 2010 Oct 13;304(14):1584-91. PMID: 20940384.
87. Yung RL, Chen K, Abel GA, Gesten GA, Roohan PJ, Boscoe FP, Sinclair AH, Schymura MJ, **Schrag D**. Cancer Disparities in the Context of Medicaid Insurance: A Comparison of Survival for Acute Myeloid Leukemia and Hodgkin's Lymphoma by Medicaid Enrollment. *The Oncologist*. 2011; 16:1082-1091. PMID: 21873583.
88. Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, Muzikansky A, Clark JW, Kwak EL, **Schrag D**, Jors KR, Fuchs CS, Iafrate AJ, Borger DR, Ryan DP. Phase 1-2 study of everolimus in advanced hepatocellular carcinoma. *Cancer*. 2011 Apr 27;117(22):5094-102. PMID: 21538343.
89. Martin MY, Pisu M, Oster RA, Urmie JM, **Schrag D**, Huskamp HA, Lee J, Kiefe CI, Fouad MN. Racial variation in willingness to trade financial resources for life-prolonging cancer treatment. *Cancer*. 2011 Apr 26;117(15):3476-84. PMID: 21523759.

90. Sher DJ, Neville BA, Chen AB, **Schrag D**. Predictors of IMRT and Conformal Radiotherapy Use in Head and Neck Squamous Cell Carcinoma: A SEER-Medicare Analysis. *Int J Radiat Oncol Biol Phys*. 2011 May 17;81(4):197-206. PMID: 21596483.
91. Chan JA, Blaszkowsky LS, Enzinger PC, Ryan DP, Abrams TA, Zhu AX, Temel JS, **Schrag D**, Bhargava P, Meyerhardt JA, Wlopin BM, Fidias P, Zheng H, Florio S, Regan E, Fuchs CS. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. *Ann Oncol*. 2011 Jun;22(6):1367-73. PMID: 21217058.
92. Boscoe FP, **Schrag D**, Chen K, Roohan PJ, Schymura MJ. Building Capacity to Assess Cancer Care in the Medicaid Population in New York State. *Health Serv Res*. 2011 Jun;46(3):805-20. PMID: 21158856.
93. Greenberg CC, Lipsitz SR, Neville B, In H, Hevelone N, Porter SA, Weeks C, Jha AK, Gawande AA, **Schrag D**, Weeks JC. Receipt of Appropriate Surgical Care for Medicare Beneficiaries With Cancer. *Arch Surg*. 2011 Jun 20;146(10):1128-34. PMID: 21690439.
94. Chen AB, Neville BA, Sher DJ, Chen K, **Schrag D**. Survival Outcomes After Radiation Therapy for Stage III Non-Small-Cell Lung Cancer After Adoption of Computed Tomography-Based Simulation. *J Clin Oncol*. 2011 Jun 10;29(17):2305-11. PMID: 21537034.
95. Abrams TA, Brightly R, Mao J, Kirkner G, Meyerhardt JA, **Schrag D**, Fuchs CS. Patterns of Adjuvant Chemotherapy Use in a Population-Based Cohort of Patients with Resected Stage II or III Colon Cancer. *J Clin Oncol*. 2011 Aug 20;29(24):3255-62. PMID: 21768462.
96. Zafar SY, Malin JL, Grambow SC, Abbott DH, **Schrag D**, Kolimaga JT, Zullig LL, Weeks JC, Fouad MN, Ayanian JZ, Wallace R, Kahn KL, Ganz PA, Catalano P, West DW, Provenzale D. Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study. *Cancer*. 2011 Aug 16; 11 (1):354. PMID: 21846341.
97. Atkinson TM, Li Y, Coffey CW, Sit L, Shaw M, Lavene D, Bennett AV, Fruscione M, Rogak L, Hay J, Gönen M, **Schrag D**, Basch E. Reliability of adverse symptom event reporting by clinicians. *Qual Life Res*. 2012 Sep;21(7):1159-64. PMID: 21984468.
98. Weiser MR, Gönen M, Chou JF, Kattan MW, **Schrag D**. Predicting survival after curative colectomy for cancer: individualizing colon cancer staging. *J Clin Oncol*. 2011 Dec 20;29(36):4796-802. PMID: 22084366.
99. Delate T, Witt DM, Ritzwoller D, Weeks JC, Kushi L, Hornbrook MC, Aiello Bowles EJ, **Schrag D**. Outpatient use of low molecular weight heparin monotherapy for first-line treatment venous thromboembolism in advanced cancer. *Oncologist*. 2012;17(3):419-27. PMID: 22334451.
100. Zhu J, Sharma DB, Gray SW, Chen AB, Weeks JC, **Schrag D**. Carboplatin and Paclitaxel with vs Without Bevacizumab in Older Patients with Advanced Non-Small Cell Lung Cancer. *JAMA*. 2012;307(15):1593-1601. PMID: 22511687.
101. Panageas KS, Sima CS, Liberman L, **Schrag D**. Use of high technology imaging for surveillance of early-stage breast cancer. *Breast Cancer Res Treat*. 2012 Jan;131(2):663-70. PMID: 21947679.
102. Elkin EB, Snow JG, Leoce NM, Atoria CL, **Schrag D**. Mammography capacity and appointment wait times: barriers to breast cancer screening. *Cancer Causes Control*. 2012 Jan;23(1):45-50. PMID: 22037904.

103. Sanoff HK, Carpenter WR, Martin CF, Sargent DJ, Meyerhardt JA, Stürmer T, Fine JP, Weeks J, Niland J, Kahn KL, Schymura MJ, **Schrag D**. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. *J Natl Cancer Inst*. 2012 Feb 8;104(3):211-27. PMID: 22266473.
104. Meyerhardt JA, Li L, Sanoff HK, Carpenter W 4th, **Schrag D**. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare insured patients with stage IV colorectal cancer. *J Clin Oncol*. 2012 Feb 20;30(6):608-15. PMID: 22253466.
105. Romanus D, Kindler HL, Archer L, Basch E, Niedzwiecki D, Weeks J, **Schrag D**. Cancer and Leukemia Group B. Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). *J Pain Symptom Manage*. 2012 Feb;43(2):205-17. PMID: 22104618.
106. Gollub MJ, Gultekin DH, Akin O, Do RK, Fuqua JL 3rd, Gonen M, Kuk D, Weiser M, Saltz L, **Schrag D**, Goodman K, Paty P, Guillem J, Nash GM, Temple L, Shia J, Schwartz LH. Dynamic contrast enhanced MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer. *Eur Radiol*. 2012 Apr;22(4):821-31. PMID: 22101743.
107. Yung RL, Hassett MJ, Chen K, Gesten FC, Roohan PJ, Boscoe FP, Sinclair AH, Schymura MJ, **Schrag D**. Initiation of Adjuvant Hormone Therapy by Medicaid Insured Women with Non-metastatic Breast Cancer; *J Natl Cancer Inst*. 2012 Jun;104(14):1102-5. PMID: 22773822.
108. Sanoff HK, Carpenter WR, Stürmer T, Goldberg RM, Martin CF, Fine JP, McCleary NJ, Meyerhardt JA, Niland J, Kahn KL, Schymura MJ, **Schrag D**. Effect of Adjuvant Chemotherapy on Survival of Patients With Stage III Colon Cancer Diagnosed After Age 75 Years. *J Clin Oncol*. 2012 Jul 20;30(21):2624-34. PMID: 22665536.
109. Morikawa T, Tanaka N, Kuchiba A, Nosho K, Yamauchi M, Hornick JL, Swanson RS, Chan AT, Meyerhardt JA, Huttenhower C, **Schrag D**, Fuchs CS, Ogino S. Predictors of Lymph Node Count in Colorectal Cancer Resections: Data from US Nationwide Prospective Cohort Studies. *Arch Surg*. 2012 Aug;147(8):715-23. PMID: 22508672.
110. Sanoff HK, Carpenter WR, Freburger J, Li L, Chen K, Zullig LL, Goldberg RM, Schymura MJ, **Schrag D**. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: A Population-based analysis. *Cancer*. 2012 Sep 1;118(17):4309-20. PMID: 22294436.
111. Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL, **Schrag D**. Patients' Expectations about Chemotherapy for Advanced Cancer. *N Engl J Med*. 2012 Oct; 367:1616-25. PMID: 23094723
112. Knudsen AB, Hur C, Gazelle GS, **Schrag D**, McFarland EG, Kuntz KM. Rescreening of persons with a negative colonoscopy result: results from a microsimulation model. *Ann Intern Med*. 2012 Nov 6;157(9):611-20. PMID: 23128861.
113. Feuer EJ, Lee M, Mariotto AB, Cronin KA, Scoppa S, Penson DF, Hachey M, Cynkin L, Carter GA, Campbell D, Percy-Laurry A, Zou Z, **Schrag D**, Hankey BF. The Cancer Survival Query System: Making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant. *Cancer*. 2012 Nov 15;118(22):5652-62. PMID: 22569947.
114. Sinclair AH, Schymura MJ, Boscoe FP, Yung RL, Chen K, Roohan P, Tai E, **Schrag D**. Measuring colorectal cancer carequality for the publicly insured in New York State. *Cancer Med*. 2012 Dec;1(3):363-71. PMID: 23342286.

115. Abel GA, Chen K, Taback N, Hassett MJ, **Schrag D**, Weeks JC. Impact of oncology-related direct-to-consumer advertising: Association with appropriate and inappropriate prescriptions. *Cancer*. 2013 Mar 1;119(5):1065-72. PMID: 23132702.
116. Hassett MJ, Ritzwoller DP, Taback N, Carroll N, Cronin AM, Ting GV, **Schrag D**, Warren JL, Hornbrook MC, Weeks JC. Validating Billing? Encounter Codes as Indicators of Lung, Colorectal, Breast, and Prostate Cancer Recurrence Using 2 Large Contemporary Cohorts. *Med Care*. 2014 Oct;52(10):65-73. PMID: 23222531.
117. Dodgion CM, Neville BA, Lipsitz SR, Hu YY, **Schrag D**, Breen E, Greenberg CC. Do older Americans undergo stoma reversal following low anterior resection for rectal cancer? *J Surg Res*. 2013 Jul;183(1):238-45. PMID: 23298948.
118. Khrizman P, Niland JC, Ter Veer A, Milne D, Bullard Dunn K, Carson WE 3rd, Engstrom PF, Shibata S, Skibber JM, Weiser MR, **Schrag D**, Benson AB 3<sup>rd</sup>. Postoperative Adjuvant Chemotherapy Use in Patients With Stage II/III Rectal Cancer Treated With Neoadjuvant Therapy: A National Comprehensive Cancer Network Analysis. *J Clin Oncol*. 2013 Jan 1; 31(1):30-8. PMID: 23169502.
119. McCleary NJ, Wigler D, Berry D, Sato K, Abrams T, Chan J, Enzinger P, Ng K, Wolpin B, **Schrag D**, Fuchs CS, Hurria A, Meyerhardt JA. Feasibility of computer-based self-administered cancer-specific geriatric assessment in older patients with gastrointestinal malignancy. *Oncologist*. 2013 Jan 3;18(1):64-72. PMID: 23287880.
120. Chen AB, Cronin A, Weeks JC, Chrischilles EA, Malin J, Hayman JA, **Schrag D**. Palliative Radiation Therapy Practice in Patients with Metastatic Non-Small-Cell Lung Cancer: A Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study. *J Clin Oncol*. 2013 Feb 10;31(5):558-64. PMID: 23295799.
121. Zafar SY, Peppercorn JM, **Schrag D**, Taylor DH, Goetzinger AM, Zhong X, Abernethy AP. The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience. *Oncologist*. 2013 Feb 26; 18(4):381-90. PMID: 23442307.
122. Greenberg CC, Wind JK, Chang GJ, Chen RC, **Schrag D**. Stakeholder engagement for comparative effectiveness research in cancer care: experience of the DEClDE Cancer Consortium. *J Comp Eff Res*. 2013 Mar;2(2):117-25. PMID: 24236554.
123. Wolpin BM, Ng K, Zhu AX, Abrams T, Enzinger PC, McCleary NJ, **Schrag D**, Kwak EL, Allen JN, Bhargava P, Chan JA, Goessling W, Blaszkowsky LS, Supko JG, Elliot M, Sato K, Regan E, Meyerhardt JA, Fuchs CS. Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients with Refractory, Metastatic Colorectal Cancer. *Oncologist*. 2013 April 11;18(4):377-8. PMID: 23580238
124. Elkin EB, Paige NJ, Pinheiro LC, Atoria CL, **Schrag D**. Changes in access to screening mammography, 2008-2011. *Cancer Causes Control*. 2013 May;24(5):1057-9. PMID: 23468282.
125. Johnson BE, Weeks JC, **Schrag D**. Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer. *Cancer*. 2013 Jun 1;119(11):2048-60. PMID: 23564469.
126. Brooks GA, Li L, Sharma DB, Weeks JC, Hassett MJ, Yabroff KR, **Schrag D**. Regional Variation in Spending and Survival for Older Adults with Advanced Cancer. *J Natl Cancer Inst*. 2013 May 1;105(9):634-42. PMID: 23482657.
127. Yeh, JM, Hur, C, **Schrag D**, Kuntz, KM, Ezzati, M, Stout, N, Ward, Z, Goldie, SJ. Contribution of H. pylori and Smoking Trends to US Incidence of Intestinal-Type Noncardia Gastric Adenocarcinoma: A Microsimulation Model. *PLoS Med*. 2013 May 21;10(5):1-13. PMID: 23700390.

128. Soeteman DI, Stout NK, Ozanne EM, Greenberg C, Hassett MJ, **Schrag D**, Punglia RS. Modeling the Effectiveness of Initial Management Strategies for Ductal Carcinoma in Situ. *J Natl Cancer Inst.* 2013 Jun 5;105(11):774-781. PMID: 23644480.
129. Chen AB, Cronin A, Weeks JC, Chrischilles EA, Malin J, Hayman JA, **Schrag D**. Expectations About the Effectiveness of Radiation Therapy Among Patients with Incurable Lung Cancer. *J Clin Oncol.* 2013 Jul 20;31(21):2730-5. PMID: 23775958.
130. Mack JW, Chen K, Boscoe FP, Gesten FC, Roohan PJ, Weeks JC, Schymura MJ, **Schrag D**. Underuse of hospice care by Medicaid-insured patients with stage IV lung cancer in New York and California. *J Clin Oncol.* 2013 Jul 10;31(20):2569-79. PMID: 23733768.
131. Judson TJ, Bennett AV, Rogak LJ, Sit L, Barz A, Kris MG, Hudis CA, Scher HI, Sabattini P, **Schrag D**, Basch E. Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy. *J Clin Oncol.* 2013 Jul 10;31(20):2580-5. PMID: 23733753.
132. Chawla N, Yabroff KR, Mariotto A, McNeel T, **Schrag D**, Warren J. PS1-39: Diagnosis Codes for Cancer Metastasis on Medicare Claims Have Limited Accuracy and Completeness. *Clin Med Res.* 2013 Sep;11(3):131. PMCID: PMC3788546.
133. Shih YC, Ganz PA, Aberle D, Abernethy A, Bekelman J, Brawley O, Goodwin JS, Hu JC, **Schrag D**, Temel JS, Schnipper L. Delivering High-Quality and Affordable Care Throughout the Cancer Care Continuum. *J Clin Oncol.* 2013 Nov 10;31(32):4151-7. PMID: 24127450.
134. Zullig LL, Peppercorn JM, **Schrag D**, Taylor DH Jr, Lu Y, Samsa G, Abernethy AP, Zafar SY. Financial Distress, Use of Cost-Coping Strategies, and Adherence to Prescription Medication Among Patients with Cancer. *J Oncol Pract.* 2013 Nov;9(6S):60s-63s. PMID: 29431038.
135. Elkin EB, Atoria CL, Leoce N, Bach PB, **Schrag D**. Changes in the availability of screening mammography, 2000-2010. *Cancer.* 2013 Nov 1;119(21):3847-53. PMID: 23943323.
136. Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, Petrelli NJ, Ryan K, **Schrag D**, Wong SL, Benson AB 3rd; ASCO. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: ASCO clinical practice guideline endorsement. *J Clin Oncol.* 2013 Dec 10;31(35):4465-70. PMID: 24220554.
137. Neuman HB, Weiss JM, **Schrag D**, Ronk K, Havlena J, Loconte NK, Smith MA, Greenberg CC. Patient Demographic and Tumor Characteristics Influencing Oncologist Follow-Up Frequency in Older Breast Cancer Survivors. *Ann Surg Oncol.* 2013 Dec;20(13):4128-36. PMID: 23943027.
138. Rutter CM, Johnson EA, Feuer EJ, Knudsen AB, Kuntz KM, **Schrag D**. Secular Trends in Colon and Rectal Cancer Relative Survival. *J Natl Cancer Inst.* 2013 Dec 4;105(23):1806-13. PMID: 24174654.
139. Martin MY, Fouad MN, Oster RA, **Schrag D**, Urmie J, Sanders S, Pisu M. What do cancer patients worry about when making decisions about treatment? Variation across racial/ethnic groups. *Support Care Cancer.* 2014 Jan;22(1):233-44. PMID: 24037412.
140. Reyngold M, Niland J, Ter Veer A, Milne D, Bekaii-Saab T, Cohen SJ, Lai L, **Schrag D**, Skibber JM, Small W Jr, Weiser M, Wilkinson N, Goodman KA. Neoadjuvant Radiotherapy Use in Locally Advanced Rectal Cancer at NCCN Member Institutions. *J Natl Compr Canc Netw.* 2014 Feb;12(2):235-43. PMID: 24586085.

141. Abrams TA, Meyer G, **Schrag D**, Meyerhardt JA, Moloney J, Fuchs CS. Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer. *J Natl Cancer Inst.* 2014 Feb;106(2). PMID: 24511107.
142. Brooks GA, Abrams TA, Meyerhardt JA, Enzinger PC, Sommer K, Dalby CK, Uno H, Jacobson JO, Fuchs CS, **Schrag D**. Identification of potentially avoidable hospitalizations in patients with GI cancer. *J Clin Oncol.* 2014 Feb 20;32(6):496-503. PMID: 24419123.
143. **Schrag D**, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, Reidy-Lagunes DL, Gollub MJ, Shia J, Guillem JG, Temple LK, Paty PB, Saltz LB. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. *J Clin Oncol.* 2014 Feb 20;32(6). PMID: 24419115.
144. Hay JL, Atkinson TM, Reeve BB, Mitchell SA, Mendoza TR, Willis G, Minasian LM, Clauser SB, Denicoff A, O'Mara A, Chen A, Bennett AV, Paul DB, Gagne J, Rogak L, Sit L, Viswanath V, **Schrag D**, Basch E; NCI PRO-CTCAE Study Group. Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). *Qual Life Res.* 2014 Feb;23(1):257-69. PMID: 23868457.
145. Wang Y, **Schrag D**, Brooks GA, Dominici F. National trends in pancreatic cancer outcomes and pattern of care among Medicare beneficiaries, 2000 through 2010. *Cancer.* 2014 Apr 1;120(7):1050-8. PMID: 24382787.
146. Arvold ND, Wang Y, Zigler C, **Schrag D**, Dominici F. Hospitalization burden and survival among older glioblastoma patients. *Neuro-Oncology.* 2014 Apr 28;1-11. PMID: 24778086.
147. Bestvina CM, Zullig LL, Rushing C, Chino F, Samsa GP, Altomare I, Tulskey J, Ubel P, **Schrag D**, Nicolla J, Abernethy AP, Peppercorn J, Zafar SY. Patient-oncologist cost communication, financial distress, and medication adherence. *J Oncol Pract.* 2014 May;10(3):162-7. PMID: 24839274.
148. Wolpin BM, Rubinson DA, Wang X, Chan JA, Cleary JM, Enzinger PC, Fuchs CS, McCleary NJ, Meyerhardt JA, Ng K, **Schrag D**, Sikora AL, Spicer BA, Killion L, Mamon H, Kimmelman AC. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. *Oncologist.* 2014 Jun;19(6):637-8. PMID: 24821822.
149. Weeks JC, Uno H, Taback N, Ting G, Cronin A, D'Amico TA, Friedberg JW, **Schrag D**. Interinstitutional Variation in Management Decisions for Treatment of 4 Common Types of Cancer: A Multi-institutional Cohort Study. *Ann Intern Med.* 2014 Jul 1;161(1):20-30. PMID: 24979447.
150. Tejani MA, Ter Veer A, Milne D, Ottesen R, Bekaii-Saab T, Benson AB 3rd, **Schrag D**, Shibata S, Skibber J, Weiser M, Wilkinson N, Cohen SJ. Systemic Therapy for Advanced Appendiceal Adenocarcinoma: An Analysis From the NCCN Oncology Outcomes Database for Colorectal Cancer. *J Natl Compr Canc Netw.* 2014 Aug;12(8):1123-30. PMID: 25099444.
151. Uno H, Claggett B, Tian L, Inoue E, Gallo P, Miyata T, **Schrag D**, Takeuchi M, Uyama Y, Zhao L, Skali H, Solomon S, Jacobus S, Hughes M, Packer M, Wei LJ. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. *J Clin Oncol.* 2014 Aug 1;32(22):2380-5. PMID: 24982461.
152. Wong AC, Stock S, **Schrag D**, Kahn KL, Salz T, Charlton ME, Rogers SO Jr, Goodman KA, Keating NL. Physicians' Beliefs About the Benefits and Risks of Adjuvant Therapies for Stage II and Stage III Colorectal Cancer. *J Oncol Pract.* 2014 Sep;10(5):e360-7. PMID: 24986112.

153. Trinh QD, **Schrag D**. Measuring the Effectiveness of Androgen-Deprivation Therapy for Prostate Cancer in the Medicare Population: Adequate Data Are Neither the Same as Nor the Enemy of Perfect Data. *JAMA Intern Med*. 2014 Sep;174(9):1468-9. PMID: 25023522.
154. Chawla N, Yabroff KR, Mariotto A, McNeel TS, **Schrag D**, Warren JL. Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage. *Ann Epidemiol*. 2014 Sep;24(9):666-72, 672. PMID: 25066409.
155. Dodgion CM, Neville BA, Lipsitz SR, **Schrag D**, Breen E, Zinner MJ, Greenberg CC. Hospital variation in sphincter preservation for elderly rectal cancer patients. *J Surg Res*. 2014 Sep;191(1):161-8. PMID: 24750983.
156. Kehl KL, Arora NK, **Schrag D**, Ayanian JZ, Clauser SB, Klabunde CN, Kahn KL, Fletcher RH, Keating NL. Discussions about clinical trials among patients with newly diagnosed lung and colorectal cancer. *J Natl Cancer Inst*. 2014 Sep 13;106(10). PMID: 25217775.
157. Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, **Schrag D**. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). *J Natl Cancer Inst*. 2014 Sep 29;106(9). PMID: 25265940.
158. Brooks GA, Li L, Uno H, Hassett MJ, Landon BE, **Schrag D**. Acute hospital care is the chief driver of regional spending variation in medicare patients with advanced cancer. *Health Aff (Millwood)*. 2014 Oct 1;33(10):1793-800. PMID: 25288424.
159. Greenberg CC, Habel LA, Hughes ME, Nekhlyudov L, Achacoso N, Acton L, **Schrag D**, Jiang W, Edge S, Weeks JC, Punglia RS. Characterization and Treatment of Local Recurrence Following Breast Conservation for Ductal Carcinoma In Situ. *Ann Surg Oncol*. 2014 Nov;21(12):3766-73. PMID: 24859938.
160. Yeo H, Niland J, Milne D, Veer AT, Bekaii-Saab T, Farma JM, Lai L, Skibber JM, Small W Jr, Wilkinson N, **Schrag D**, Weiser MR. Incidence of minimally invasive colorectal cancer surgery at national comprehensive cancer network centers. *J Natl Cancer Inst*. 2014 Dec 19;107(1). PMID: 25527640.
161. Lee KH, Haneuse S, **Schrag D**, Dominici F. Bayesian semi-parametric analysis of semi-competing risks data: investigating hospital readmission after a pancreatic cancer diagnosis. *J R Stat Soc Ser C Appl Stat*. 2015 Feb 1;64(2):253-273. PMID: 25977592.
162. Hiatt RA, Tai CG, Blayney DW, Deapen D, Hogarth M, Kizer KW, Lipscomb J, Malin J, Phillips SK, Santa J, **Schrag D**. Leveraging state cancer registries to measure and improve the quality of cancer care: a potential strategy for California and beyond. *J Natl Cancer Inst*. 2015 Mar 11;107(5). PMID: 25766400.
163. Brooks, GA, Jacobson JO, **Schrag, D**. Clinician perspectives on potentially avoidable hospitalizations in patients with cancer. *JAMA Oncol*. 2015 April;1(1)109-110. PMID: 26146663.
164. Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, **Schrag D**, Smith TJ, Yu PP, Hudis CA, Schilsky RL. ASCO statement: A conceptual framework to assess the value of cancer treatment options. *J Clin Oncol*. 2015 Aug 10;33(23):2563-77. PMID: 26101248.

165. Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM, O'Mara AM, Li Y, Clauser SB, Bryant DM, Bearden JD 3rd, Gillis TA, Harness JK, Siegel RD, Paul DB, Cleeland CS, **Schrag D**, Sloan JA, Abernethy AP, Bruner DW, Minasian LM, Basch E; National Cancer Institute PRO-CTCAE Study Group. Validity and reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). *JAMA Oncol*. 2015 Nov;1(8):1051-9. PMID: 26270597.
166. Morgans AK, van Bommel AC, Stowell C, Abrahm JL, Basch E, Bekelman JE, Berry DL, Bossi A, Davis ID, de Reijke TM, Denis LJ, Evans SM, Fleshner NE, George DJ, Kiefert J, Lin DW, Matthew AG, McDermott R, Payne H, Roos IA, **Schrag D**, Steuber T, Tombal B, van Basten JP, van der Hoeven JJ, Penson DF; Advanced Prostate Cancer Working Group of the International Consortium for Health Outcomes Measurement. Development of a standardized set of patient-centered outcomes for advanced prostate cancer: An international effort for a unified approach. *Eur Urol*. 2015 Nov;68(5):891-8. PMID: 26129856.
167. Mack JW, Chen K, Boscoe FP, Gesten FC, Roohan PJ, Schymura MJ, **Schrag D**. High intensity end-of-life care among adolescent and young adult cancer patients in the New York State Medicaid Program. *Med Care*. 2015 Dec;53(12):1018-26. PMID: 26492211.
168. Enzinger AC, Zhang B, **Schrag D**, Prigerson HG Outcomes of prognostic disclosure: Associations with prognostic understanding, distress, and relationship with physician among patients with advanced cancer. *J Clin Oncol*. 2015 Nov 10;33(32):3809-16. PMID: 26438121.
169. Brooks GA, Cronin AM, Uno H, **Schrag D**, Keating NL, Mack JW. Intensity of Medical Interventions between diagnosis and death in patients with advanced lung and colorectal cancer: A CanCORS analysis. *J Palliat Med*. 2016 Jan;19(1):42-50. PMID: 26600474.
170. Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, **Schrag D**. Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial. *J Clin Oncol*. 2016 Feb 20;34(6):557-65. PMID: 26644527.
171. Hassett MJ, Jiang W, Habel LA, Nekhlyudov L, Achacoso N, Acton L, Schnitt SJ, **Schrag D**, Punglia RS. Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community. *Breast Cancer Res Treat*. 2016 Feb;155(3):541-9. PMID: 26843057.
172. Hassett MJ, Schymura MJ, Chen K, Boscoe FP, Gesten FC, **Schrag D**. Variation in breast cancer care quality in New York and California based on race/ethnicity and Medicaid enrollment. *Cancer*. 2016 Feb 1;122(3):420-31. PMID: 26536043.
173. Bennett AV, Dueck AC, Mitchell SA, Mendoza TR, Reeve BB, Atkinson TM, Castro KM, Denicoff A, Rogak LJ, Harness JK, Bearden JD, Bryant D, Siegel RD, **Schrag D**, Basch E; National Cancer Institute PRO-CTCAE Study Group. Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). *Health Qual Life Outcomes*. 2016 Feb 19;14(1):24. PMID: 26892667.
174. Yeh JM, Hur C, Ward Z, **Schrag D**, Goldie SJ. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. *Gut*. 2016 Apr;65(4):563-74. PMID: 25779597.

175. Lathan CS, Cronin A, Tucker-Seeley R, Zafar SY, Ayanian JZ, **Schrag D**. Association of Financial Strain with Symptom Burden and Quality of Life for Patients With Lung or Colorectal Cancer. *J Clin Oncol*. 2016 May 20;34(15):1732-40. PMID: 26926678.
176. Basch E, Wood WA, **Schrag D**, Sima CS, Shaw M, Rogak LJ, Kris MG, Shouery M, Bennett A, Atkinson T, Pietanza MC. Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial. *Clin Trials*. 2016 Jun;13(3):331-7. PMID: 26542025.
177. **Schrag D**. Reimbursing Wisely? CMS's Experiment with Part B Drug Reimbursement. *N Engl J Med*. 2016 Jun 2;374(22):2101-5. PMID: 27248616.
178. Nipp RD, Zullig LL, Samsa G, Peppercorn JM, **Schrag D**, Taylor DH Jr, Abernethy AP, Zafar SY. Identifying cancer patients who alter care or lifestyle due to treatment-related financial distress. *Psychooncology*. 2016 Jun;25(6):719-25. PMID: 26149817.
179. Jazić I, **Schrag D**, Sargent DJ, Haneuse S. Beyond Composite Endpoints Analysis: Semi-competing Risks as an Underutilized Framework for Cancer Research. *J Natl Cancer Inst*. 2016 Jul 5;108(12). PMID: 27381741.
180. Popescu I, **Schrag D**, Ang A, Wong M. Racial/Ethnic and Socioeconomic Differences in Colorectal and Breast Cancer Treatment Quality: The Role of Physician-level Variations in Care. *Med Care*. 2016 Aug;54(8):780-8. PMID: 27326547.
181. Halpern MT, **Schrag D**. Effects of state-level medicaid policies and patient characteristics on time to breast cancer surgery among medicaid beneficiaries. *Breast Cancer Res Treat*. 2016 Aug;158(3):573-81. PMID: 27422241.
182. Keating NL, Landrum MB, Huskamp HA, Kouri EM, Prigerson HG, **Schrag D**, Maciejewski PK, Hornbrook MC, Haggstrom DA. Dartmouth Atlas Area-Level Estimates of End-of-Life Expenditures: How Well Do They Reflect Expenditures for Prospectively Identified Advanced Lung Cancer Patients? *Health Serv Res*. 2016 Aug;51(4):1584-94. PMID: 26799913.
183. Warren JL, Mariotto A, Melbert D, **Schrag D**, Doria-Rose P, Penson D, Yabroff KR. Sensitivity of Medicare Claims to Identify Cancer Recurrence in Elderly Colorectal and Breast Cancer Patients. *Med Care*. 2016 Aug;54(8):e47-54. PMID: 24374419.
184. Neuman HB, Rathouz PJ, Winslow E, Weiss JM, LoConte NK, Lin CP, Wurm M, Smith MA, **Schrag D**, Greenberg CC. Use of a novel statistical technique to examine the delivery of breast cancer follow-up care by different types of oncology providers. *J Eval Clin Pract*. 2016 Oct;22(5):737-44. PMID: 26991311.
185. Abdel-Misih SR, Wei L, Benson AB 3rd, Cohen S, Lai L, Skibber J, Wilkinson N, Weiser M, **Schrag D**, Bekaii-Saab T. Neoadjuvant Therapy for Rectal Cancer Affects Lymph Node Yield and Status Without Clear Implications on Outcome: The Case for Eliminating a Metric and Using Preoperative Staging to Guide Therapy. *J Natl Compr Canc Netw*. 2016 Dec;14(12):1528-1534. PMID: 27956537.
186. Arvold N, Cefalu M, Wang Y, Zigler C, **Schrag D**, Dominici F. Comparative effectiveness of radiology with vs. without temozolomide in older patients with glioblastoma. *J Neurooncol*. 2017 Jan;131(2):301-311. PMID: 27770280.
187. Punglia RS, Cronin AM, Uno H, Stout NK, Ozanne EM, Greenberg CC, Frank ES, **Schrag D**. Association of Regional Intensity of Ductal Carcinoma In Situ Treatment With Likelihood of Breast Preservation. *JAMA Oncol*. 2017 Jan 1;3(1):101-104. PMID: 27442038.

188. Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, Ukaegbu CI, Brais LK, McNamara PG, Mayer RJ, **Schrag D**, Meyerhardt JA, Ng K, Kidd J, Singh N, Hartman AR, Wenstrup RJ, Syngal S. Cancer Susceptibility Gene Mutations in Individuals with Colorectal Cancer. *J Clin Oncol*. 2017 Apr 1;35(10):1086-1095. PMID: 28135145.
189. Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, **Schrag D**, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB 3rd, Mulkerin DL, Mayer RJ, Blanke C. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. *JAMA*. 2017 Jun 20;317(23):2392-2401. PMID: 28632865.
190. Mendoza TR, Dueck AC, Bennett AV, Mitchell SA, Reeve BB, Atkinson TM, Li Y, Castro KM, Denicoff A, Rogak LJ, Piekarz RL, Cleeland CS, Sloan JA, **Schrag D**, Basch E. Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE. *Clin Trials*. 2017 Jun;14(3):255-263. PMID: 28545337.
191. Kastrinos F, Uno H, Ukaegbu C, Alvero C, McFarland A, Yurgelun MB, Kulke MH, **Schrag D**, Meyerhardt JA, Fuchs CS, Mayer RJ, Ng K, Steyerberg EW, Syngal S. Development and Validation of the PREMM<sub>5</sub> Model for Comprehensive Risk Assessment of Lynch Syndrome. *J Clin Oncol*. 2017 Jul 1;35(19):2165-2172. PMID: 28489507.
192. Del Paggio JC, Sullivan R, **Schrag D**, Hopman WM, Azariah B, Pramesh CS, Tannock IF, Booth CM. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. *Lancet Oncol*. 2017 Jul;18(7):887-894. PMID: 28583794.
193. Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, **Schrag D**. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. *JAMA*. 2017 Jul 11;318(2):197-198. PMID: 28586821.
194. Basch E, Dueck A, Rogak L, Minasian L, Kelly W, O'Mara A, Denicoff A, Seisler D, Atherton P, Paskett E, Carey L, Dickler M, Heist R, Himmelstein A, Rugo H, Sikov W, Socinski M, Venook A, Weckstein D, Lake D, Biggs D, Freedman R, Kuzma C, Kirshner J, **Schrag D**. Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. *JAMA Oncol*. 2017 Aug 1;3(8):1043-1050. PMID: 28208174.
195. Tramontano AC, Sheehan DF, Yeh JM, Kong CY, Dowling EC, Rubenstein JH, Abrams JA, Inadomi JM, **Schrag D**, Hur C. The Impact of a Prior Diagnosis of Barrett's Esophagus on Esophageal Adenocarcinoma Survival. *Am J Gastroenterol*. 2017 Aug;112(8):1256-1264. PMID: 28374815
196. Abrams TA, Meyer G, Meyerhardt JA, Wolpin BM, **Schrag D**, Fuchs CS. Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer. *Oncologist*. 2017 Aug;22(8):925-933. PMID: 28476943.
197. Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, **Schrag D**, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. *J Natl Cancer Inst*. 2017 Aug 1;109(8). PMID: 28376195.
198. Enzinger AC, Wind JK, Frank E, McCleary NJ, Porter L, Cushing H, Abbott C, Cronin C, Enzinger PC, Meropol NJ, **Schrag D**. A stakeholder-driven approach to improve the informed consent process for palliative chemotherapy. *Patient Educ Couns*. 2017 Aug;100(8):1527-1536. PMID: 28359659.
199. Yeh J, Tramontano A, Hur C, **Schrag D**. Comparative effectiveness of adjuvant chemoradiotherapy after gastrectomy among older patients with gastric adenocarcinoma: a SEER-Medicare study. *Gastric Cancer*. 2017 Sep;20(5):811-824. PMID: 28205057.

200. Pomerantz MM, Spisák S, Jia L, Cronin AM, Csabai I, Ledet E, Sartor AO, Rainville I, O'Connor EP, Herbert ZT, Szállási Z, Oh WK, Kantoff PW, Garber JE, **Schrag D**, Kibel AS, Freedman ML. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. *Cancer*. 2017 Sep 15;123(18):3532-3539. PMID: 28608931.
201. Mack JW, Jacobson J, Frank D, Cronin AM, Horvath K, Allen V, Wind J, **Schrag D**. Evaluation of Patient and Family Outpatient Complaints as a Strategy to Prioritize Efforts to Improve Cancer Care Delivery. *J Qual Patient Saf*. 2017 Oct;43(10):498-507. PMID: 28942774.
202. Reyngold M, Niland J, Ter Veer A, Bekaii-Saab T, Lai L, Meyer JE, Nurkin SJ, **Schrag D**, Skibber JM, Benson AB, Weiser MR, Crane CH, Goodman KA. Trends in intensity modulated radiation therapy use for locally advanced rectal cancer at National Comprehensive Cancer Network centers. *Adv Radiat Oncol*. 2017 Oct 12;3(1):34-41. PMID: 29556578.
203. Keating NL, Huskamp HA, **Schrag D**, McWilliams JM, McNeil BJ, Landon BE, Chernew ME, Normand ST. Diffusion of Bevacizumab Across Oncology Practices: An Observational Study. *Med Care*. 2018 Jan;56(1):69-77. PMID: 29135615.
204. Nipp R, Tramontano AC, Kong CY, Pandharipande P, Dowling EC, **Schrag D**, Hur C. Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer. *Cancer Med*. 2018 Feb;7(2):525-535. PMID: 29322643.
205. Hassett MJ, Jiang W, Hughes ME, Edge S, Javid SH, Niland JC, Theriault R, Wong YN, **Schrag D**, Punglia RS. Treating Second Breast Events After Breast-Conserving Surgery for Ductal Carcinoma in Situ. *J Natl Compr Canc Netw*. 2018 Apr;16(4):387-394. PMID: 29632058.
206. Selvaraj S, Bhatt DL, Claggett B, Djoussé L, Shah SJ, Chen J, Imran TF, Qazi S, Sesso HD, Gaziano JM, **Schrag D**. Lack of Association Between Heart Failure and Incident Cancer. *J Am Coll Cardiol*. 2018 Apr 10;71(14):1501-1510. PMID: 29622155.
207. Lam MB, Li L, Cronin A, **Schrag D**, Chen AB. Palliative radiation and fractionation in Medicare patients with incurable non-small cell lung cancer. *Adv Radiat Oncol*. 2018 Apr 23;3(3):382-390. PMID: 30202806.
208. Tramontano AC, Nipp R, Mercaldo ND, Kong CY, **Schrag D**, Hur C. Survival Disparities by Race and Ethnicity in Early Esophageal Cancer. *Dig Dis Sci*. 2018 Apr 23;3(3):382-390. PMID: 30109578
209. Snyder RA, Hu CY, Cuddy A, Francescatti AB, Schumacher JR, Van Loon K, You YN, Kozower BD, Greenberg CC, **Schrag D**, Venook A, McKellar D, Winchester DP, Chang GJ. Association Between Intensity of Posttreatment Surveillance Testing and Detection of Recurrence in Patients with Colorectal Cancer. Alliance for Clinical Trials in Oncology Network Cancer Surveillance Optimization Working Group. *JAMA*. 2018 May 22;319(20):2104-2115. PMID: 29800181.
210. Horiguchi M, Tian L, Uno H, Cheng S, Kim DH, **Schrag D**, Wei LJ. Quantification of Long-term Survival Benefit in a Comparative Oncology Clinical Study. *JAMA Oncol*. 2018 Jun 1;4(6):881-882. PMID: 29801103.
211. Rebbeck T, Burns-White K, Chan A, Emmons K, Freedman M, Hunter D, Kraft P, Laden F, Mucci L, Parmigiani G, **Schrag D**, Syngal S, Tamimi R, Viswanath V, Yurgelun M, Garber J. Precision Prevention and Early Detection of Cancer: Fundamental Principles. *Cancer Discov*. 2018 Jul;8(7):803-811. PMID: 29907587.

212. Keating NL, Huskamp HA, Kouri E, **Schrag D**, Hornbrook MC, Haggstrom DA, Landrum MB. Factors Contributing to Geographic Variation in End-Of-Life Expenditures For Cancer Patients. *Health Aff (Millwood)*. 2018 Jul;37(7):1136-1143. PMID: 29985699.
213. Schoen MW, Basch E, Hudson LL, Chung AE, Mendoza TR, Mitchell SA, St Germain D, Baumgartner P, Sit L, Rogak LJ, Shouery M, Shalley E, Reeve BB, Fawzy MR, Bhavsar NA, Cleeland C, **Schrag D**, Dueck AC, Abernethy AP. Software for Administering the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study. *JMIR Hum Factors*. 2018 Jul 16;5(3). PMID: 30012546.
214. McCleary NJ, Greenberg TL, Barysaukas CM, Guerette EJ, Hassan M, Jacobson JO, **Schrag D**. Oncology Patient Portal Enrollment at a Comprehensive Cancer Center: A Quality Improvement Initiative. *J Oncol Pract*. 2018 Aug;14(8). PMID: 30096276.
215. Chen CT, Li L, Brooks G, Hassett M, **Schrag D**. Medicare Spending for Breast, Prostate, Lung, and Colorectal Cancer Patients in the Year of Diagnosis and Year of Death. *Health Serv Res*. 2018 Aug;53(4):2118-2132. PMID: 28748564.
216. Chen AB, Li L, Cronin AM, Brooks GA, Kavanagh BD, **Schrag D**. Estimating Costs of Care Attributable to Cancer: Does the Choice of Comparison Group Matter? *Health Serv Res*. 2018 Aug;53 Suppl 13227-3244. PMID: 28858372.
217. Basch E, Dueck AC, Rogak LJ, Mitchell SA, Minasian LM, Denicoff AM, Wind JK, Shaw MC, Heon N, Shi Q, Ginos B, Nelson GD, Meyers JP, Chang GJ, Mamon HJ, Weiser MR, Kolevska T, Reeve BB, Bruner DW, **Schrag D**. Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. *J Clin Oncol*. 2018 Sept 11; PMID: 30204536.
218. Haneuse S, Dominici F, Normand S, **Schrag D**. Assessment of Between-Hospital Variation in Readmission and Mortality After Cancer Surgical Procedures. *JAMA Net*. 2018 Oct 5;1(6): e183038. PMID: 30646221.
219. Brooks GA, Austin AM, Uno H, Dragnev K, Tosteson A, **Schrag D**. Hospitalization and Survival of Medicare Patients Treated with Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Non-squamous, Non-Small Cell Lung Cancer. *JAMA Net*. 2018 Oct 5;1(6). PMID: 30646220.
220. Kehl KL, Lathan CS, Johnson BE, **Schrag D**. Race, Poverty, and Initial Implementation of Precision Medicine for Lung Cancer. *J Natl Cancer Inst*. 2019 Apr 1;111(4):431-434. PMID: 30576459.
221. Chung AE, Shoenbill K, Mitchell SA, Dueck AC, **Schrag D**, Bruner DW, Minasian LM, St Germain D, O'Mara AM, Baumgartner P, Rogak LJ, Abernethy AP, Griffin AC, Basch EM. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). *J Am Med Inform Assoc*. 2019 Apr 1;26(4):276-285. PMID: 30840079.
222. **Schrag D**, Weiser M, Saltz L, Mamon H, Gollub M, Basch E, Venook A, Shi Q. Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance). *Clin Trials*. 2019 Apr;16(2):165-175. PMID: 30688523.
223. Ng K, Nimeiri HS, McCleary NJ, Abrams TA, Yurgelun MB, Cleary JM, Rubinson DA, **Schrag D**, Miksad R, Bullock AJ, Allen J, Zuckerman D, Chan E, Chan JA, Wolpin BM, Constantine M, Weckstein DJ, Faggen MA, Thomas CA, Kournioti C, Yuan C, Ganser C, Wilkinson B, Mackintosh C, Zheng H, Hollis BW, Meyerhardt JA, Fuchs CS. Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With

Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial. *JAMA*. 2019 Apr 9;321(14):1370-1379. PMID: 30964527.

224. Brooks GA, Uno H, Aiello Bowles EJ, Menter AR, O'Keeffe-Rosetti M, Tosteson ANA, Ritzwoller DP, **Schrag D**. Hospitalization Risk During Chemotherapy for Advanced Cancer: Development and Validation of Risk Stratification Models Using Real-World Data. *JCO Clin Cancer Inform*. 2019 Apr;3:1-10. PMID: 30995122.
225. Kehl KL, Yang S, Awad MM, Palmer N, Kohane IS, **Schrag D**. Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. *Cancer Immunol Immunother*. 2019 Jun;68(6):917-926. PMID: 30877325.
226. Mossanen M, Krasnow RE, Zlatev DV, Tan WS, Preston MA, Trinh QD, Kibel AS, Sonpavde G, **Schrag D**, Chung BI, Chang SL. Examining the relationship between complications and perioperative mortality following radical cystectomy: A population-based analysis. *BJU Int*. 2019 Jul;124(1):40-46. PMID: 30499636.
227. Choi JG, Nipp RD, Tramontano A, Ali A, Zhan T, Pandharipande P, Dowling EC, Ferrone CR, Hong TS, **Schrag D**, Fernandez-Del Castillo C, Ryan DP, Kong CY, Hur C. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. *Oncologist*. 2019 Jul;24(7):945-954. PMID: 30559125.
228. Cleary JM, Horick NK, McCleary NJ, Abrams TA, Yurgelun MB, Azzoli CG, Rubinson DA, Brooks GA, Chan JA, Blaszkowsky LS, Clark JW, Goyal L, Meyerhardt JA, Ng K, **Schrag D**, Savarese DMF, Graham C, Fitzpatrick B, Gibb KA, Boucher Y, Duda DG, Jain RK, Fuchs CS, Enzinger PC. FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. *Cancer*. 2019 Jul 1;125(13):2213-2221. PMID: 30913304.
229. Kehl KL, Elmarakeby H, Nishino M, Van Allen EM, Lepisto EM, Hassett MJ, Johnson BE, **Schrag D**. Assessment of Deep Natural Language Processing in Ascertaining Oncologic Outcomes from Radiology Reports. *JAMA Oncol*. 2019 Jul 25;5(10):1421-1429. PMID: 31343664.
230. Griffith SD, Tucker M, Bowser B, Calkins G, Chang CJ, Guardino E, Khozin S, Kraut J, You P, **Schrag D**, Miksad RA. Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer. *Adv Ther*. 2019 Aug;36(8):2122-2136. PMID: 31140124.
231. Griffith SD, Miksad RA, Calkins G, You P, Lipitz NG, Bourla AB, Williams E, George DJ, **Schrag D**, Khozin S, Capra WB, Taylor MD, Abernethy AP. Characterizing the Feasibility and Performance of Real-World Tumor Progression Find Points and Their Association with Overall Survival in a Large Advanced Non-Small-Cell Lung Cancer Data Set. *JCO Clin Cancer Inform*. 2019 Aug;3:1-13. PMID: 31403818.
232. Uno H, **Schrag D**, Kim DH, Tang D, Tian L, Rugo HS, Wei LJ. Assessing Clinical Equivalence in Oncology Biosimilar Trials with Time-to-Events Outcomes. *JNCI Cancer Spectr*. 2019 Aug 1;3(4): PMID: 32337484.
233. Kehl KL, Hassett MJ, **Schrag D**. Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era. *Cancer Med*. 2020 Mar;9(6):2019-2029. PMID: 31989786.
234. Smyth LM, Zhou Q, Nguyen B, Yu C, Lepisto EM, Arnedos M, Hassett MJ, Lenoue-Newton ML, Blauvelt N, Dogan S, Micheel CM, Wathoo C, Horlings H, Hudecek J, Gross BE, Kundra R, Sweeney SM, Gao J, Schultz N, Zarski A, Gardos SM, Lee J, Sheffler-Collins S, Park BH, Sawyers CL, Andre F, Levy M, Meric-Bernstam F, Bedard PL, Iasonos A, **Schrag**

- D, Hyman DM, Genie Consortium AP. Characteristics and outcome of AKT1 E17K-mutant breast cancer defined through AACR GENIE, a clinic-genomic registry. *Cancer Discov.* 2020 Apr;10(4):526-535. PMID: 31924700.
235. J Griffith SD, Tucker M, Bowser B, Calkins G, Chang CJ, Guardino E, Khozin S, Kraut J, You P, **Schrag D**, Miksad RA. *Real World RECIST Adv Ther.* 2020 Apr;37(4):1691-1693. PMID: 32056085.
236. Milligan MG, Cronin AM, Colson Y, Kehl K, Yeboa DN, **Schrag D**, Chen AB. Overuse of Diagnostic Brain Imaging Among Patients with Stage IA Non-Small Cell Lung Cancer. *J Natl Compr Canc Netw.* 2020 May;18(5):547-554. PMID: 32380461.
237. Kehl KL, **Schrag D**, Hassett MJ, Uno H. Assessment of Temporal Selection Bias in Genomic Testing in a Cohort of Patients with Cancer. *JAMA Netw Open.* 2020 Jun 1;3(6):e206976. PMID: 32511717.
238. Leiter RE, Santus E, Jin Z, Lee K, Yusuf M, Chien I, Ramaswamy A, Moseley ET, Qian Y, **Schrag D**, Lindvall C.J. Deep natural language processing to identify symptom documentation in clinical notes for patients with heart failure undergoing cardiac resynchronization therapy. *J Pain Symptom Manage.* 2020 Jun 22; S0885-3924(20)30524-8. PMID: 32585181.
239. Enzinger AC, Uno H, McCleary N, Frank E, Sanoff H, Van Loon K, Matin K, Bullock A, Cronin C, Cibotti H, Bagley J, **Schrag D**. Effectiveness of a Multimedia Educational Intervention to Improve Understanding of the Risks and Benefits of Palliative Chemotherapy in Patients with Advanced Cancer: A Randomized Clinical Trial. *JAMA Oncol.* 2020 Aug 1;6(8):1265-1270. PMID: 32672806.
240. Enzinger AC, Uno H, McCleary N, Frank E, Sanoff H, Van Loon K, Matin K, Bullock A, Cronin C, Bagley J, **Schrag D**. The Effect of Disclosing Life Expectancy Information on Patients' Prognostic Understanding: Secondary Outcomes From a Multicenter Randomized Trial. *J Pain Symptom Manage.* 2020 Aug 7;S0885-3924(20)30636-9. PMID: 32777456.
241. Kehl K, Xu W, Lepisto E, Elmarakeby H, Hassett MJ, Van Ellen EM, Johnson BE, **Schrag D**. Natural Language Processing to Ascertain Cancer Outcomes From Medical Oncologist Notes. *JCO Clin Cancer Inform.* 2020 Aug;4:680-690. PMID: 32755459.
242. Kunst N, Alarid-Escudero F, Aas E, Coupé VMH, **Schrag D**, Kuntz KM. Estimating population-based recurrence rates of colorectal cancer over time in the United States. *Cancer Epidemiol Biomarkers Prev.* 2020 Sep 30;cebp.0490.2020. PMID: 32998946.
243. Goyal L, Chaudhary SP, Kwak EL, Abrams TA, Carpenter AN, Wolpin BM, Wadlow RC, Allen JN, Heist R, McCleary NJ, Chan JA, Goessling W, **Schrag D**, Ng K, Enzinger PC, Ryan DP, Clark JW. A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer. *Invest New Drugs.* 2020 Oct;38(5):1533-1539. PMID: 31898183.
244. Basch E, Stover AM, **Schrag D**, Chung A, Jansen J, Henson S, Carr P, Ginos B, Deal A, Spears PA, Jonsson M, Bennett AV, Mody G, Thanarajasingam G, Rogak LJ, Reeve BB, Snyder C, Kottschade LA, Charlot M, Weiss A, Bruner D, Dueck AC. Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial. *JCO Clin Cancer Inform.* 2020 Oct;4:947-957. PMID: 33112661.
245. Brown JC, Rosenthal MH, Ma C, Zhang S, Nimeiri HS, McCleary NJ, Abrams TA, Yurgelun MB, Cleary JM, Rubinson DA, **Schrag D**, Bullock AJ, Allen J, Zuckerman D, Chan E, Chan JA, Wolpin B, Constantine M, Weckstein DJ, Faggen MA, Thomas CA, Kournioti C, Yuan C, Zheng H, Hollis BW, Fuchs CS, Ng K, Meyerhardt JA. Effect of High-Dose vs

Standard-Dose Vitamin D<sub>3</sub> Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial. *Cancers* (Basel). 2020 Nov 20;12(11):3451. PMID: 33233566.

246. Kehl KL, Riely GJ, Lepisto EM, Lavery JA, Warner JL, LeNoue-Newton ML, Sweeney SM, Rudolph JE, Brown S, Yu C, Bedard PL, **Schrag D**, Panageas KS; American Association of Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) Consortium. Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients with Non-Small Cell Lung or Colorectal Cancer. *JAMA Netw Open*. 2021 Jul 1;4(7). PMID: 34309669.
247. Chen AB, Niu J, Cronin AM, Shih YT, Giordano S, **Schrag D**. Variations in Use of High-Cost Technologies for Palliative Radiation Therapy by Radiation Oncologists. *J Natl Compr Canc Netw*. 2021 Feb 12;19(4):421-431. PMID: 33578375.
248. Basch E, Becker C, Rogak LJ, **Schrag D**, Reeve BB, Spears P, Smith ML, Gounder MM, Mahoney MR, Schwartz GK, Bennett AV, Mendoza TR, Cleeland CS, Sloan JA, Bruner DW, Schwab G, Atkinson TM, Thanarajasingam G, Bertagnolli MM, Dueck AC. Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). *Clin Trials*. 2021 Feb;18(1):104-114. PMID: 33258687.
249. Cleary JM, Raghavan S, Wu Q, Li YY, Spurr LF, Gupta HV, Rubinson DA, Fetter IJ, Hornick JL, Nowak JA, Siravegna G, Goyal L, Shi L, Brais LK, Loftus M, Shinagare AB, Abrams TA, Clancy TE, Wang J, Patel AK, Brichory F, Vaslin Chessex A, Sullivan RJ, Keller RB, Denning S, Hill ER, Shapiro GI, Pokorska-Bocci A, Zanna C, Ng K, **Schrag D**, Janne PA, Hahn WC, Cherniack AD, Corcoran RB, Meyerson M, Daina A, Zoete V, Bardeesy N, Wolpin BM. FGFR2 Extracellular Domain In-Frame Deletions are Therapeutically Targetable Genomic Alterations that Function as Oncogenic Drivers in Cholangiocarcinoma. *Cancer Discov*. 2021 Apr 29: PMID: 33926920
250. Haeuser L, Marchese M, **Schrag D**, Trinh QD, Chang SL, Kibel AS, Gore JL, Noldus J, Mossanen M. The impact of smoking on radical cystectomy complications increases in elderly patients. *Cancer*. 2021 May; 1;127(9):1387-1394. PMID: 33351967.
251. Kehl KL, Greenwald S, Chamoun NG, Manberg PJ, **Schrag D**. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients with Advanced Non-Small Cell Lung Cancer. *JAMA Netw Open*. 2021 May 3;4(5): PMID: 34019086.
252. Shih YT, Xu Y, Zhao H, **Schrag D**, Yao J. Financial Burden of Discarded Weight-based Antineoplastic Drugs to Payers and Patients in the Private Insurance Market. *JNCI Cancer Spectr*. 2021 May 18;5(4). PMID: 34350376.
253. Kehl KL, Groha S, Lepisto EM, Elmarakeby H, Lindsay J, Gusev A, Van Allen EM, Hassett MJ, **Schrag D**. Clinical Inflection Point Detection on the Basis of EHR Data to Identify Clinical Trial-Ready Patients with Cancer. *JCO Clin Cancer Inform*. 2021 Jun; 5:622-630. PMID: 34097438.
254. Nadauld LD, McDonnell CH 3rd, Beer TM, Liu MC, Klein EA, Hudnut A, Whittington RA, Taylor B, Oxnard GR, Lipson J, Lopatin M, Shaknovich R, Chung KC, Fung ET, **Schrag D**, Marinac CR. The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice. *Cancers* (Basel). 2021 Jul 13;13(14):3501. PMID: 34298717.
255. Gupta S, Short SAP, Sise ME, Prosek JM, Madhavan SM, Soler MJ, Ostermann M, Herrmann SM, Abudayyeh A, Anand S, Glezerman I, Motwani SS, Murakami N, Wanchoo R, Ortiz-Melo DI, Rashidi A, Sprangers B, Aggarwal V, Malik AB, Loew S, Carlos CA, Chang WT, Beckerman P, Mithani Z, Shah CV, Renaghan AD, Seigneux S, Campedel L,

- Kitchlu A, Shin DS, Rangarajan S, Deshpande P, Coppock G, Eijgelsheim M, Seethapathy H, Lee MD, Strohbahn IA, Owen DH, Husain M, Garcia-Carro C, Bermejo S, Lumlertgul N, Seylanova N, Flanders L, Isik B, Mamlouk O, Lin JS, Garcia P, Kaghazchi A, Khanin Y, Kansal SK, Wauters E, Chandra S, Schmidt-Ott KM, Hsu RK, Tio MC, Sarvode Mothi S, Singh H, **Schrag D**, Jhaveri KD, Reynolds KL, Cortazar FB, Leaf DE; ICPI-AKI Consortium Investigators. Acute kidney injury in patients treated with immune checkpoint inhibitors. *J Immunother Cancer*. 2021 Oct;9(10): PMID: 34625513.
256. Manz CR, Odayar VS, **Schrag D**. Disparities in cancer prevalence, incidence, and mortality for incarcerated and formerly incarcerated patients: *Cancer Med*. 2021 Oct;10(20):72777288. PMID: 34477309.
257. Mody GN, Stover AM, Wang M, King-Kallimanis BL, Jansen J, Henson S, Chung AE, Jonsson M, Bennett A, Smith AB, Wood WA, Deal A, Ginos B, Dueck AC, **Schrag D**, Basch E. Electronic patient-reported outcomes monitoring during lung cancer chemotherapy: A nested cohort within the PRO-TECT pragmatic trial (AFT-39). *Lung Cancer*. 2021 Dec;162:1-8. PMID: 34634754
258. Weeks LD, Marinac CR, Redd RA, Abel GA, Lin AE, Agrawal M, Stone RM, **Schrag D**, Ebert BL. Age-related Diseases of Inflammation in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. *Blood*. 2021 Dec 7: Blood.2021 PMID: 34875037.
259. Kehl KL, Xu W, Gusev A, Bakouny Z, Choueiri TK, Riaz IB, Elmarakeby H, Van Allen EM, **Schrag D**. Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset. *Nat Commun*. 2021 Dec 15;12(1):7304. PMID: 34911934.
260. Mehtsun WT, McCleary NJ, Maduekwe UN, Wolpin BM, **Schrag D**, Wang J. Patterns of Adjuvant Chemotherapy Use and Association With Survival in Adults 80 Years and Older With Pancreatic Adenocarcinoma. *JAMA Oncol*. 2022 Jan 1;8(1):88-95. PMID: 34854874.
261. Hassett MJ, Cronin C, Tsou TC, Wedge J, Bian J, Dizon DS, Hazard-Jenkins H, Osarogiagbon RU, Wong S, Basch E, Austin T, McCleary N, **Schrag D**. eSyM: An Electronic Health Record-Integrated Patient-Reported Outcomes-Based Cancer Symptom Management Program Used by Six Diverse Health Systems. *JCO Clin Cancer Inform*. 2022 Jan; 6: PMID: 34985914.
262. Brown S, Lavery JA, Shen R, Martin AS, Kehl KL, Sweeney SM, Lepisto EM, Rizvi H, McCarthy CG, Schultz N, Warner JL, Park BH, Bedard PL, Riely GJ, **Schrag D**, Panageas KS. Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies. AACR Project GENIE Consortium. *JAMA Oncol*. 2022 Feb 1;8(2):287-291. PMID: 34734967
263. Lavery JA, Lepisto EM, Brown S, Rizvi H, McCarthy C, LeNoue-Newton M, Yu C, Lee J, Guo X, Yu T, Rudolph J, Sweeney S; AACR Project GENIE Consortium, Park BH, Warner JL, Bedard PL, Riely G, **Schrag D**, Panageas KS. A Scalable Quality Assurance Process for Curating Oncology Electronic Health Records: The Project GENIE Biopharma Collaborative Approach. *JCO Clin Cancer Inform*. 2022 Feb; 6: PMID: 35192403
264. Comparison of Oncologist and Model Estimates of Risk for Hospitalization During Systemic Therapy for Advanced Cancer. Emery LP, Muralikrishnan S, **Schrag D**, Tosteson ANA, Brooks GA. *JCO Oncol Pract*. 2023 Mar;19(3). PMID: 36475736.
265. Alarid-Escudero F, **Schrag D**, Kuntz KM. CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis. *Value Health*. 2022 Mar;25(3):409-418. PMID: 35227453

266. Lipsyc-Sharf M, Ou FS, Yurgelun MB, Rubinson DA, **Schrag D**, Dakhil SR, Stella PJ, Weckstein DJ, Wender DB, Faggen M, Zemla TJ, Heying EN, Schuetz SR, Noble S, Meyerhardt JA, Bekaii-Saab T, Fuchs CS, Ng K. Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial. *Oncologist*. 2022 Apr 5;27(4):292-298. PMID: 35380713.
267. LeNoue-Newton ML, Chen SC, Stricker T, Hyman DM, Blauvelt N, Bedard PL, Meric-Bernstam F, Punglia RS, **Schrag D**, Lepisto EM, Andre F, Smyth L, Dogan S, Yu C, Wathoo C, Levy M, Eli LD, Xu F, Mann G, Lalani AS, Ye F, Micheel CM, Arnedos M. Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE. *Clin Cancer Res*. 2022 May 13;28(10):2118-2130. PMID: 35190802.
268. Frere C, Farge D, **Schrag D**, Prata PH, Connors JM. Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials. *J Hematol Oncol*. 2022 May 21;15(1):69. PMID: 35598026.
269. Stavrou E, Qiu J, Zafar A, Tramontano AC, Isakoff S, Winer E, **Schrag D**, Manz C. Breast Medical Oncologists' Perspectives of Telemedicine for Breast Cancer Care: A Survey Study. *JCO Oncol Pract*. 2022 Jun 7. PMID: 35671420.
270. Papke DJ, Lindeman NI, **Schrag D**, Iorgulescu JB. Underutilization of Guideline-Recommended Mismatch Repair/Microsatellite Instability Biomarker Testing in Advanced Colorectal Cancer. *Cancer Epidemiol Biomarkers Prev*. 2022 PMID: 35767976.
271. Basch E, **Schrag D**, Henson S, Jansen J, Ginos B, Stover AM, Carr P, Spears PA, Jonsson M, Deal AM, Bennett AV, Thanarajasingam G, Rogak LJ, Reeve BB, Snyder C, Bruner D, Cella D, Kottschade LA, Perlmutter J, Geoghegan C, Samuel-Ryals CA, Given B, Mazza GL, Miller R, Strasser JF, Zylla DM, Weiss A, Blinder VS, Dueck AC. Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial. *JAMA*. 2022 Jun 28;327(24):2413-2422. PMID: 35661856.
272. Hassett MJ, Wong S, Osarogiagbon RU, Bian J, Dizon DS, Jenkins HH, Uno H, Cronin C, **Schrag D**; SIMPRO Co-Investigators. Implementation of patient-reported outcomes for symptom management in oncology practice through the SIMPRO research consortium: a protocol for a pragmatic type II hybrid effectiveness-implementation multi-center cluster-randomized stepped wedge trial. *Trials*. 2022 Jun 16;23(1):506. PMID: 35710449.
273. Reliability and validity of PRO-CTCAE® daily reporting with a 24-hour recall period. Lee MK, Basch E, Mitchell SA, Minasian LM, Langlais BT, Thanarajasingam G, Ginos BF, Rogak LJ, Mendoza TR, Bennett AV, **Schrag D**, Mazza GL, Dueck AC. *Qual Life Res*. 2023 Jul;32(7):2047-2058. PMID: 36897529.
274. Haneuse S, **Schrag D**, Dominici F, Normand SL, Lee KH. Measuring performance for end-of-life care. *Ann Appl Stat*. 2022 Sep;16(3):1586-1607. PMID: 36483542.
275. Garcia Farina E, Rowell J, Revette A, Haakenstad EK, Cleveland JLF, Allende R, Hassett M, **Schrag D**, McCleary NJ. Barriers to Electronic Patient-Reported Outcome Measurement Among Patients with Cancer and Limited English Proficiency. *JAMA Netw Open*. 2022 Jul 1;5(7). PMID: 35867056.
276. Merola D, Schneeweiss S, **Schrag D**, Lii J, Lin KJ. An algorithm to predict data completeness in oncology electronic medical records for comparative effectiveness research. *Ann Epidemiol*. 2022 Dec ;76: 143-149. PMID: 35878784.

277. Manz CR, Tramontano AC, Uno H, Parikh RB, Bekelman JE, **Schrag D**. Association of Oncologist Participation in Medicare's Oncology Care Model with Patient Receipt of Novel Cancer Therapies. *JAMA Netw Open*. 2022 Sep 1;5(9) PMID: 36173630.
278. Weiser MR, Chou JF, Kim JK, Widmar M, Wei IH, Pappou EP, Smith JJ, Nash GM, Paty PB, Cercek A, Saltz LB, Romesser PB, Crane CH, Garcia-Aguilar J, **Schrag D**, Gönen M. A Dynamic Clinical Calculator for Estimating Conditional Recurrence-Free Survival After Total Neoadjuvant Therapy for Rectal Cancer and Either Surgery or Watch-and-Wait Management. *JAMA Netw Open*. 2022 Sep 1;5(9). PMID: 36173634.
279. Nassar AH, Adib E, Abou Alaiwi S, El Zarif T, Groha S, Akl EW, Nuzzo PV, Mouhieddine TH, Perea-Chamblee T, Taraszka K, El-Khoury H, Labban M, Fong C, Arora KS, Labaki C, Xu W, Sonpavde G, Haddad RI, Mouw KW, Giannakis M, Hodi FS, Zaitlen N, Schoenfeld AJ, Schultz N, Berger MF, MacConaill LE, Ananda G, Kwiatkowski DJ, Choueiri TK, **Schrag D**, Carrot-Zhang J, Gusev A. Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. *Cancer Cell*. 2022 Oct 10;40(10):1161-1172. PMID: 36179682.
280. Pappou EP, Temple LK, Patil S, Smith JJ, Wei IH, Nash GM, Guillem JG, Widmar M, Weiser MR, Paty PB, **Schrag D**, Garcia-Aguilar J. Quality of life and function after rectal cancer surgery with and without sphincter preservation. *Front Oncol*. 2022 Oct 21;12:944843. PMID: 36353560.
281. Schumacher JR, Neuman HB, Yu M, Vanness DJ, Si Y, Burnside ES, Ruddy KJ, Partridge AH, **Schrag D**, Edge SB, Zhang Y, Jacobs EA, Havlena J, Francescatti AB, Winchester DP, McKellar DP, Spears PA, Kozower BD, Chang GJ, Greenberg CC; Alliance ACS-CRP CCRD Breast Cancer Surveillance Working Group. Surveillance Imaging vs Symptomatic Recurrence Detection and Survival in Stage II-III Breast Cancer (AFT-01). *J Natl Cancer Inst*. 2022 Oct 6;114(10):1371-1379. PMID: 35913454.
282. Merola D, Young J, **Schrag D**, Lin KJ, Robert N, Schneeweiss S. Oncology Drug Effectiveness from Electronic Health Record Data Calibrated Against RCT Evidence: The PARSIFAL Trial Emulation. *Clin Epidemiol*. 2022 Oct 10;14:1135-1144. PMID: 36246306.
283. Merola D, Young J, **Schrag D**, Lin KJ, Alwardt S, Schneeweiss S. Effectiveness research in oncology with electronic health record data: A retrospective cohort study emulating the PALOMA-2 trial. *Pharmacoepidemiol Drug Saf*. 2023 Apr;32(4):426-434. PMID: 36345809.
284. Van Egeren D, Kohli K, Warner JL, Bedard PL, Riely G, Lepisto E, **Schrag D**, LeNoue-Newton M, Catalano P, Kehl KL, Michor F; AACR Project GENIE Consortium represented by Shawn Sweeney. Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis. *Sci Rep*. 2022 Nov 9;12(1):19055. PMID: 36351964.
285. Groha S, Alaiwi SA, Xu W, Naranbhai V, Nassar AH, Bakouny Z, El Zarif T, Saliby RM, Wan G, Rajeh A, Adib E, Nuzzo PV, Schmidt AL, Labaki C, Ricciuti B, Alessi JV, Braun DA, Shukla SA, Keenan TE, Van Allen E, Awad MM, Manos M, Rahma O, Zubiri L, Villani AC, Fairfax B, Hammer C, Khan Z, Reynolds K, Semenov Y, **Schrag D**, Kehl KL, Freedman ML, Choueiri TK, Gusev A. Germline variants associated with toxicity to immune checkpoint blockade. *Nat Med*. 2022 Dec;28(12):2584-2591. PMID: 36526723.
286. Keller RB, Mazor T, Sholl L, Aguirre AJ, Singh H, Sethi N, Bass A, Nagaraja AK, Brais LK, Hill E, Hennessey C, Cusick M, Del Vecchio Fitz C, Zwiesler Z, Siegel E, Ovalle A, Trukhanov P, Hansel J, Shapiro GI, Abrams TA, Biller LH, Chan JA, Cleary JM, Corsello SM, Enzinger AC, Enzinger PC, Mayer RJ, McCleary NJ, Meyerhardt JA, Ng K, Patel AK, Perez KJ, Rahma OE, Rubinson DA, Wisch JS, Yurgelun MB, Hassett MJ, MacConaill L, **Schrag D**, Cerami E, Wolpin BM, Nowak

- JA, Giannakis M. Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer. *JCO Precis Oncol*. 2023 Jan;7; PMID: 36634297.
287. Moon I, LoPiccolo J, Baca SC, Sholl LM, Kehl KL, Hassett MJ, Liu D, **Schrag D**, Gusev A. Utilizing Electronic Health Records (EHR) and Tumor Panel Sequencing to Demystify Prognosis of Cancer of Unknown Primary (CUP) patients. *Res Sq* 2023 Jan 10; PMID: 36711812.
288. Leiter RE, Varas MTB, Miralda K, Muneton-Castano Y, Furtado G, Revette A, Cronin C, Soares HP, Lopez A, Hayman LL, Lindsay AC, **Schrag D**, Enzinger AC. Adaptation of a Multimedia Chemotherapy Educational Intervention for Latinos: Letting Patient Narratives Speak for Themselves. *J Cancer Educ*. 2023 Feb 11. PMID: 36773178.
289. Kehl KL, Uno H, Gusev A, Groha S, Brown S, Lavery JA, **Schrag D**, Panageas KS. Elucidating Analytic Bias Due to Informative Cohort Entry in Cancer Clinico-genomic Datasets. *Cancer Epidemiol Biomarkers Prev*. 2023 Mar 6;32(3):344-352. PMID: 36626408.
290. Liddicoat Yamarik R, Chiu LA, Flannery M, Van Allen K, Adeyemi O, Cuthel AM, Brody AA, Goldfeld KS, **Schrag D**, Grudzen CR, On Behalf Of The EMPaIA Investigators. Engagement, Advance Care Planning, and Hospice Use in a Telephonic Nurse-Led Palliative Care Program for Persons Living with Advanced Cancer. *Cancers (Basel)*. 2023 Apr 15;15(8):2310. PMID: 37190238. PMCID: PMC10136814.
291. Manz CR, Odayar VS, **Schrag D**. Cancer Screening Rates and Outcomes for Justice-Involved Individuals; *J Correct Health Care*. 2023 Jun;29(3):220-231. PMID: 37074345.
292. Basch E, Dueck AC, Mitchell SA, Mamon H, Weiser M, Saltz L, Gollub M, Rogak L, Ginos B, Mazza GL, Colgrove B, Chang G, Minasian L, Denicoff A, Thanarajasingam G, Musher B, George T, Venook A, Farma J, O'Reilly E, Meyerhardt JA, Shi Q, **Schrag D**. Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048). *J Clin Oncol*. 2023 Jun 4; PMID: 37270691. PMCID: PMC10351948.
293. **Schrag D**, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, Goldberg J, Al Baghdadi T, Goodman KA, McWilliams RR, Farma JM, George TJ, Kennecke HF, Shergill A, Montemurro M, Nelson GD, Colgrove B, Gordon V, Venook AP, O'Reilly EM, Meyerhardt JA, Dueck AC, Basch E, Chang GJ, Mamon HJ. Preoperative Treatment of Locally Advanced Rectal Cancer. *N Engl J Med*. 2023 Jun 4. PMID: 37272534. PMCID: PMC10775881.
294. **Schrag D**, Uno H, Rosovsky R, Rutherford C, Sanfilippo K, Villano JL, Drescher M, Jayaram N, Holmes C, Feldman L, Zattra O, Farrar-Muir H, Cronin C, Basch E, Weiss A, Connors JM; CANVAS Investigators. Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial. *JAMA*. 2023 Jun 13;329(22):1924-1933. PMID: 37266947. PMCID: PMC10265290.
295. Kennecke HF, Auer R, Cho M, Dasari NA, Davies-Venn C, Eng C, Dorth J, Garcia-Aguilar J, George M, Goodman KA, Kreppel L, Meyer JE, Monzon J, Saltz L, **Schrag D**, Smith JJ, Zell JA, Das P; NCI Rectal-Anal Task Force. NCI Rectal-Anal Task Force Consensus Recommendations for Design of Clinical Trials in Rectal Cancer. *J Natl Cancer Inst*. 2023 Aug 3:djad143. PMID: 37535679.
296. Moon I, LoPiccolo J, Baca SC, Sholl LM, Kehl KL, Hassett MJ, Liu D, **Schrag D**, Gusev A. Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary. *Nat Med*. 2023 Aug;29(8):2057-2067. PMID: 37550415.

297. Blinder VS, Deal AM, Ginos B, Jansen J, Dueck AC, Mazza GL, Henson S, Carr P, Rogak LJ, Weiss A, Rapperport A, Jonsson M, Spears PA, Cella D, Gany F, **Schrag D**, Basch E. Financial Toxicity Monitoring in a Randomized Controlled Trial of Patient-Reported Outcomes During Cancer Treatment (Alliance AFT-39). *J Clin Oncol*. 2023 Aug 25; PMID: 37625107.
298. Choudhury NJ, Lavery JA, Brown S, de Bruijn I, Jee J, Tran TN, Rizvi H, Arbour KC, Whiting K, Shen R, Hellmann M, Bedard PL, Yu C, Leigh N, LeNoue-Newton M, Micheel C, Warner JL, Ginsberg MS, Plodkowski A, Girshman J, Sawan P, Pillai S, Sweeney SM, Kehl KL, Panageas KS, Schultz N, **Schrag D**, Riely GJ; AACR GENIE BPC Core Team. The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non-Small Cell Lung Cancer. *Clin Cancer Res*. 2023 Sep 1;29(17):3418-3428. PMID: 37223888.
299. Elmarakeby HA, Trukhanov PS, Arroyo VM, Riaz IB, **Schrag D**, Van Allen EM, Kehl KL. Empirical evaluation of language modeling to ascertain cancer outcomes from clinical text reports. *BMC Bioinformatics*. 2023 Sep 2;24(1):328. PMID: 37658330.
300. Doolin JW, Haakenstad EK, Neville BA, Lipsitz SR, Zhang S, Cleveland JLF, Hiruy S, Hassett MJ, Revette A, **Schrag D**, Basch E, McCleary NJ. Feasibility of Weekly Electronic Health Record-Embedded Patient-Reported Outcomes for Patients Starting Oral Cancer-Directed Therapy. *JCO Clin Cancer Inform*. 2023 Sep;7:e2300043. PMID: 37788407.
301. **Schrag D**, Beer TM, McDonnell CH 3rd, Nadauld L, Dilaveri CA, Reid R, Marinac CR, Chung KC, Lopatin M, Fung ET, Klein EA. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. *Lancet*. 2023 Oct 7;402(10409):1251-1260. PMID: 37805216.
302. Smith AW, DiMartino L, Garcia SF, Mitchell SA, Ruddy KJ, Smith JD, Wong SL, Cahue S, Cella D, Jensen RE, Hassett MJ, Hodgdon C, Kroner B, Osarogiagbon RU, Popovic J, Richardson K, **Schrag D**, Cheville AL; IMPACT Consortium. Systematic symptom management in the IMPACT Consortium: rationale and design for 3 effectiveness-implementation trials. *JNCI Cancer Spectr*. 2023 Oct 31;7(6). PMID: 37930033.
303. Griffin JM, Kroner BL, Wong SL, Preiss L, Smith AW, Cheville AL, Mitchell SA, Lancki N, Hassett MJ, **Schrag D**, Osarogiagbon RU, Ridgeway JL, Cella D, Jensen RE, Flores AM, Austin JD, Yanez B; IMPACT Consortium. Disparities in Electronic Health Record Portal Access and Use among Patients with Cancer. *J Natl Cancer Inst*. 2023 Nov 1. PMID: 37930884.
304. Grabski IN, Heymach JV, Kehl KL, Kopetz S, Lau KS, Riely GJ, **Schrag D**, Yaeger R, Irizarry RA, Haigis KM. Effects of KRAS genetic interactions on outcomes in cancers of the lung, pancreas, and colorectum. *Cancer Epidemiol Biomarkers Prev*. 2024 Jan 9. PMID: 37943166.
305. Paudel R, Tramontano AC, Cronin C, Wong SL, Dizon DS, Jenkins HH, Bian J, Osarogiagbon RU, **Schrag D**, Hassett MJ. Assessing Patient Readiness for an Electronic Patient-Reported Outcome-Based Symptom Management Intervention in a Multisite Study. *JCO Oncol Pract*. 2023 Nov 27: PMID: 38011613.
306. de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, Li X, Ochoa A, Zhao G, Lai B, Abeshouse A, Baiceanu D, Ciftci E, Dogrusoz U, Dufilie A, Erkoc Z, Garcia Lara E, Fu Z, Gross B, Haynes C, Heath A, Higgins D, Jagannathan P, Kalletla K, Kumari P, Lindsay J, Lisman A, Leenknecht B, Lukasse P, Madela D, Madupuri R, van Nierop P, Plantalech O, Quach J, Resnick AC, Rodenburg SYA, Satravada BA, Schaeffer F, Sheridan R, Singh J, Sirohi R, Sumer SO, van Hagen S, Wang A, Wilson M, Zhang H, Zhu K, Rusk N, Brown S, Lavery JA, Panageas KS, Rudolph JE, LeNoue-Newton ML, Warner JL, Guo X, Hunter-Zinck H, Yu TV, Pilai S, Nichols C, Gardos SM, Philip J; AACR Project GENIE BPC Core Team, AACR Project GENIE Consortium; Kehl KL, Riely GJ, **Schrag D**, Lee J, Fiandalo MV, Sweeney SM, Pugh TJ, Sander C, Cerami E, Gao J, Schultz N. Analysis and Visualization of Longitudinal Genomic and Clinical Data from

- the AACR Project GENIE Biopharma Collaborative in cBioPortal. *Cancer Res.* 2023 Dec 1;83(23):3861-3867. PMID: 37668528.
307. Doolin JW, Haakenstad EK, Neville BA, Lipsitz SR, Zhang S, Cleveland JLF, Hiruy S, Hassett MJ, Revette A, **Schrag D**, Basch E, McCleary NJ. Feasibility of Weekly Electronic Health Record-Embedded Patient-Reported Outcomes for Patients Starting Oral Cancer-Directed Therapy. *JCO Clin Cancer Inform.* 2023 Sep;7:e2300043. PMID: 37788407.
308. Sanz-Garcia E, Brown S, Lavery JA, Weiss J, Fuchs HE, Newcomb A, Postle A, Warner JL, LeNoue-Newton ML, Sweeney SM, Pillai S, Yu C, Nichols C, Mastrogiacomo B, Kundra R, Schultz N, Kehl KL, Riely GJ, **Schrag D**, Govindarajan A, Panageas KS, Bedard PL. Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry. *Cancer Res Commun.* 2024 Feb 20;4(2):475-486. PMID: 38329392;
309. Hassett MJ, Dias S, Cronin C, **Schrag D**, McCleary N, Simpson J, Poirier-Shelton T, Bian J, Reich J, Dizon D, Begnoche M, Jenkins HH, Tasker L, Wong S, Pearson L, Paudel R, Osarogiagbon RU. Strategies for Implementing an Electronic Patient-Reported Outcomes-Based Symptom Management Program Across Six Cancer Centers. *Res Sq* [Preprint]. 2024 Jan 24:rs.3.rs-3879836. PMID: 38343857;
310. Paudel R, Enzinger AC, Uno H, Cronin C, Wong SL, Dizon DS, Hazard Jenkins H, Bian J, Osarogiagbon RU, Jensen RE, Mitchell SA, **Schrag D**, Hassett MJ. Effects of a change in recall period on reporting severe symptoms: an analysis of a pragmatic multisite trial. *J Natl Cancer Inst.* 2024 Mar 5:djae049. PMID: 38445744.
311. Kehl KL, Lavery JA, Brown S, Fuchs H, Riely G, **Schrag D**, Newcomb A, Nichols C, Micheel CM, Bedard PL, Sweeney SM, Fiandalo M, Panageas KS; AACR Project GENIE BPC Core Team. Biomarker Inference and the Timing of Next-Generation Sequencing in a Multi-Institutional, Cross-Cancer Clinicogenomic Data Set. *JCO Precis Oncol.* 2024 Mar;8:e2300489. PMID: 38484212.
312. Griffin JM, Kroner BL, Wong SL, Preiss L, Wilder Smith A, Cheville AL, Mitchell SA, Lancki N, Hassett MJ, **Schrag D**, Osarogiagbon RU, Ridgeway JL, Cella D, Jensen RE, Flores AM, Austin JD, Yanez B. Disparities in electronic health record portal access and use among patients with cancer. *J Natl Cancer Inst.* 2024 Mar 7;116(3):476-484. doi: 10.1093/jnci/djad225. PMID: 37930884.
313. Grabski IN, Heymach JV, Kehl KL, Kopetz S, Lau KS, Riely GJ, **Schrag D**, Yaeger R, Irizarry RA, Haigis KM. Effects of KRAS Genetic Interactions on Outcomes in Cancers of the Lung, Pancreas, and Colorectum. *Cancer Epidemiol Biomarkers Prev.* 2024 Jan 9;33(1):158-169. doi: 10.1158/1055-9965.EPI-23-0262. PMID: 37943166.
314. Paudel R, Tramontano AC, Cronin C, Wong SL, Dizon DS, Jenkins HH, Bian J, Osarogiagbon RU, **Schrag D**, Hassett MJ. Assessing Patient Readiness for an Electronic Patient-Reported Outcome-Based Symptom Management Intervention in a Multisite Study. *JCO Oncol Pract.* 2024 Jan;20(1):77-84. doi: 10.1200/OP.23.00339. Epub 2023 Nov 27. PMID: 38011613.
315. Sanz-Garcia E, Brown S, Lavery JA, Weiss J, Fuchs HE, Newcomb A, Postle A, Warner JL, LeNoue-Newton ML, Sweeney SM, Pillai S, Yu C, Nichols C, Mastrogiacomo B, Kundra R, Schultz N, Kehl KL, Riely GJ, **Schrag D**, Govindarajan A, Panageas KS, Bedard PL. Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry. *Cancer Res Commun.* 2024 Feb 20;4(2):475-486. doi: 10.1158/2767-9764.CRC-23-0409. PMID: 38329392.
316. Hassett MJ, Dias S, Cronin C, **Schrag D**, McCleary N, Simpson J, Poirier-Shelton T, Bian J, Reich J, Dizon D, Begnoche M, Jenkins HH, Tasker L, Wong S, Pearson L, Paudel R, Osarogiagbon RU. Strategies for Implementing an Electronic

- Patient-Reported Outcomes-Based Symptom Management Program Across Six Cancer Centers. Res Sq [Preprint]. 2024 Jan 24;rs.3.rs-3879836. doi: 10.21203/rs.3.rs-3879836/v1. Update in: BMC Health Serv Res. 2024 Nov 12;24(1):1386. doi: 10.1186/s12913-024-11536-5. PMID: 38343857.
317. Paudel R, Enzinger AC, Uno H, Cronin C, Wong SL, Dizon DS, Hazard Jenkins H, Bian J, Osarogiagbon RU, Jensen RE, Mitchell SA, **Schrag D**, Hassett MJ. Effects of a change in recall period on reporting severe symptoms: an analysis of a pragmatic multisite trial. *J Natl Cancer Inst*. 2024 Jul 1;116(7):1137-1144. doi: 10.1093/jnci/djae049. PMID: 38445744.
318. Kehl KL, Lavery JA, Brown S, Fuchs H, Riely G, **Schrag D**, Newcomb A, Nichols C, Micheel CM, Bedard PL, Sweeney SM, Fiandalo M, Panageas KS; AACR Project GENIE BPC Core Team. Biomarker Inference and the Timing of Next-Generation Sequencing in a Multi-Institutional, Cross-Cancer Clinicogenomic Data Set. *JCO Precis Oncol*. 2024 Mar;8:e2300489. doi: 10.1200/PO.23.00489. PMID: 38484212.
319. Kehl KL, Mazor T, Trukhanov P, Lindsay J, Galvin MR, Farhat KS, McClure E, Giordano A, Gandhi L, **Schrag D**, Hassett MJ, Cerami E. Identifying Oncology Clinical Trial Candidates Using Artificial Intelligence Predictions of Treatment Change: A Pilot Implementation Study. *JCO Precis Oncol*. 2024 Mar;8:e2300507. doi: 10.1200/PO.23.00507. PMID: 38513166.
320. Mazza GL, Dueck AC, Ginos B, Jansen J, Deal AM, Carr P, Blinder VS, Thanarajasingam G, Jonsson M, Lee MK, Rogak LJ, Mody GN, **Schrag D**, Basch E. Optimization of alert notifications in electronic patient-reported outcome (ePRO) remote symptom monitoring systems (AFT-39). *Qual Life Res*. 2024 Jul;33(7):1985-1995. doi: 10.1007/s11136-024-03675-3. Epub 2024 May 21. PMID: 38771558.
321. Bange EM, Daly RM, Lipitz-Snyderman A, Kuperman G, Polubriaginof FCG, Liebertz C, Doshi SD, Stevanovic K, Chan K, Bernal C, Charvadeh YK, Chen Y, Chimonas S, Stetson P, **Schrag D**, Morris MJ, Panageas KS. Transforming patient-centered cancer care using telehealth: the MATCHES Center. *J Natl Cancer Inst Monogr*. 2024 Jun 26;2024(64):76-82. doi: 10.1093/jncimonographs/lgae004. PMID: 38924792.
322. Wong JS, Uno H, Tramontano AC, Fisher L, Pellegrini CV, Abel GA, Burstein HJ, Chun YS, King TA, **Schrag D**, Winer E, Bellon JR, Cheney MD, Hardenbergh P, Ho A, Horst KC, Kim JN, Leonard KL, Moran MS, Park CC, Recht A, Soto DE, Shiloh RY, Stinson SF, Snyder KM, Taghian AG, Warren LE, Wright JL, Punglia RS. Hypofractionated vs Conventionally Fractionated Postmastectomy Radiation After Implant-Based Reconstruction: A Randomized Clinical Trial. *JAMA Oncol*. 2024 Oct 1;10(10):1370-1378. doi: 10.1001/jamaoncol.2024.2652. PMID: 39115975.
323. McCleary NJ, Merle JL, Richardson JE, Bass M, Garcia SF, Cheville AL, Mitchell SA, Jensen R, Minter S, Austin JD, Tesch N, DiMartino L, Hassett MJ, Osarogiagbon RU, Wong S, **Schrag D**, Cella D, Smith AW, Smith JD; IMPACT Consortium. Bridging clinical informatics and implementation science to improve cancer symptom management in ambulatory oncology practices: experiences from the IMPACT consortium. *JAMIA Open*. 2024 Sep 4;7(3):ooae081. doi: 10.1093/jamiaopen/ooae081. PMID: 39234146.
324. Uno H, Xiong H, Cronin C, **Schrag D**, Connors JM. Predictors of recurrent venous thromboembolism and major bleeding in patients with cancer: A secondary analysis of the CANVAS trial. *Thromb Res*. 2024 Dec;244:109184. doi: 10.1016/j.thromres.2024.109184. Epub 2024 Oct 13. PMID: 39406159.
325. Mead-Harvey C, Basch E, Rogak LJ, Langlais BT, Thanarajasingam G, Ginos BF, Lee MK, Yee C, Mitchell SA, Minasian LM, Mendoza TR, Bennett AV, **Schrag D**, Dueck AC, Mazza GL. Statistical properties of items and summary scores from the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-

CTCAE®) in a diverse cancer sample. Clin Trials. 2024 Oct 23;17407745241286065. doi: 10.1177/17407745241286065. Epub ahead of print. PMID: 39440720.

326. Lee MK, Mitchell SA, Basch E, Mazza GL, Langlais BT, Thanarajasingam G, Ginos BF, Rogak L, Meek EA, Jansen J, Deal AM, Carr P, Blinder VS, Jonsson M, Mody GN, Mendoza TR, Bennett AV, **Schrag D**, Dueck AC. Identification of meaningful individual-level change thresholds for worsening on the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®). Qual Life Res. 2024 Nov 6. doi: 10.1007/s11136-024-03819-5. Epub ahead of print. PMID: 39503942.
327. Jee J, Fong C, Pichotta K, Tran TN, Luthra A, Waters M, Fu C, Altoe M, Liu SY, Maron SB, Ahmed M, Kim S, Pirun M, Chatila WK, de Bruijn I, Pasha A, Kundra R, Gross B, Mastrogiacomo B, Aprati TJ, Liu D, Gao J, Capelletti M, Pekala K, Loudon L, Perry M, Bandlamudi C, Donoghue M, Satravada BA, Martin A, Shen R, Chen Y, Brannon AR, Chang J, Braunstein L, Li A, Safonov A, Stonestrom A, Sanchez-Vela P, Wilhelm C, Robson M, Scher H, Ladanyi M, Reis-Filho JS, Solit DB, Jones DR, Gomez D, Yu H, Chakravarty D, Yaeger R, Abida W, Park W, O'Reilly EM, Garcia-Aguilar J, Socci N, Sanchez-Vega F, Carrot-Zhang J, Stetson PD, Levine R, Rudin CM, Berger MF, Shah SP, **Schrag D**, Razavi P, Kehl KL, Li BT, Riely GJ, Schultz N; MSK Cancer Data Science Initiative Group. Automated real-world data integration improves cancer outcome prediction. Nature. 2024 Nov 6. doi: 10.1038/s41586-024-08167-5. Epub ahead of print. PMID: 39506116.
328. Kehl KL, Jee J, Pichotta K, Paul MA, Trukhanov P, Fong C, Waters M, Bakouny Z, Xu W, Choueiri TK, Nichols C, **Schrag D**, Schultz N. Shareable artificial intelligence to extract cancer outcomes from electronic health records for precision oncology research. Nat Commun. 2024 Nov 12;15(1):9787. doi: 10.1038/s41467-024-54071-x. PMID: 39532885.
329. Hassett M, Dias S, Cronin C, **Schrag D**, McCleary N, Simpson J, Poirier-Shelton T, Bian J, Reich J, Dizon D, Begnoche M, Jenkins HH, Tasker L, Wong S, Pearson L, Paudel R, Osarogiagbon RU. Strategies for implementing an electronic patient-reported outcomes-based symptom management program across six cancer centers. BMC Health Serv Res. 2024 Nov 12;24(1):1386. doi: 10.1186/s12913-024-11536-5. PMID: 39533260.
330. Doshi SD, Charvadeh YK, Seier K, Bange EM, Daly B, Lipitz-Snyderman A, Polubriaginof FCG, Buckley M, Kuperman G, Stetson PD, **Schrag D**, Morris MJ, Panageas KS. Perspectives on Telemedicine Visits Reported by Patients With Cancer. JAMA Netw Open. 2024 Nov 4;7(11):e2445363. doi: 10.1001/jamanetworkopen.2024.45363. PMID: 39546309.
331. Marinac CR, McDonnell CH, Nadauld LD, Dilaveri CA, Reid R, Chung KC, Lopatin M, Fung ET, **Schrag D**, Shaknovich R, Klein EA. Clinical Evaluation of Cancer Signal Origin Prediction and Diagnostic Resolution Following Multi-Cancer Early Detection Testing in the PATHFINDER Study. Cancer Prev Res (Phila). 2025 Apr 23. doi: 10.1158/1940-6207.CAPR-24-0468. PMID: 40265568.
332. Nadauld L, McDonnell CH 3rd, Dilaveri CA, Klein EA, Reid R, Marinac CR, Chung KC, Lopatin M, Fung ET, **Schrag D**, Patrick DL. Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study. Lancet Oncol. 2025 Feb;26(2):165-174. PMID: 39818231.
333. Winer EP, Levit LA, Basch E, Chavez-MacGregor M, Dubois R, Eckhardt SG, Ellis LM, Hudis CA, **Schrag D**, Speers C, Wilky BA, Tibbits M, Spence R, Garrett-Mayer E. Promoting Reasonable Career Expectations and Maximizing Professional Fulfillment for Academic Oncologists: ASCO Recommendations for Academic Medical Centers. J Clin Oncol. 2025 Jun 10;43(17):2017-2023. PMID: 39928904.

334. Rahman SA, Poort H, **Schrag D**, Tung SC, Zhou ES, Wiley A, Finkelstein LB, Elguenaoui E, Nolan M, Mayer EL, Joffe H. Incidence of patient-reported fatigue developing on palbociclib and endocrine therapy for advanced HR+ HER2-breast cancer. *Oncologist*. 2024 Dec 19. PMID: 39703168.
335. Mallow J, Bailey A, Tasker L, Hazard H, Hassett M, Cronin C, Paudel R, Bian J, Dizon DS, Osarogiagbon RU, **Schrag D**, Wong SL. Perceptions of an Electronic Patient Symptom Reporting Tool by Clinicians. *Comput Inform Nurs*. 2025 Apr 21. PMID: 40257368.
336. Mazor T, Farhat KS, Trukhanov P, Lindsay J, Galvin M, Mallaber E, Paul MA, Hassett MJ, **Schrag D**, Cerami E, Kehl KL. Clinical Trial Notifications Triggered by Artificial Intelligence-Detected Cancer Progression: A Randomized Trial. *JAMA Netw Open*. 2025 Apr 1;8(4):e252013. PMID: 40257799.
337. Khan F, Tritschler T, Marx CE, Lanting V, Rochweg B, Tran A, Fernando SM, Lorenzetti DL, Wunsch H, Holodinsky J, Fiest K, Stelfox HT, Delluc A, Fergusson DA, Le Gal G, Wells PS, Wang TF, Sanfilippo K, van Es N, **Schrag D**, Connors JM, Carrier M. Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis. *Eur Heart J*. 2025 Jun 22. PMID: 40579365.
338. Alvarez J, Zambare W, George M, Garcia R, Gallagher P, Kitchens C, Bercz A, Kim MJ, Romesser PB, Cercek A, Garcia-Aguilar J, Sanoff H, George TJ, Hong TS, Yothers G, Philip PA, Al Baghdadi T, Alese OB, Shergill A, O'Reilly EM, Meyerhardt JA, Horvat N, Dasari A, Hall WA, Shi Q, **Schrag D**, Smith JJ. Utilizing Patient Input in Rectal Cancer Trial Design. *J Natl Cancer Inst*. 2025 Jul 1;117(7):1421-1428. PMID: 40108482.
339. Basch E, **Schrag D**, Jansen J, Henson S, Ginos B, Stover AM, Carr P, Spears PA, Jonsson M, Deal AM, Bennett AV, Thanarajasingam G, Rogak L, Reeve BB, Snyder C, Bruner D, Cella D, Kottschade LA, Perlmutter J, Geoghegan C, Given B, Mazza GL, Miller R, Strasser JF, Zylla DM, Weiss A, Blinder VS, Wolf AP, Dueck AC. Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial. *Nat Med*. 2025 Apr;31(4):1225-1232. PMID: 39920394.

#### Viewpoints, Editorials and Letters:

1. Garber JE, **Schrag D**. Testing for inherited cancer susceptibility. *JAMA*. 1996;275(24):1928-9. PMID: 8648875.
2. **Schrag D**, Weeks JC. Costs and cost-effectiveness of colorectal cancer prevention and therapy. *Semin Oncol*. 1999;26(5):561-8. PMID: 10528905.
3. **Schrag D**. Defining optimal treatment for stage II colon cancer: does decision analysis help? *Gastroenterology*. 1999;117(4):1005-8. PMID: 10500083.
4. Bach PB, **Schrag D**. Risk charts: putting cancer in context. *J Natl Cancer Inst*. 2002 Oct 16;94(20):1584-1586. PMID: 12381716.
5. Begg CB, **Schrag D**. Attribution of deaths following cancer treatment. *J Natl Cancer Inst*. 2002;94(14):1044-5. PMID: 12122090.
6. Bach PB, **Schrag D**, Begg CB. Resurrecting treatment histories of dead patients: a study design that should be laid to rest. *JAMA*. 2004;292(22):2765-70. PMID: 15585737.

7. **Schrag D.** Enhancing Cancer Registry Data to Promote Rational Health System Design. *J Natl Cancer Inst.* 2008;100(6):399-406. PMID: 18334703.
8. Yabroff KR, **Schrag D.** Challenges and opportunities for use of cost-effectiveness analysis. *J Natl Cancer Inst.* 2009;101(7):1161-3. PMID: 19666852.
9. **Schrag D.** Evaluating the impact of organizational changes in health care delivery: challenges in study design. *J Clin Oncol.* 2009;27(11):1744-5. PMID: 19273700.
10. Greenberg CC, Ashley SW, **Schrag D.** Centralization of Cancer Surgery: What Does It Mean for Surgical Training? *J Clin Oncol.* 2009;27(28):4671-8. PMID: 19720900.
11. Ng K, **Schrag D.** Microsatellite Instability and Adjuvant Fluorouracil Chemotherapy: A Mismatch? *J Clin Oncol.* 2010 May 24;28(20):3207-10. PMID: 20498398.
12. Lajous M, Mozaffarian D, Mozaffarian R, **Schrag D,** Adami HO. Lifestyle prescriptions for cancer survivors and their communities. *J Intern Med.* 2011 Jan;269(1):88-93. PMID: 21158981.
13. Weeks JC, Mack JW, **Schrag D.** Talking to Patients about Dying. *N Engl J Med.* 2013 Jan 31;368(5):480-1. PMID: 23363507.
14. **Schrag D.** Evolving role of neoadjuvant therapy in rectal cancer. *Curr Treat Options Oncol.* 2013 Sep;14(3):350-64. PMID: 23828092.
15. Weiser MR, Fichera A, **Schrag D,** Boughey JC, You YN. Progress in the PROSPECT trial: precision treatment for rectal cancer? *Bull Am Coll Surg.* 2015 Apr;100(4):51-2. PMID: 25939207.
16. **Schrag D.** Optimizing Treatment for Locally Advanced Pancreas Cancer: Progress but No Precision. *JAMA.* 2016 May 3;315(17):1837-1838. PMID: 27139054.
17. Schiff D, **Schrag D.** Living in the material world: tumor-treating fields at the top of the charts. *Neuro Oncol.* 2016 Aug;18(8):1033-4. PMID: 27382117.
18. Burstein HJ, **Schrag D.** Biosimilar Therapy for ERBB2 (HER2)-Positive Breast Cancer: Close Enough? *JAMA.* 2017 Jan 3;317(1):30-32. PMID: 27918782.
19. Schwartzberg L, Kim ES, Liu D, **Schrag D.** Precision Oncology: Who, How, What, When, and When Not? *Am Soc Oncol Educ Book.* 2017. PMID: 28561651.
20. **Schrag D,** Basch E. Oncology in Transition: Changes, Challenges, and Opportunities. *JAMA.* 2018 Dec 4;320(21):2203-2204. PMID: 30419140.
21. Nass S, Rothenberg M, Pentz R, Hricak H, Abernethy A, Anderson K, Wagner Gee A, Harvey D, Piantadosi S, Bertagnolli M, **Schrag D,** Schilsky R. Accelerating anticancer drug development – opportunities and trade-offs. *Nat Rev Clin Oncol.* 2018 Dec;15(12):777-786. PMID: 30275514.

22. Taylor JW, Armstrong T, Kim AH, Venere M, Acquaye A, **Schrag D**, Wen PY. The lomustine crisis: awareness and impact of the 1500% price hike. *Neuro Oncol*. 2019 Jan 1;21(1):1-3. PMID: 30590836.
23. Basch E, **Schrag D**. The Evolving Uses of "Real-World" Data. *JAMA*. 2019 Apr 9;321(14):1359-1360. PMID: 30964515.
24. Ivatury SJ, Hazard-Jenkins HW, Brooks GA, McCleary NJ, Wong SL, **Schrag D**. Translation of Patient-Reported Outcomes in Oncology Clinical Trials to Everyday Practice. *Ann Surg Oncol*. 2020 Jan;27(1):65-72. PMID: 31452053.
25. Manz C, **Schrag D**. Racial disparities in colorectal cancer recurrence and mortality: equitable care, inequitable outcomes? *J Natl Cancer Inst*. 2020 Nov 24. PMID: 33231610.
26. Basch E, Wilfong L, **Schrag D**. Adding Patient-Reported Outcomes to Medicare's Oncology Value-Based Payment Model. *JAMA*. 2020 Jan 21;323(3):213-214. PMID: 31895416.
27. Haneuse S, **Schrag D**, Nevo D. Dual Outcome Intention-to-treat Analyses in the Women's Health Initiative Randomized Controlled Hormone Therapy Trials. *Am J Epidemiol*. 2020 Sep 1;189(9):982-984. PMID: 32314782.
28. **Schrag D**, Hershman DL, Basch E. Oncology Practice During the COVID-19 Pandemic. *JAMA*. 2020 May 26;323(20):2005-2006. PMID: 32282023.
29. Ng K, May FP, **Schrag D**. US Preventive Services Task Force Recommendations for Colorectal Cancer Screening: Forty-Five Is the New Fifty. *JAMA*. 2021 May 18;325(19):1943-1945. PMID: 34003238
30. Biller LH, **Schrag D**. A Review of the Diagnosis and Treatment of Metastatic Colorectal Cancer-Reply. *JAMA*. 2021 Jun 15;325(23):2405. PMID: 34129001.
31. Stadler ZK, **Schrag D**. Genetic Testing for Cancer Susceptibility. *JAMA*. 2023 Jun 5. PMID: 37276548.
32. **Schrag D**. Preoperative Treatment of Locally Advanced Rectal Cancer. Letter. *N Engl J Med*. 2023 Oct 26;389(17):1631-1632. PMID: 37888930.
33. Basch E, Dueck A, Weiser M, **Schrag D**. Reply to F. Dossa et al. *J Clin Oncol*. 2024 Jan 1;42(1):121. Epub 2023 Oct 10. PMID: 37816205.
34. Rivera DR, Eckert JC, Rodriguez-Watson C, Lerro CC, Bertagnolli MM, Hubbard RA, Kushi LH, Lund JL, **Schrag D**, Wang SV, Wood WA, Lee JJ, Okafor C, Ghauri K, Winckler SC, Klutz PG. The Oncology QCARD Initiative: Fostering efficient evaluation of initial real-world data proposals. *Pharmacoepidemiol Drug Saf*. 2024 Nov;33(11):e5818. doi: 10.1002/pds.5818. PMID: 39462868.

#### Chapters and Reviews:

1. **Schrag D**, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR. American Society of Clinical Oncology Technology Assessment: Chemotherapy Sensitivity and Resistance Assays. *J Clin Oncol*. 2004;22(17):3631-38. PMID: 15289488.

2. Benson AB, **Schrag D**, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M, Charette M, Haller DG. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. *J Clin Oncol*. 2004;22(16):3408-19. PMID: 15199089.
3. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, **Schrag D**, Jamison PM, Jemal A, Wu XC, Friedman C, Harlan L, Warren J, Anderson RN, Pickle LW. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. *J Natl Cancer Inst*. 2005;97(19):1407-27. PMID: 16204691.
4. Jeong SY, Chessin DB, **Schrag D**, Riedel E, Wong WD, Guillem JG. Re: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. *J Natl Cancer Inst* 2005 Nov 16;97(22):1705-1706. PMID: 16288127.
5. Paskett ED, **Schrag D**, Kornblith A, Lamont EB, Weeks JC, Marshall JR, Shapiro C, Holland J. Cancer and Leukemia Group B cancer control and health outcomes committee: origins and accomplishments. *Clin Cancer Res*. 2006 Jun 1;12:3601s-3605s. PMID:16740792.
6. Nahas CS, Shia J, Joseph R, **Schrag D**, Minsky B, Weiser M, Guillem J, Paty P, Klimstra D, Tang L, Wong W, Temple L. Squamous-cell carcinoma of the rectum: a rare but curable tumor. *Dis Colon Rectum*. 2007 Sep;50(9):1393-1400. PMID: 17661147.
7. Desch CE, McNiff KK, Schneider EC, **Schrag D**, McClure J, Lepisto E, Donaldson MS, Kahn KL, Weeks JC, Ko CY, Stewart AK, Edge SB. American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. *J Clin Oncol*. 2008 Jul 20;26(21):3631-3637. PMID: 18640941.
8. Iasonos A, **Schrag D**, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. *J Clin Oncol*. 2008 Mar 10;26(8):1364-70. PMID: 18323559.
9. Meropol NJ, **Schrag D**, Smith TJ, Mulvey TM, Langdon RM, Blum D, Ubel PA, Schnipper LE. American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care. *J Clin Oncol*. 2009;27(23):3868-74. PMID: 19581533.
10. Wideroff L, Phillips KA, Randhawa G, Ambs A, Armstrong K, Bennett CL, Brown ML, Donaldson MS, Follen M, Goldie SJ, Hiatt RA, Khoury MJ, Lewis G, McLeod HL, Piper M, Powell I, **Schrag D**, Schulman KA, Scott J. A Health Services Research Agenda for Cellular, Molecular, and Genomic Technologies in Cancer Care. *Pub Health Genomics*. 2009;12(4):233-44. PMID: 19367091.
11. Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd GD 3rd, Dorfman GS, Eng C, Fong Y, Giusti AF, Lu D, Marsland TA, Michelson R, Poston GJ, **Schrag D**, Seidenfeld J, Benson AB 3rd. American Society of Clinical Oncology 2009 Clinical Evidence Review on Radiofrequency Ablation of Hepatic Metastases From Colorectal Cancer. *J Clin Oncol*. 2009;28(3):493-508. PMID: 19841322.
12. Burstein HJ, Mangu PB, Somerfield MR, **Schrag D**, Samson D, Holt L, Zelman D, Ajani JA, American Society of Clinical Oncology. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. *J Clin Oncol*. 2011 Aug 20; 29(24):3328-30. PMID: 21788567.
13. Garcia-Aguilar J, Glynne-Jones R, **Schrag D**, Multimodal Rectal Cancer Treatment: In Some Cases, Less May Be More. *Am Soc Clin Oncol Educ Book*. 2016;35:92-102. PMID: 27249690.
14. Ivatury SJ, Wong SL, **Schrag D**. Patient-Reported Outcomes-Bench to Bedside. *Ann Surg Oncol*. 2019 Nov 18;10.1234-019-07920-9. PMID: 31741111.

15. Kehl KL, Keating NL, Giordano SH, **Schrag D**. Insurance Networks and Access to Affordable Cancer Care. *J Clin Oncol*. 2019 Dec 5;PMID: 31804867.
16. Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB 3rd, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, **Schrag D**, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. *Nat Rev Clin Oncol*. 2020 Dec;17(12):757-770. PMID: 32632268.
17. Biller L, **Schrag D**. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. *JAMA*. 2021 Feb 16;325(7):669-685. PMID: 33591350.
18. National Academy of Medicine: Report of the Committee on Weight-Based Medications, *National Academy*, 2021.
19. Osarogiagbon RU, Mullangi S, **Schrag D**. Medicare Spending, Utilization, and Quality in the Oncology Care Model. *JAMA*. 2021 Nov 9;326(18):1805-1806. PMID: 34751724.
20. Yu JB, **Schrag D**, Robin Yabroff K. Health Economics Research in Cancer Treatment: Current Challenges and Future Directions. *J Natl Cancer Inst Monogr*. 2022 Jul 5;2022(59):51-56. PMID: 35788370.

Educational Materials for Patients:

*No materials below were sponsored by commercial entities. Development was sponsored by either Dana Farber Cancer Institute, Memorial Sloan Kettering, or by funding received from the NCI or PCORI.*

2000	Chemotherapy drug and regimen-specific patient educational materials at Memorial Sloan Kettering	Developer of educational materials for general care and regimen-specific guidance for patients with gastrointestinal cancer used at MSK. Led development of regimen-specific guides with patient, family, pharmacist, and nursing stakeholder input (Institutional support for this work). These guides served as the foundation for chemotherapy treatment practice and have been modernized and maintained for >2 decades.
2017	Chemotherapy informed consent videos	Developed a series of videos (part of a multi-component intervention) that describe chemotherapy from patient, caregiver, and clinician perspectives. These include videos in Spanish that are tailored to the needs of the Hispanic population. These are now in use at centers across the US and are intended to optimize cancer treatment decisions and decrease disparities. (PCORI funding for this work)
2019	Symptom management Tip sheets for integration into the Epic Electronic Health Record	Developed a series of “tip sheets” for 56 common symptoms that occur following administration of cancer chemotherapy and/or after major surgery for cancer or benign conditions. I coordinated assembly of content and review by multi-disciplinary team including oncologists, surgeons, nurses, and patient advocates. These materials are now in use at 6 cancer centers for supporting patient education and have been integrated into Epic’s “turbo charge” foundation for dissemination across sites that run the Epic system. The eSyM platform is now available across all health systems that rely on EPIC. (NCI-funding for this work from a Moonshot award)

2019	Track your cancer journey	Developed tools for patients to track their cancer histories including treatments received, responses to treatment and tolerance of treatment to support patient-directed curation of clinical data. Software in development to support scalability. The system fulfills the need to understand cancer trajectories as patients transition across health care systems and clinicians. (Foundation funding)

Articles and Other Media:

*Articles, interviews, and information products in the national and global popular and scientific media (on-line, in print, broadcast news, etc.) have covered my research; highlights (complete listing not maintained). Selections include:*

1. Grady D. Scientists Do the Math to Fight Breast Cancer. New York Times. Science Times section. February 8, 2000.
2. Charlie Rose Science Series Explores Developments in Cancer Research. Episode 4 of Science Series to Examine Cancer, its Genetics, Prevention and Treatment. Filmed segment with host Charlie Rose. With co-host Sir Paul Nurse, Nobel Laureate, President of Rockefeller University, and leading experts. April 17, 2007.
3. The Aspen Ideas Festival. The future of health care July 5-7th, 2007. Public forum discussion Aspen Institute, Aspen Colorado.
4. Kolata G, Pollack A. Costly Cancer Drug Offers Hope, but Also a Dilemma. New York Times. July 6, 2008.
5. Honan D. Big Think Breakthroughs: Cancer. Big Think Knowledge Forum. September 22, 2011.
6. Schultz D. Many Terminal Cancer Patients Mistakenly Believe a Cure is Possible. National Public Radio (NPR). Segment on Shots, a Health News Program. November 2013 Recorded segment.
7. The New Yorker Festival 2013 Understanding the Affordable Care Act.
8. The New Yorker Festival 2015 Translating Knowledge from Research to Routine Care Settings
9. TEDMED: From Efficacy to Effectiveness to Implementation in Health Care Delivery
10. Davos Annual Meeting, Davos, Switzerland invited speaker and panelist 2014. Harnessing Electronic Health Records to Accelerate Research
11. Aspen Ideas Festival: Panelist: The Future of Precision Medicine 2015, Aspen, Colorado.
12. Quoted in more than 90 news items about the PROSPECT Rectal Cancer Trial from ASCO 2023 including a home page featured story in the in the [New York Times](#).

13. Quoted in multiple news items about Multi-Cancer Early Detection Testing following publications of the PATHFINDER study in the Lancet in 2023.